your reliable source of primary cells and · product catalog 2015-2016. allcells 1 toll free phone:...

BIOS

ERVI

CES

IMM

UNOL

OGY

HEM

ATOL

OGY

YOUR RELIABLE

SOURCE OF

PRIMARY CELLS

AND

BIOSERVICES

PRODUCT CATALOG 2015-2016

ALLCELLS

1

Toll Free Phone: 1-888-535-3444 www.allcells.com For In Vitro Research Use Only

1

AllCells, LLC Toll Free Phone: 1-888-535-3444 www.allcells.com For In Vitro Research Use

Only

AllCells, LLC

1301 Harbor Bay Parkway, Suite 200

Alameda, California 94502

Phone: 1-888-535-3444, 510-521-2600

Fax: 510-521-7600

www.allcells.com3-2015

Cover Image:Various images of AllCells team members, our products, and facilities located in Alameda, CA.

Thank you for trusting us with your research!

ALLCELLS®

We appreciate the opportunity to serve as your hematology/immunology research partner...and we'vebeen proud to stand by you for the past 17 years.

-The AllCells Team

2

ALLCELLS Toll Free Phone: 1-888-535-3444 www.allcells.com For In Vitro Research Use Only

A Message to Our Valued Customers:

Dear Valued Customer,

Welcome to AllCells’ new 2015-16 Product Catalog. It is my sincere hope you find our new catalog to be an informative, useful resource in helping plan your hematology & immunology primary cell-based research.

AllCells was founded upon a commitment to service the primary cell needs of life science researchers worldwide, who depend upon obtaining just the right cell phenotype, human donor profile, tissue cellularity, clinical report data, and other essentials for enabling cell-based research. In addition to standard catalog items and Bioservices offering, our aim at AllCells is to accommodate your unique research project requirements. Our core capabilities span custom hematologic tissue procurement through AllCells’ clinical division, LeukoLab, and established clinical (diseased tissue) collection network, custom cell isolation manufacturing, cell biology characterization, and even custom delivery -- when cells simply must arrive at your lab on that special day. We’re pleased to announce that AllCells now offers weekend Whole Bone Marrow, and Leuko Pak collections as customized products, enabling Monday morning delivery in most cases. Providing service excellence is fundamental to AllCells culture, and we invite you to challenge our team with your customized primary cell project requirements!

Thanks to your ongoing support, AllCells successfully completed the expansion, relocation, and consolidation of its operations to Alameda, CA. We dramatically increased our production capacity to handle your large primary cell projects in 2015, and beyond. The contiguous placement of our clinical division, LeukoLab, with cell manufacturing, packaging & shipping, and administrative functions now provides for an unprecedented, optimal work-flow, vital for consistently delivering a high level of quality assurance.

More than ever, we’re eager to learn how AllCells can serve as a vital partner in helping fulfill your research project goals & objectives. We encourage you to contact any of our Sales Representatives, Customer Service, or authorized Distributors worldwide, to discuss how we can add value to your research efforts.

We are thankful for your business and look forward to continuing to earn your trust.

Yours truly,

Jay TongJay Tong, M.D.

President & CEO

ALLCELLS

3


TABLE OF CONTENTS

A Message to Our Customers 2

Helpful Information

Using the Catalog 5

Ordering/Delivery Information 6-8

Getting Support 9

General Product Information 10-11

Terms & Conditions 12-14

Tissue Collection Facility

Background Information 15-16

Mobilization, Donor Criteria, Capabilities 17

Lead Times, Matched Sample Collection 18

Bioservices


Immunoassays 21

Hematopoietic Assays 22

Flow Cytometry Services 23

Tissue Culture Services 24

Protein Analysis 25

Genotyping 26

Custom HLA-Typing 27

Human Primary Cells & Tissue


Non-Diseased Custom Products 30-32

Normal Peripheral Blood

Background Information 34

Leuko Pak (Apheresis Collection) 35

Whole Blood 36-37

Plasma 38

Mononuclear Cells (MNC) 39

Stem/Progenitor Cells (CD34+) 40

Lymphoid Cells

B Cells (CD19+, CD19+/IgD+, Memory) 41-42

T Cells (CD3+ Pan, CD4+ Helper, CD4+/CD25+, 43-49

CD4+/CD45RA+/CD25- Naive Helper,

CD4+/CD45RO+ Memory, CD8+ Cytotoxic,

CD8+/CD45RA+ Naive Cytotoxic)

Dendritic Cells (BDCA4+ Lymphoid/Plasmacytoid) 50

Natural Killer Cells (CD56+) 51

Myeloid Cells

Basophils 52

Eosinophils 53

Neutrophils 54

Red Blood Cells/Mature Erythrocytes 55

Platelets 56

Monocytes

CD14+ Monocytes 57

Dendritic Cells (Monocyte-Derived) 58

Macrophages 59

Mobilized Peripheral Blood


Leuko Pak (Apheresis Collection) 61

Mononuclear Cells

MNC 62

CD34-Depleted MNC 63

Stem/Progenitor Cells

CD34+ 64

CD133+ 65

Myeloid Cells

Monocytes (CD14+) 66

Bone Marrow


Aspirates—Bone Marrow (Whole) 68

Mononuclear Cells (MNC)

MNC 69



CD34+ 71

Myeloid Cells

Early Erythroid Progenitor Cells (CD36+) 72

Mesenchymal Cells

Endothelial Cells (CD105+) 73

Mesenchymal Stem Cells 74

Cord Blood


Plasma 76

4



MNC 77



CD34+ 79

Myeloid Cells

Early Erythroid Progenitor Cells (CD36+) 80


Lymphoid Cells

B Cells (CD19+) 82

T Cells (CD3+ Pan, CD4+ Helper, CD8+ Cytotoxic, 83-86

CD4+/CD45RA+ Naive)


Non-Hematopoietic Stem Cells & Tissue


Adipose-derived Stem Cells 89

Amniotic/Placental Cells 90

Dental Pulp Cells 91

Diseased Cells & Tissue


Diseased Custom Products 94

Leukemia


Acute Lymphoid Leukemia (ALL) 97-98

Acute Myeloid Leukemia (AML) 99-100

Chronic Lymphoid Leukemia (CLL) 101-102

Chronic Myeloid Leukemia (CML) 103-104

Multiple Myeloma (MM) 105-107

Myelodysplastic Syndrome (MDS) 108-109

Non-Hodgkin's Lymphoma 110-111

Autoimmune


Grave's Thyroid 113

Hashimoto's Thyroiditis 114

Multiple Sclerosis (MS) 115

Osteoarthritis (OA) 116

Psoriasis (PSO) 117

Rheumatoid Arthritis (RA) 118

Systemic Lupus Erythematosus 119

Type I Diabetes (DIA1) 120

Type II Diabetes (DIA2) 121

Autoimmune: Inflammatory Bowel Disease


Crohn's Disease 123

Ulcerative Colitis 124

Animal Primary Cells & Tissue


Non-Human Primate Cells 126

Mouse Cells 127-132

Rat Cells 133-141

Pig Cells 142

Cell Culture Products


Basic Cell Culture & Cryopreservation Media 144

Defined Cell Culture Media 145

Cytokines 146-148

Technical Notes

How to Count Cells 150

How to Thaw Frozen Cells 151

How to Freeze Cell Products 152-153

How to Purify Bone Marrow MNC 154-155

How to Count Leuko Pak 156

How to Deplete Red Blood Cells 157

How to Passage & Subculture Cells 158-159

How to Isolate MNC using a Ficoll Gradient 160

Index

Alphabetical Index 161-163

Notes 164

Quick Reference Guide 165-166

TABLE OF CONTENTS

ALLCELLS

5


Using The Catalog

We are excited to share our new 2015-2016 Product Catalog with you. We have worked hard to ensure the catalog is a good resource

for you. Here are some tips on how to get the most benefit from our new catalog.

General Information:

The section on pages 6 - 14 features helpful information on ordering, delivery, lead times, technical support, AllCells.com website,

general product information, and terms and conditions. Use this information to become more familiar with our ordering process and how

best to reach us.

Service Sections:

We have outlined some of our unique research capabilities in the Tissue Collection Facility, Bioservices, and Custom Products/Projects

sections.

Product Sections:

Beginning on page 28 you will find our product information, categorized by species and tissue type. Use the Table of Contents on page 3

to find the section you desire. Each section then has a background page to help you find what you are looking for quickly. Look for the

'For more information visit: www...' guides to explore more on our website.

Technical Notes:

At the back of our new catalog we feature updated protocols, 'how-to' technical guides for the most common research techniques we

utilize at AllCells. Follow these notes to help ensure the best results with our cell products. For more information you may access videos

and printed guides here:

www.allcells.com/support/how-to

Quick Reference Guide:

The last pages of the catalog contain commonly-used reference tables and diagrams as a resource for

your research.

6


Ordering & Delivery Information

Order, price, and delivery date are confirmed after AllCells receives your purchase order or credit card information. Please provide us with your email address so we can notify you about the shipment status. All International orders must be paid in full prior to shipment.

Media Shipment & Delivery Information

Media Package Examples Courier

Stimulatory SupplementPackaged in dry ice at shipment.

MSC Stimulatory SupplementPackages are shipped using FedEx Priority Overnight service with a delivery commitment of 10:30am local time. Other delivery services, including same day delivery, are available upon request.

Basal MediumPackaged with a cold gel pack at shipment.

MSC Basal Medium

Contact InformationPhone

Toll-Free

(510) 521-2600

(888) 535-3444

Fax (510) 521-7600

Email [email protected]

Online allcells.com

Ordering Information

Delivery Information

Lead Times*

Product Format Normal Peripheral Blood Mobilized Peripheral Blood Whole Blood Bone Marrow Cord Blood

Fresh

Leuko Paks and

Leuko Pak derivatives:

2 weeks

Leuko Paks and

Leuko Pak derivatives:

4 weeks

1-2 weeks 2 weeks 2 weeks

Frozen 1-2 business days

*Lead times apply to healthy donor products only. Diseased tissue and cells are limited by stock availability. Lead times may vary due to the nature of the disease and sensitivity of patients. Custom product lead times may vary. See Custom Product section on pg. 30 and 94.

Address1301 Harbor Bay Parkway, Suite 200Alameda, CA 94502

Office Hours Monday through Friday8:30am to 5:30pm (Pacific Time)

ALLCELLS

7


Cell Type Fresh Frozen*/Lysates Courier

Whole tissueTransferred to a conical tube containing DPBS buffer. Shipped at room temperature.

Lysates are packaged in dry ice at shipment.

Packages are shipped using FedEx Priority Overnight service with a delivery commitment of 10:30am local time. Other delivery services, including same day delivery (limited to Bay Area or California), are available upon request.

Plasma/Platelets

Shipped at room temperature.Snap Frozen. Packaged in dry ice at shipment.

Whole Blood Drawn into a blood bag, syringe(s), or blood tube(s). Shipped at room temperature.

RBC

Transferred to a 50mL conical tube containing fresh RBCs and shipped in donor plasma. Packaged with a cold gel pack.


Transferred to a 50mL conical tube with shipping media (2mM EDTA). Packaged with a cold gel pack.

Frozen MNC are stored in a solution of 50% IMDM, 40% FBS, 10% DMSO (0.2 µm filtered) in the vapor phase of liquid nitrogen storage until ready for shipment. Packaged in dry ice at shipment. (Exception: BM-MNC are stored in standard CryoStor media.)

Purified Cells

Transferred to a small centrifuge tube containing shipping media (IMDM + 10% FBS + 2mM EDTA). Packaged with a cold gel pack.

Frozen cells are stored in a solution of 50% IMDM, 40% FBS, 10% DMSO (0.2 µm filtered) in liquid nitrogen storage until ready for shipment. Packaged in dry ice at shipment.

Leuko Pak(non-mobilized + mobilized)

One-liter blood bag containing peripheral blood cell MNCs and autologous plasma. Shipped at room temperature. Two-day collections are shipped out separately.

Cultured Cells

Cells are cultured and transported in flasks or an OptiCell plate that has two 50cm2 gas permeable, optically clear growth membranes.**

Frozen cells are stored in a solution of 50% IMDM, 40% FBS, 10% DMSO (0.2 µm filtered) in liquid nitrogen storage until ready for shipment. Packaged in dry ice at shipment.

RNAStored in a 500µL microtube with 20 to 100 µL DEPC water. Packaged in dry ice at shipment.

cDNAAliquoted at a base concentration of one PCR reaction/2µL DEPC-H2O. Packaged in dry ice at shipment.


8


Cell product packages contain:

A Certificate of Analysis The Certificate of Analysis lists the following:

• Catalog number• Catalog description• Donor information (as provided)• Viral results (HIV, HBV, HCV)

If applicable:• Cell viability• Cell purity• Cell count

What additional information will accompany my AllCells Products?

In addition, each purified cell product package contains:

Flow Cytometric Analysis

The figure below is a sample Flow Cytometric Analysis of our CD34+ enriched progenitor cells from human mobilized peripheral blood. The upper right panel shows the viability of cells and the lower right panel displays the purity of cells. The lower left panel represents the control. Samples were collected on a BD FACSCaliburTM.


S

ide

scat

ter

S

ide

scat

ter

ALLCELLS

9


Getting Support

Technical Support

At AllCells we are committed to providing the best support

possible for our customers. We are dedicated to sharing our

expertise in the hematology field to compliment our industry-

leading products.

You may find multiple resources on our

website including:

Technical notes, product 'How to' guides,

BioTube technical videos:

www.allcells.com/support/how-to

Webinars, support presentations:

www.allcells.com/support/webinars

Publications, research citing AllCells

products and services:

www.allcells.com/publications

Product Data Sheets, request Certificate of

Analysis, MSDS, and Clinical Reports

(diseased products only):

www.allcells.com/info-request

Account Manager support:

www.allcells.com/sales

Technical support:

www.allcells.com/technical-support

How to reach us

Customer service is a way of life at AllCells and we pride

ourselves on going 'above and beyond' to answer any support

questions you may have. If you were not able to find an answer

to your question on our website please contact us directly.

General product information, availability, sales inquiries and

ordering: [email protected]

For technical questions or order inquiries:

www.allcells.com/contact-us

Facebook: www.facebook.com/allcells

LinkedIn: www.linkedin.com/company/allcells-llc

Twitter: twitter.com/allcells_bio

Phone: (888) 535-3444, (510) 521-2600

Fax: (510) 521-7600

Mailing address:

AllCells, LLC

1301 Harbor Bay Parkway, Suite 200

Alameda, CA 94502

AllCells Shanghai

Shanghai Ju Ke Science Park

333 Guiping Road

Building 7, 2nd Floor

Xuhui District, 200233

Shanghai, China

Phone: +86-(0)-21-6485-3421

Fax: +86-(0)-21-64885-0144

www.china.allcells.com

10


GENERAL PRODUCT INFORMATION

STATEMENT OF ETHICAL STANDARDS

We, the staff members of AllCells, LLC, commit ourselves to the following principles, which we recognize are the standards of ethical behavior and excellence in practice that are fundamental to all activities in biotechnology:

Respect for Human Individuals We recognize that all humans have inherent dignity and that the welfare, rights, beliefs, perceptions, customs and cultural heritage of individuals should be taken into account. We treat clients, donors, colleagues, and all others who seek information about our organization with this respect.

Respect for Animals Animals have inherent value in their being as well as in their relation to human culture and research. We believe the welfare and humane treatment of animals should be maintained.

Respect for the Natural Environment The natural environment is our common heritage and sustains all life. We recognize that the natural environment and the natural resources of the earth are more than a means to satisfy human ends. The safeguarding of biodiversity, ecosystems, and the beauty of the natural environment should always be considered for both the present time and in the interest of future generations.

Respect for the Public Good We recognize that our individual and group activities occur in the context of social and institutional relationships. The “public good” is a collective good that should be taken into account along with individual interests. AllCells is committed to ensuring that this respect is embedded in the way we do business.

Benefit and Harm We believe human activities have social, economic, and environmental impacts. Human activities should promote good and avoid harm. At AllCells, LLC, we strive to create a positive impact in these areas and on the scientific research community as a whole.

Justice and Equity We believe that the benefits and burdens resulting from biotechnological activities should be distributed equitably throughout society so that no particular group is inequitably advantaged or disadvantaged now or in the future.

Probity We believe that our activities should be conducted honestly, truthfully, lawfully, impartially, competently, and with considered regard for transparency of processes.

Accountability We recognize that individuals and institutions are inherently responsible for their actions and the justification, purpose, and consequences of any action should be taken into account when determined. The principles noted here provide guidance for the application of ethical behavior in our work as members of the biotechnology community.

ALLCELLS

11


Purified primary cells are processed by positive or negative

isolation using immunomagnetic microbead labeling systems.

Microbeads are super paramagnetic particles. They are

conjugated to highly specific antibodies. Labeling does not

affect viability or function of the cells. In addition, these

particles have no known effect on structure and do not

interfere with subsequent experiments. Microbeads are

biodegradable and typically will detach from the cells after a

few days of cell culture.

Positive Selection: Cells of interest are magnetically labeled

with microbeads and isolated. This is the most direct and

specific way to isolate target cells from heterogeneous

cell suspensions.

We guarantee that positively-selected cells have a purity of

>90% (unless otherwise specified).

Negative Selection: Negative or untouched cell isolation is

the depletion of unwanted cells. Non-

target cells are magnetically labeled and eliminated from the

cell mixture by immunomagnetic separation. The non-labeled,

untouched cell fraction contains the targeted cells.

Untouched cells are less likely to be activated by antibodies.

We guarantee that the cell purity is >85% (unless otherwise

specified).

AllCells provides a wide range of primary hematopoietic and

immunological cells, which are available from numerous sources,

including normal peripheral blood (NPB), G-CSF (neupogen) or

CXCR4 (mozobil) mobilized peripheral blood (MPB), bone marrow

(BM), and cord blood (CB). Primary hematopoietic and

immunological cells have a limited life span in vitro.

Non-human primate, rat, porcine (pig) and mouse primary cells are

available as well.

AllCells human/animal primary cells are available in fresh or

frozen (cryopreserved). Please note that lysate, cell pellet, Total

RNA, and/or cDNA products may be available by request for

particular tissue/cell types.

Please note that we guarantee >70% viability of frozen cells after

thaw and normal range is between 70% to 98%.

Cell Separation

General Product Information

Cell Formats

12


General Terms:

1. These outlined conditions regarding sale and delivery from AllCells, LLC apply to all contracts of supply between AllCells, LLC and our customers.

2. The Customer is deemed to agree to these terms and conditions of sale and delivery upon placing an order.

3. Any rights awarded to the Customer arising during the course of business with AllCells, LLC are not transferable.

4. Any amendment to the conditions of sale and delivery, or any recognition of the Customer’s conflicting purchase conditions must be confirmed in writing by AllCells, LLC.

Prices:

1. AllCells, LLC prices are subject to change without prior notice. Please call, fax, or e-mail to confirm current pricing with AllCells, LLC.

2. All shipping and handling charges will be reflected on the invoice upon the delivery of product. Shipping and handling charges will vary according to the weight of the package and the shipping options. Please contact AllCells, LLC directly for current shipping and handling prices.

3. AllCells, LLC prices quoted in the catalog are net prices; sales tax will be included where applicable. All shipments to California destinations are subject to California State sales tax unless AllCells, LLC has a resale certificate on file, or product is derived from human tissue.

Order Policies (Order, Changes, Cancellation, and Rescheduling):

1. Once you have placed your order, AllCells will recruit and schedule donors for tissue collection according to your requirements.

2. Fresh product orders which are cancelled or rescheduled within the Lead Time Period required for each collection will incur a 10% Cancellation/Rescheduling Fee according to the Table below. For example, Lead Time Period for Bone Marrow collection is 2 weeks, therefore if order is cancelled or rescheduled within 2 weeks from the scheduled collection time, customer will be charged a 10% Cancellation/Rescheduling Fee.

3. Orders may not be cancelled within 24 hours of the scheduled collection time.

4. For existing orders, any request for change in volume of fresh product 10 business days prior to scheduled draw date is not guaranteed, and must be requested and approved in writing by Customer Service at [email protected].

5. AllCells is not responsible for incomplete orders due to the following conditions beyond our control (i) Donors who do not show-up for tissue collection on a scheduled draw date, (ii) Donors who fail to complete the collection process due to their inability to tolerate the full tissue collection procedure, (iii) Donors fail to complete their drug mobilization injections, and (iv) Donors do not pass CBC eligibility on day of draw.

6. All direct international orders are subject to the same Terms & Conditions that are outlined in AllCells basic policy except for the following:

7. Direct international orders must be pre-paid. Customers can pre-pay via bank wire transfer or credit card (Visa, MC, AMEX).

8. International orders are shipped using customer’s courier account only. AllCells is not liable for the package once it leaves our facilities. AllCells recommends customers declare the full value of products to their courier in case of delay or damage. Customer is responsible for filing any claims with their courier.

9. All international couriers must include an after-hours contact name and phone number for the end user.

Back-up Donors:

1. Back-up donors are available for an extra fee for fresh orders involving same-day multiple donor draws, and when adhering to delivery schedules is essential. If you decline a back-up donor option, you will be responsible for accepting delivery, and invoiced for the lower volume of product that AllCells is able to collect for your order.

2. AllCells will not be responsible for the following circumstances (i) Back-up donors cannot be scheduled, (ii) Back-up donor does not appear on the scheduled draw date, and (iii) Back-up donor cannot tolerate the full procedure, and the total volume needed is not collected for your order.

Terms & Conditions

Product Format* Product Type Lead Time Period

Fresh Mobilized Leuko Pak 4 weeks

Leuko Pak 2 weeks

Bone Marrow 2 weeks

Whole Blood 1-2 weeks

Frozen All Products 2 business days

*Lead times apply to healthy donor products only. Diseased tissue and cells are limited by stock availability. Lead times may vary due to the nature of the disease and sensitivity of patients.

ALLCELLS

13


Delivery:

1. All orders are shipped via Federal Express Priority Overnight delivery unless otherwise specified.

2. Estimated delivery times can be specified; however, estimated delivery times are not legally binding.

3. Same day delivery is available in the San Francisco Bay Area with prior arrangement with AllCells, LLC.

4. All deliveries take place at the customer’s risk. The transfer of risk occurs on the handing over of goods to the carrier or shipper. The course of delivery method is at the discretion of AllCells, LLC with exclusion of any and all liability.

Payment:

1. For established customers, payments must be made within 30 days of delivery.

2. Invoices not paid within the designated terms may be subject to a 10% late fee of the initial balance and a 1.5% per month (18% annum) interest fee.

3. Failure to make payment within 120 days will result in credit-hold, and may result in legal and collection proceedings upon expiration of the payment period without further warning.

4. AllCells, LLC accepts only US currency in the form of company checks, cashier checks, money orders, AMEX, VISA or MasterCard payments. All funds must be withdrawable from a US bank account; foreign bank accounts and foreign currency will not be accepted as appropriate payment. Please make checks payable to AllCells, LLC.

5. For all other customers (including International), prepayment via wire fund, credit card (VISA, MasterCard or American Express), or a check in US dollars is required.

6. If AllCells, LLC conditions of payment are not met, or if “justifiable concerns” exist with regard to the Customer’s ability or willingness to pay, AllCells, LLC is entitled to deem any contract with the Customer null and void and demand the return of the delivered goods in the condition in which they were shipped. The cost of this return of delivery will be the responsibility of the Customer. In addition, all outstanding claims the Customer may have with AllCells, LLC will become due.

7. “Justifiable concerns” referred to above include, but are not restricted to: initiation of insolvency or bankruptcy proceedings, deterioration of financial circumstances, and default of payment for any other reason.

Use of Goods:

1. All products received from AllCells, LLC are intended exclusively for in vitro use only. These products are not intended for use on human beings, animals, or for any private use. Please note that any use of AllCells, LLC products for any purpose other than intended including use for therapeutic or diagnostic purposes will result in legal ramifications.

2. AllCells, LLC does not accept any liability for the improper use of our products. We deliver our products only to research and teaching institutions, commercial enterprises, and public researchers. Any signs of improper use of AllCells, LLC products by a customer will result in refusal of delivery and termination of any contract associated with this customer.

3. AllCells, LLC opposes any research in violation of any ethical, legal, or governmental standards within the United States and the import countries of our customers. We do not accept any liability for such research or use by our customers.

4. AllCells products are not permitted for resale or as a source for deriving other cell processing without written authorization from AllCells, LLC.

Liability:

1. AllCells, LLC represents and warrants that it has (1) obtained ownership rights with respect to products and that such products were provided to AllCells, LLC with every donor’s informed consent and in compliance with all applicable laws and regulations, (2) obtained all necessary and appropriate releases from the donor wherein there are no restrictions on use of products that would prohibit customers from using them in any commercial pharmaceutical research conducted in vitro, (3) complied with all applicable United States and foreign statutes and their respective rules and regulations in connection with handling, export, import, and use of the products.

2. AllCells, LLC represents and warrants that it has no obligation to any third party that would interfere with AllCells, LLC providing products to customers. In addition, any products that AllCells, LLC provides to customers are not the proprietary property of any third party.

3. In no event will AllCells, LLC be liable to a customer or anyone else for any damages or injury resulting from the use or misuse of our products, nor for any action taken by a customer relying on information, either verbal or written, from any source.

4. The Customer agrees that AllCells, LLC’s liability, if any,

Terms & Conditions

14


Terms & Conditions

for damages (including liability, arising from physical or mental harm, caused by any product liability, arising out of contract, negligence, strict liability or tort) shall not exceed the cost of the product, which the Customer purchased from AllCells, LLC.

5. The Customer agrees to indemnify and to hold harmless, AllCells, LLC and all other parties involved, including their owners, officers, affiliates, associates, and employees for any and all damages incurred as a result of the products used. These parties shall not be liable under any circumstances.

6. By ordering any products from AllCells, LLC, the Customer acknowledges the above terms, conditions, and disclaimers, included but not limited to the above disclaimers and any additional warnings and cautions. The Customer agrees to carefully abide by these terms, conditions, and disclaimers.

Warranty:

1. AllCells, LLC warrants that our products will meet the claimed product specifications, such as viability, number of viable cells, and purity. AllCells, LLC does not warrant any biological properties associated with our products.

2. AllCells, LLC will replace any products that do not meet the specifications claimed on our certificate of analysis free of charge. In no event shall AllCells, LLC’s liability exceed the purchase price paid by the Customer.

3. AllCells, LLC shall not be liable for any damages or injuries to persons or property arising from the use of its products. AllCells, LLC is not liable for a product that has been misused or has been rendered unusable due to improper storage or handling.

4. All AllCells, LLC products are “For In Vitro Research Use Only” and are neither approved for human nor veterinary use in vivo, diagnostic, nor clinical applications.

5. This limited warranty has a one-year period starting from the time of shipment.

6. AllCells, LLC’s products are not permitted for re-sale without written authorization from AllCells, LLC.

Return Policy:

Catalog products may not be returned for credit without the express prior written authorization of AllCells, LLC. A Restocking Fee will be applied to returns in which the purchaser is at fault. A Restocking Fee of $50 or 15% of the purchase price will be applied, whichever is greater. Returns involving fresh cell products must be requested

within 24 hours of product delivery. Returns involving frozen cell products must be requested within 1 month of product delivery. Products must be returned in their original containers with original AllCells label affixed and unaltered. For product returns to be considered, customer must certify that product was maintained under recommended storage conditions while in its possession, and will be packaged and delivered back to AllCells according to the same conditions as the original shipment. Final acceptance of returned product is at the sole discretion of AllCells, LLC. No returns will be accepted for custom product orders. No return will be accepted without a written return-authorization number issued by AllCells, LLC.

Disclaimer:

This catalog may contain typographical errors or inaccuracies and may not be complete or current. AllCells therefore reserves the right to correct any errors, inaccuracies or omissions (including after an order has been submitted) and to change or update information at any time without prior notice. Please note that such errors, inaccuracies or omissions may relate to pricing and availability, and we reserve the right to cancel or refuse to accept any order placed based on incorrect pricing or availability information. We apologize for any inconvenience.

ALLCELLS

15


Product Description

TISSUE COLLECTION FACILITY

Photo credit: Miltenyi Biotec CliniMACS®

16



Background

AllCells, LLC has been operating its own private tissue collection facility under IRB-approved protocols since 2007,

following a 10-year partnership with a local community hospital. Our facility employs a staff of registered nurses each

with over 17 years of blood collection experience from healthy donors. A licensed physician, board certified in the

specialties of hematology and oncology, is the medical director and principal investigator for all our healthy donor related

cell collection studies.

We are committed to making the safety and well-being of our donors our first priority. Participating donors receive safe

and attentive care guided by community standards, the FDA, and the California State Department of Health regulations

for blood product donation.

We are dedicated to providing donors with a confidential experience. Donor identity is rigorously protected observing

federally-recognized standards. All staff members are experienced and compliant regarding the protection of human

research subject health information and privacy issues per the Health Insurance Portability and Accountability Act of

1996 (HIPAA) Privacy and Security Rules.

Equipment

A complete blood count (CBC) sample is collected from all donors prior to blood and/or bone marrow donation to verify

donor eligibility. The samples are analyzed on site with results available in about one minute.

All apheresis cell separation procedures are performed by specially trained registered nurses using state-of-the-art,

continuous flow Apheresis System (hardware, software, and disposable kits).

Whole blood collections are completed on site. Samples are collected into receptacles of the customer’s choice, such as

blood transfer packs or vacutainer tubes. Customers may request specific collection receptacles, or provide specific

collection receptacles directly to AllCells, LLC if they prefer.

Bone marrow aspirations are performed by physicians only. A local anesthetic is applied to the donor’s skin and

aspiration site first for donor comfort. Customers have the option of requesting specific collection receptacles.

IRB

All cell collection protocols are overseen and approved by an independent Institutional Review Board (IRB) on an

annual basis.

ALLCELLS

17



Mobilization

AllCells has been a pioneer in the use of G-CSF (Neupogen®) stimulation in normal healthy donors since 1998. The

protocols in use for our Mobilized Peripheral Blood (MPB – pg. 61) products have been approved by an IRB and are

overseen by clinical physicians. In addition all donors are monitored during the injection, collection procedure and

post-collection to ensure the health of our donors is a priority. AllCells is one of only a few providers of Mobilized

Peripheral Blood in the world.

In addition AllCells now offers Plerixafor (Mozobil®) mobilization of stem cells from healthy donors. Mozobil, a selective

CXCR4 antagonist, has been particularly beneficial as an adjuvant stem cell mobilization agent on top of the G-CSF

regimen. The Mozobil regimen requires only 1 injection as opposed to the G-CSF 3-5 day protocol. AllCells is currently

the only source of Plerixafor-mobilized cells in the world. For more information on this exciting new mobilization agent

visit our Mobilized Peripheral Blood section on page 61.

• Age 18-55 years old for whole blood and Leuko Pak

• Age 18-65 years old for bone marrow aspiration

• Weight > 130 lbs for whole blood

• Weight >140 lbs for Leuko Pak

• Complete Blood Count lab test must meet protocol specs

• Donors are screened for HIV (HIV 1 & 2 Ab),

Hepatitis B (Surface Antigen HbsAg) & HCV (HCVAb)

• Donors cannot be pregnant

• Donors must be in good health

• Donors are required to sign consent form prior to collection

Donor CriteriaNon-mobilized Products-

• All Non-Mobilized criteria

• Age 18-40 years old

• Minimum 12 months between donations

• Twice-in-a-lifetime maximum donation

Mobilized Products-

Capabilities

Having our own tissue collection facility allows us to customize a variety of project variables including protocols,

techniques, equipment, donor characteristics, and delivery.

Customization Bone Marrow Apheresis Whole Blood

Custom Collection Protocols

• Anticoagulant type ( i.e. Heparin, ACDA)

• Syringe size

• Mobilized vs. Non-mobilized• Product volumes ( i.e., cells vs.

autologous plasma)• Product Hematocrit

• Anticoagulant type (i.e. Heparin, EDTA, ACDA)

• Collection receptacles (i.e, heparinized syringes, vacutainer tubes, transfer packs, etc.)

Donor Customization

• Demographics (i.e. age,

ethnicity, gender, etc.)

• Past medical history (i.e. health

habits, allergies, medications,

smokers vs. non-smokers, etc.)

• HLA typing

• ABO typing

• Other typing upon request

• Demographics (i.e. age,

ethnicity, gender, etc.)




• HLA typing

• ABO typing


• Demographics (i.e. age, ethnicity,

gender, etc.)




• HLA typing

• ABO typing


Other Customization

Same day delivery available for local customers



18



Matched Sample Collection

In addition to the capabilities illustrated here, AllCells has the ability to collect multiple types of tissues from the same

donor on the same day. Various combinations of product types can be mixed and matched including Bone Marrow, Whole

Blood, and Apheresis. Cetain restrictions apply and 3-4 weeks advance notice is required. Please see our ‘Combo Pak’

product information on page 35 for more information or contact us directly.

Contact us for your specific research needs at www.allcells.com/contact-us or fill out our ‘Project Request Form’ online

at: www.allcells.com/technical-support/

Standard Collection — Lead Times

When placing your order with our team please keep the following lead times in mind for our standard

collection products:

Collection Type Lead Time

Mobilized Peripheral Blood (Leuko Pak) 4 weeks

Normal Peripheral Blood (Leuko Pak) 2 weeks

Bone Marrow Aspiration 2 weeks

Whole Blood 1-2 weeks

ALLCELLS

19


BIOSERVICES

Photo credit: BD FACSCanto II®

20


BIOSERVICES

Your Trusted Partner in Hematology/Immunology Based Research & Development Since 1998, AllCells has been the industry leader in providing high quality hematopoietic and immunological cell products to leading

researchers. Our scientists have over 50 years of combined experience developing a wide range of hematopoietic assays. We are

proud to offer the following services as part of our Bioservices division:

For more information visit: www.allcells.com/bioservices/

Immunoassays

• ELISA (single, multiplex)

• ELISpot

• Luminex® (single, multiplex)

Hematopoietic Assays

• Hematopoietic Stem Cell Based Assays (Colony Formation)

—CFU-G, CFU-M, CFU-GM, BFU-E

—CFU-Mk

—LTC-IC

• Mesenchymal Stem Cells

• HSC/Progenitor differentiation

—Megakaryocytes, Dendritic cells

Flow Cytometry Services

• Multivariable Flow Cytometric Analysis, up to 13 colors

• Immunophenotyping (extracellular and intracellular)

• DNA Analysis

• ISHAGE

—CD34 enumeration

—Leukocyte characterization

Tissue Culture Services

• Luminex® Multianalyte Assays

• In vitro Proliferation/Inhibition Assays (EC50)

• CFSE

• Cell Proliferation Assays (viability, cell counting)

• MTS/MTT/CTG

• Toxicology Studies

• Diseased Cells Analysis

Protein Analysis Services

• Protein Electrophoresis

• Western Blot

• Immunoprecipitation

Genotyping

• gDNA Extraction

• Mutation Analysis

• CD16 Genotyping

Custom HLA-Typing

Bioservices Table of Contents

Immunoassays 21Hematopoietic Assays 22Flow Cytometry Services 23Tissue Culture Services 24

Protein Analysis 25Genotyping 26Custom HLA-Typing 27

ALLCELLS

21


BIOSERVICES

Immunoassays

As part of our Bioservices offering, AllCells specializes in Immunoassays. Immunoassays are a robust method of detecting cellular

response and assessing drug efficacy through protein expression/secretion. These assays have industry applications in

autoimmunity, transplantation, vaccine development, therapeutic development, and many others. AllCells provides immunoassay

services including ELISA, ELISpot, Luminex, and Human Donor HLA Typing amongst others.

ELISpot

Enzyme-linked immunospot assay, or ELISpot, is a colorimetric assay which enables quantitative, single cell analysis of protein

expression levels. Due to its high sensitivity and reproducibility, the ELISpot is an industry standard in antigenic response in the form

of cytokine secretion.

T cell proliferation assay

Labeling of T cells with the fluorescent dye 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) allows for quantitative

phenotyping of T cell division in response to antigen or other stimuli by flow cytometric methods. T cell proliferation assays are

essential for peptide epitope mapping of naïve T cells and for characterizing full protein immunogenicity in DC-T cell assays.

Figure. CD4+ (A) and CD8+ (B) T cells were isolated from peripheral human blood and labeled with

5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE). Labeled cells were cultured 7d with or without a stimulatory

antibody cocktail. Fluorescence was measured by flow cytometry.

Luminex (single, multiplex)

The Luminex Bead Array System allows for a high throughput, multi-target analysis of cytokines, proteins, and nucleic acids for

researchers. The system is important for many clinical and research applications. Our Bioservices team can provide customized

applications of the system to accelerate your research. Inquire with us today by filling out our Technical Support form at

www.allcells.com/technical-support/

22


BIOSERVICES

Hematopoietic Assays

As a leader in the provision of hematological samples to the research community, AllCells has over 20 years of experience

performing hematopoietic stem cell assays. AllCells offers services in colony formation assays and the expansion and

differentiation of stem and progenitor cells, including hematopoietic and mesenchymal stem cells.

Hematopoietic Stem Cell (HSC) potential is routinely measured through myeloid colony forming units (CFU) in a semi-solid

culture environment. In the presence of cytokines, unipotent progenitor cells are capable of giving rise to colonies with

granulocytes (CFU-G), macrophages (CFU-M), erythrocytes (BFU-E) and megakaryocytes (CFU-Mk) while stem/progenitor

cells with multipotency give rise to colonies with multiple lineages (CFU-GM and CFU-GEMM). Long term culture-initiating cell

(LTC-IC) assays are used to identify the most primitive HSC which is capable of maintaining its multipotency after long term

culture.

Mesenchymal Stem Cells/Multipotent Stromal Cells (MSC) are isolated by AllCells from multiple sources, including bone

marrow, cord blood, adipose tissue and dental pulp from deciduous teeth. MSC have been shown to possess multilineage

differentiation potential, including but not limited to adipocytes, chondrocytes, osteoblasts, neurons and myocytes. AllCells

offers custom services for the quantification of MSC using colony forming fibroblast (CFU-F) assays and characterization of

MSC derived adipocytes, chondrocytes and osteoblasts.

In addition to characterization of HSC and MSC potential, AllCells offers services in custom differentiation of our stem and

progenitor cells. AllCells can provide our customers with populations of difficult to isolate cells which have been expanded

and differentiated in culture, including megakaryocytes, dendritic cells and early erythroid cells.

Case study: Samples were treated with different compounds, cultured, and colonies were manually counted. Graph below

displays various colony types after compound treatment.

ALLCELLS

23


BIOSERVICES

Flow Cytometry Services

AllCells utilizes our 20+ years of Flow Cytometry experience and state-of-the-art equipment to provide customized research solutions. We offer Multivariable Flow Cytometric Analysis with up to 13 colors simultaneously using our FACSCalibur®, FACSCanto II® and FACS Aria II® machines. We also offer custom Multivariable Cell Sorting using our FACS Aria II®. Our services include Immunophenotyping of intracellular and extracellular molecules, DNA Analysis, and CD34 Enumeration and Leukocyte Characterization using ISHAGE guidelines.

Our Immunophenotyping services can be applied to cellular characterization of both intracellular and extracellular molecules using fluorescently-labeled antibodies. These include but are not limited to MHC/HLA Typing, Cancer Cell Analysis (focusing on

Hematological Malignancies), and other custom analyses.

Our DNA Analysis services can provide information on the percentage of cells in each phase of the cell cycle. This output can be used in drug screening applications, inhibition, proliferation, senescence, etc.

Flow-cytometric enumeration of CD34+ hematopoietic stem and progenitor cells (HSCs) is widely used for evaluation of graft adequacy of peripheral blood and bone marrow stem cell grafts. The International Society of Hematotherapy and Graft Engineering (ISHAGE) has created guidelines for a gating strategy that results in replicable standards for stem and progenitor cell enumeration. AllCells Bioservices adheres to ISHAGE guidelines for characterization of leukocytes and quantification of CD34+ cells.

Fluorescence-activated Cell Sorting (FACS) utilizes the principles of flow cytometry to identify populations of cells of interest. Cells can be electrically charged and sorted into highly purified populations. At AllCells, we are capable of identification and sorting of cell populations using up to 11 colors.

Our Bioservices team can provide customized applications of the system to accelerate your research. Inquire with us today by filling out our Technical Support form at www.allcells.com/technical-support/.

Case Study: Extracellular LSK markers were placed on mouse bone marrow cells. LSK markers are an indication of mouse

hematopoietic cells (HSCs) in the mouse bone marrow.

24


BIOSERVICES

Tissue Culture Services

AllCells Bioservices includes Tissue Culture Services to help study kinetics of cellular response to external stimuli. We offer a wide

range of platforms for analysis of cell proliferation and viability. This can include MTT, MTS, CTG, and Annexin V assays.

Tissue Culture Services include:

• Luminex® (single, multiplex)

• In vitro proliferation/inhibition assays (EC50)

• CFSE (refer to Flow Cytometry Services pg. 23)

• Cell proliferation assays (viability, cell counting)

MTS/MTT/CTG – To study the kinetics of cell viability in drug compound screening, we are able to implement specific assays.

Alternatively, these assays may be used for inhibition studies, illustrating the kinetics of your cells: EC50/IC50 analysis

Toxicology Studies – Our bioservices can help with QC validation of toxic effects on cells by certain compounds.

Diseased Cells – AllCells serves as a reliable source for a variety of hematological, oncologic, and autoimmune diseased cells that

can be used with multiple bioservices including compound screening, biomarker discovery, and characterization of specific

diseased cells. We source our own cells, have control over our supply, and can customize based on research demands.

Compound treatment is one example of our Tissue Culture Services:

Compound Treatment - aliquot cells, treat with drug compounds

Proliferation - grow cells, add reagent, incubate, measure live cells labeled

Apoptosis (Annexin V/PI)

Pathway Activation

CFU-C Assay

ALLCELLS

25


BIOSERVICES

Protein Analysis

AllCells is currently offering custom services in Protein Analysis, to compliment your research. AllCells has a protein analysis

platform that includes services in Protein Electrophoresis, Western Blot and Immunoprecipitation. Our Bioservices team features

over 15 years of combined Protein Analysis experience.

Protein Electrophoresis

Protein Electrophoresis utilizes the differences in size and charge of proteins for separation and detection in a polyacrylamide gel.

Protein electrophoresis is a highly reliable method for determining the composition and relative quantities of proteins in cell samples.

Western Blot

For characterization of specific protein expression levels, further Western Blot analysis can be performed by transferring

electrophoresis separated proteins from the polyacrylamide gel onto a membrane. Semi-quantitative analysis can be performed on

protein expression levels in samples.

Immunoprecipitation

To determine which proteins are interacting in your sample, we offer immunoprecipitation services for isolation of proteins and their

binding partners. In addition our Bioservices team can optimize your immunoprecipitation process.

Our Bioservices team can provide customized applications of our system to accelerate your research. Inquire with us today by filling

out our Technical Support form at www.allcells.com/technical-support/.

Case Study: Intestinal primary myofibroblasts of mice were isolated. The cells were then analyzed using Western Blot to determine

if the cells expressed NPR-C. Figure below is the output illustrating the expression of NPR-C with Actin control:

NPR-C:

Actin:

26


BIOSERVICES

Genotyping

As part of AllCells Bioservices we now offer genotyping services. Our genotyping services focus on genomic DNA extraction

for mutation analysis, HLA genotyping, and Fc-gamma Receptor IIIa (CD16a typing). Genotyping services are useful for

minimizing variation in your sample population to increase reproducibility in downstream applications.

gDNA Isolation

Our Bioservices can package genomic DNA extraction with mutational analysis, genomic profiling, and other sequence-

based analyses.

The advancement in genetic engineering has transcended genomic DNA from the basic code of life to the pivotal tool

for next generation medicine. From gene therapy to cellular reprogramming, the DNA molecule continues to manifest

its dynamic potentials.

Because the research needs for genomic DNA may or may not be cell-type dependent, AllCells offers a customized service to

extract and purify genomic DNA from any of our available primary cell products, human as well as other available mammalians,

and from any other mammalian tissues such as human tumors provided by the research client.

AllCells also features cell-type and donor matched extractions of both genomic DNA and comprehensive RNA. Pricing may vary.

Please contact us today by filling out our Technical Support form at www.allcells.com/technical-support/for related inquiries

and requests.

Mutation Analysis

Can be used to detect abnormalities in cell populations. Examples of our mutation analysis are CD16-typing and HLA-typing.

We implement PCR-based assays, PCR genotyping with sequencing where needed. We source our own cells, have control

over our supply, and can customize based on research demands. We can also provide KIR-Typing for NK cells.

HLA Genotyping – For more information please refer to our Custom HLA Typing section on the following page.

ALLCELLS

27


BIOSERVICES

Custom HLA-Typing

Human Leukocyte Antigen, or HLA, plays a strategic role in the recognition and defense mechanisms of the human body.

The segregation and pooling of the human genome have created a wide spectrum of diverse HLA. Many research efforts are

underway to employ different HLA haplotypes for aid in identifying treatment for infectious diseases, autoimmune diseases

and cancer.

In a more direct area of medicine, recombinant and chimeric monoclonal antibodies (MAb) technologies have become the

latest super weapon against cancer, autoimmune and infectious disorders, and even graft rejection, through enhanced

pathways of ADCC (antibody dependent cell-mediated cytotoxicity) and CDC (complement dependent cytotoxicity). One

of the critical factors for mAB efficacy is its Fc portion's affinity to the effector cell's Fc receptor. One such receptor, the

FcG RIIIA(CD16), is subjected to a single nucleotide polymorphism which results in formations of F (Phenylalanine) or V

(Valine) at amino acid position 158, and causes different levels of affinity to the Fc portion of IgG. Recent breakthroughs in

antibody engineering saw the ability to possibly overcome such affinity issues. However, the quest for the perfect monoclonal

antibody continues, and AllCells welcomes the opportunity to work with all of the antibody experts in anyway we can, from cell

characterization to custom assays.

Product/Service Descriptions

HLA-A2 and HLA-B27 expressions are tested by leukocyte surface immunophenotyping. For higher resolution haplotypes,

HLA-A0201 and HLA-DRB1*0401 are analyzed by sequence specific priming PCR.

FcG-RIIIA-158 allelic expression is characterized by detection of CAPS, or Cleaved Amplifed Polymorphic Sequence. We routinely test

our human donor samples for these markers, and can provide testing services for new donors upon request.

Product/Service Type Immunological

Target

Method Catalog # Price

Immunologically Characterized Stock Products

HLA-A2+

HLA-B27+

HLA-A*0201+

HLA-DRB1*0401+

Fc Gamma ReceptorIIIA-158-FFFc Gamma ReceptorIIIA-158-VFFc Gamma ReceptorIIIA-158-VV

Immunophenotyping

Immunophenotyping

SSP Genotyping

SSP Genotyping

CAPS

C-HLA-A2

C-HLA-B27

C-HLA-A0201

C-HLA-DRB10401

C-FCG-R3A158-FF

C-FCG-R3A158-VF

C-FCG-R3A158-VV

Please contact us for pricing

28


HUMAN PRIMARY CELLS

ALLCELLS

29


Human Primary Cells & Tissue

Human cells & tissue are the most clinically-relevant model for research. AllCells provides a wide range of primary human

cells. These human primary cells include hematopoietic and immunological cells, mesenchymal cells, amniotic and placental

cells, and dental pulp cells.

These human cells are made available from numerous sources. Our normal/healthy human cells are sourced from healthy

peripheral blood, G-CSF mobilized peripheral blood, bone marrow, cord blood, amniotic & placental fluid, dental pulp and

adipose tissue. Our diseased human cells are sourced from either peripheral blood or bone marrow.

AllCells human cells product line is available in fresh or frozen format. Please contact us for any special requests or custom

isolations at www.allcells.com/technical-support/ or [email protected].

Human Primary Cells & Tissue Table of Contents

Non-Diseased Custom Products 30-32Normal Peripheral Blood 34-59Mobilized Peripheral Blood 60-66Bone Marrow 67-74Cord Blood 75-87

Non-Hematopoietic Stem Cells 88-91Diseased Cells 92-124

For more information visit: www.allcells.com/human/

HUMAN PRIMARY CELLS

30


AllCells offers a variety of customized options for non-diseased products(for disease products see page 94): donor

recruitment, collection, cell isolation, processing and services. Our Custom Product/Project Request Form appears on the

following pages and our website. For more information see our Tissue Collection Facility Capabilities on page 15.

Examples of custom primary cell isolations but not limited to:

• Custom cell isolations, small and large projects

• Lysate and cell pellet

• Custom cell numbers

• Custom processing/packaging:

-Frozen or snap frozen for RNA or cDNA

-Lysis with custom buffer/reagents

-Custom collection into tubes/blood bags

-PAXgene/Cyto Chex tubes

-Anticoagulant of choice

-Custom handling

-Custom gradient density PBMC isolation

• Multiple cell types from a single donor

• Donor-matched cells

-Matching plasma, serum, platelets, and RBC from the same donor

-Matching whole blood and bone marrow

-ABO blood typed matching donors

• Hematopoietic stem cells from mobilized peripheral blood

NON-DISEASED CUSTOM PRODUCTS

ALLCELLS

31


Custom Product/Project Request Form

Our team can provide custom research solutions depending on your project requirements. The following form will be used by

our team to help determine how best we can serve you and accelerate your research. Please fill out the form online and a

Technical Support Representative will respond usually within 24 hours. The form can be found under the Custom Product/

Project category at www.allcells.com/technical-support/.

CUSTOM PRODUCTS

32


CUSTOM PRODUCTS

Custom Product/Project Request Form (continued)

ALLCELLS

33


HEALTHY PRIMARY CELLS & TISSUE

34


NORMAL PERIPHERAL BLOOD

• Age: 18-55 years old

• Weight: >140 lbs for Leuko Pak

• Weight: > 130 for whole blood

• CBC lab tests must meet protocol specifications.

• Donors cannot be pregnant.

• Donors are screened for HIV, Hepatitis B and Hepatitis C

before donation.

• Donors must be in general good health. Donors with any of the

following will be excluded from donating:

-History of heart, lung, liver, or kidney disease

-History of asthma

-Blood and bleeding disorders, including sickle cell disease

-Neurologic disorders

-Autoimmune disorders

-Cancer

-Diabetes

-Positive: HIV, HbsAg, HCAb

• Donors must have adequate peripheral veins for apheresis.

• Donors are required to sign a procedure-specific consent form

prior to the collection procedure.

Normal Peripheral Blood Table of Contents

Apheresis Collection (Leuko Pak) 35

Whole Peripheral Blood 36-37

Plasma 38


Stem/Progenitor Cells (CD34+) 40

Lymphoid Cells

B Cells 41-42

(CD19+, CD19+/IgD+)

T Cells 43-49

(CD3+ Pan, CD4+ Helper, CD4+/CD25+,

CD4+/CD45RA+/CD25- Naive Helper,

CD4+/CD45RO+ Memory, CD8+ Cytotoxic,

CD8+/CD45RA+ Naive Cytotoxic)

Dendritic Cells (BDCA4+ Lymphoid/Plasmacytoid) 50


Myeloid Cells

Basophils 52

Eosinophils 53

Neutrophils 54

Red Blood Cells/Mature Erythrocytes 55

Platelets 56


Dendritic Cells (Monocyte-Derived) 58

Macrophages 59

Donor Criteria

For more information visit: www.allcells.com/normal-peripheral-blood/

ALLCELLS

35


Product Description

AllCells Leuko Paks are highly-enriched leukapheresis-derived products obtained from our own IRB-approved collection facil-ity. These products contain higher concentrations of mono-nuclear cells, B cells, T cells, stem/progenitor cells, dendritic cells, and other cell types as compared to standard venipunc-ture collection methods or buffy coat products.

Full/Half/Quarter Pak - Normal peripheral blood mononuclear cells are collected from healthy donors in various collection sizes. For the Full Leuko Pak, approximately 3 blood volumes are processed using the COBE SpectraTM apheresis machine and between 50 and 150 mL of autologous plasma is col-lected at the same time as the mononuclear cells.

Dual Half Pak - PB007-3A, -3B - A healthy donor undergoes an apheresis procedure using the COBE SpectraTM machine on two separate occasions. The same donor is reserved for a second apheresis procedure 6-12 weeks after the first. Each time, 1.5 blood volumes are processed and approximately 100 mL of normal peripheral blood mononuclear cells and 50 mL of autologous plasma are collected. Second Half Pak from same donor is optional.

Combo Pak - AllCells also provides an option to obtain Bone Marrow (50 or 100 mL), Whole Peripheral Blood (up to 120 mL), and a Full Leuko Pak from the same donor at the same time. Any and all combinations of these products are available. Inquire for more information.

Leuko Pak Cell Number Ranges¼ Bag: Average: 0.37x1010 Range: 0.1 to 0.7x1010

½ Bag: Average: 0.75x1010 Range: 0.6 to 1x1010

1 Bag: Average: 1.5x1010 Range: 1 to 3.5x1010

Product Format Catalog # QTY/Unit Price/Unit

Fresh PB007-2

PB007-1

PB007

PB007-3A

PB007-3B

1/4 Bag

1/2 Bag

1 Bag

1st 1/2 Bag

2nd 1/2 Bag

Inquire

Inquire

Inquire

Inquire

Inquire

HLA-Typed Products are available upon request.

Prices are subject to change without notice. Visit www.allcells.com for current pricing.

NPB-Leuko Pak

Normal Peripheral Blood—Leuko Pak (Apheresis Collection)

Related Products G-CSF Mobilized Peripheral Blood Leuko Pak

Published Papers Xiao F., et al. (2013) The Genome of Polymorphonuclear NeutrophilsMaintains Normal Coding Sequences. PLoS ONE 8(11).http://www.allcells.com/publications/0203allcells.pdf

Application

NPB Leuko Paks can be used to: • Isolate large-scale dendritic cells.• Profile and screen normal peripheral blood monocytes

and lymphocytes. • Study intercellular interactions by using the same-donor

leukocytes directly or in culture.

Lead Time

A minimum of two weeks is needed.

For more information visit: www.allcells.com/leuko-pak/

No

rma

l P

eri

ph

era

l B

loo

d

36


No

rma

l P

eri

ph

era

l B

loo

d

For more information visit: www.allcells.com/leuko-pak/


Fresh WB001-ACD

WB001-NC

WB001-NH

WB001-VACD

WB001-VK2

WB001-VNH

WB002-ACD

WB002-NC

WB002-NH

WB002-VACD

WB002-VK2

WB002-VNH

WB003-ACD

WB003-NC

WB003-NH

WB003-VACD

WB003-VK2

WB003-VNH

WB004-ACD

60 ml

60 ml

60 ml

60 ml

60 ml

60 ml

120 ml

120 ml

120 ml

120 ml

120 ml

120 ml

180 ml

180 ml

180 ml

180 ml

180 ml

180 ml

240 ml

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire


Application

Whole Blood can be used to study: • Diagnostic or early detection tools for different

diseases, blood-related or unrelated. • Serum and plasma proteins and their pathway

functions, such as metabolism and immunity. • Therapeutic antibodies or other drug screenings.

Product Description

Whole blood (WB) is anti-coagulated using heparin(catalog# notation "NH"), ACD:A(catalog# notation "ACD"), EDTA (catalog# notation "K2") or sodium citrate(catalog# notation "NC") per customer specification. Our standard anticoagulant is heparin (5 U/ml of WB). The volume of whole blood removed per donation may vary, but will not exceed 470 mL at any one time. Whole blood collection quantities are in volume increments of 60 mL up to a maximum of 470 mL however custom collections in increments of 10 ml are available upon request. Please contact us if smaller volumes are needed. WB can be collected in vacutainer tubes("V" in catalog number), syringes, or transfer packs.

Normal Peripheral Blood—Whole Blood

Lead Time

A minimum of 1-2 week is needed.

ALLCELLS

37


Published PapersNoto, Paul B., et al. (2012) Regulation of Sphingomyelin Phospho-diesterase, acid-like 3A gene (SMPDL3A) by Liver X Receptors. Molecular Pharmacology, 112.078865. http://www.allcells.com/publications/0162allcells.pdf

Zhao, Zhiwei, et al. (2008) Induction of CYP4F3 by Benzene Metabo-lites in Human White Blood Cells in Vivo Promeylocytic Leukemic Cell Lines and ex Vivo in Human Blood Neutrophils. Drug Metabolism and Disposition, 37 (2), 282-291. http://www.allcells.com/publications/0083allcells.pdf

Vose, Sara C., et al. (2007) Lysophosphatidylcholine Hydrolases of Human Erythrocytes, Lymphocytes and Brain: Sensitive Targets of Conserved Specificity for Organophosphorus Delayed Neurotoxicants. Toxicol Appl Pharmacol., 224(1), 98–104.http://www.allcells.com/publications/0089allcells.pdf


Fresh WB004-NC

WB004-NH

WB004-VACD

WB004-VK2

WB004-VNH

WB005-ACD

WB005-NC

WB005-NH

WB005-VACD

WB005-VK2

WB005-VNH

WB006-ACD

WB006-NC

WB006-NH

WB007-ACD

WB007-NC

WB007-NH

WB008-ACD

WB008-NC

WB008-NH

240 ml

240 ml

240 ml

240 ml

240 ml

300 ml

300 ml

300 ml

300 ml

300 ml

300 ml

360 ml

360 ml

360 ml

420 ml

420 ml

420 ml

470 ml

470 ml

470 ml

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire



NPB-WB

Normal Peripheral Blood—Whole Blood

Lead Time

A minimum of 1-2 week is needed.

No

rma

l P

eri

ph

era

l B

loo

d

Product Description

Whole blood (WB) is anti-coagulated using heparin, ACD:A or EDTA per customer specification. Our standard anticoagulant is heparin (5 U/ml of WB). The volume of whole blood removed per donation may vary, but will not exceed 470 mL at any one time. Whole blood collection quantities are in volume increments of 60 mL up to a maximum of 470 mL however custom collections in increments of 10 ml are available upon request. Please contact us if smaller volumes are needed. WB can be collected in vacutainer tubes("V" in catalog number), syringes, or transfer packs.

38


No

rma

l P

eri

ph

era

l B

loo

d


Fresh PB017

PB018

PB019

PB020

PB021

PB022

PB023

10 ml

20 ml

30 ml

40 ml

50 ml

100 ml

150 ml

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Frozen PB017F

PB018F

PB019F

PB020F

PB021F

PB022F

PB023F

10 ml

20 ml

30 ml

40 ml

50 ml

100 ml

150 ml

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire

Inquire


NPB-Plasma

Product Description

NPB Plasma is obtained from healthy donors through the COBE Spectra™ apheresis machine. Between 50 and 150 mL of autologous plasma is collected at the same time as the mononuclear cells.

Application

NPB-Plasma can be used to:• Analyze blood plasma components.• Study plasma transfusion efficiency for coagulopathy

and liver diseases.• Function as source of serum if platelets, fibrinogen, and

other coagulating factors are removed.• Serve as a control in studies on Factor VIII and

coagulopathies, such as hemophilia.

Lead Time

A minimum of 1-2 weeks is needed.

Related ProductsALL PlasmaAML PlasmaCB Plasma

Published PapersFrancisco, Joseph A. et al. (2003). cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 102(4), 1458-1465. http://www.allcells.com/publications/0050allcells.pdf

Normal Peripheral Blood—Plasma

ALLCELLS

39



Fresh PB001

PB002

150 million/vial

350 million/vial

Inquire

Inquire

Frozen PB003F

PB006F

PB004F

PB005F

15 million/vial

25 million/vial

50 million/vial

100 million/vial

Inquire

Inquire

Inquire

Inquire



NPB-MNC

Product Description

Mononuclear cells are collected from fresh blood during apheresis into Leuko Paks which enriches lymphocytes and monocytes while depleting mature granulocytes. The mononuclear fraction is then further processed to eliminate red blood cells and platelets.

Application

NPB-MNC can be used to:• Isolate and study MNC subpopulations.• Act as controls for therapeutic research, involving

lymphocytes and monocytes.• Study the relationship among MNC subpopulation

(for example, the relationship among T Cells, B Cells, and monocytes)

• Research anti-GVHD drugs.

Lead Time

A minimum of two weeks is needed for fresh cells.

Table: NPB Cell Subset Products

NPB Cell Subsets Average Percentage in MNC

CD34+ 0.2%

CD3+ 60%

CD4+ 30%

CD8+ 23%

CD14+ 15%

CD19+ 9%

CD56+ 7%

Basophils 0.3%

Neutrophils and Eosinophils 0.2%

RBC <0.01%

Platelets <0.01%

The table above is for reference purposes only. Please note that the average percentage of cell subsets is referring to the recovered MNC population and not the total white blood cell population. We cannot guarantee the recovery of purifica-tion products listed above. For a specific number of a certain cell type, please consider our normal peripheral blood purified products.

Normal Peripheral Blood—Mononuclear Cells

Related ProductsMPB-MNC BM-MNC CB-MNC

Published Papers

Arastu-Kapur, Shirin, et al. (2011) Nonproteasomal Targets of the Protea-some Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clinical Cancer Research, 17, 2734. http://www.allcells.com/publications/0160allcells.pdf

Xu, Yuanxin, et al. (2008) Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detec-tion of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. Journal of Translational Medicine, 6(61). http://www.allcells.com/publications/0033allcells.pdf

No

rma

l P

eri

ph

era

l B

loo

d

40


No

rma

l P

eri

ph

era

l B

loo

d


Fresh PB032-1

PB032-2

0.5 million/vial

1 million/vial

Inquire

Inquire

Frozen PB033F-1

PB033F-2

PB033F-3

0.2 million/vial

0.5 million/vial

1 million/vial

Inquire

Inquire

Inquire



NPB-CD34+ Stem/Progenitor Cells

Lead Time


Product Description

NPB-CD34+ stem/progenitor cells (NPB-CD34+) are positively isolated from mononuclear cells using an immunomagnetic CD34 MicroBead labeling system.

Application

NPB-CD34+ cells can be used to:• Study expansion, lineage generation, and transplantation

potentials. • Serve as an alternative, less invasive blood source, to

bone marrow.

Note: NPB-CD34+ cells require more source volume due to low percentages in peripheral blood.

Related ProductsBM-CD34+ Cells CB-CD34+ Cells MPB-CD34+ Cells

Published PapersMack, Amanda A., et al. (2011) Generation of Induced Pluripotent Stem Cells from CD34+ Cells across Blood Drawn from Multiple Do-nors with Non-Integrating Episomal Vectors. PLoS ONE, 6(11). http://www.allcells.com/publications/0138allcells.pdf

Iancu-Rubin, Camilia, et al. (2011) Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood, 117(17). http://www.allcells.com/publications/0149allcells.pdf

Dongjiu, Ye, et al. (2009) Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syn-dromes and acute myeloid leukemia. J Hematopathol, 2, 2-8. http://www.allcells.com/publications/0034.pdf

Normal Peripheral Blood—Stem/Progenitor Cells—CD34+ Cells

Purity

The purity is guaranteed to be at least 85% as assessed by flow cytometric analysis.

ALLCELLS

41


Cell Products


Fresh PB010 10 million/vial Inquire

Frozen PB010F 10 million/vial Inquire

Positively Selected Cell Products

Fresh PB010-P 10 million/vial Inquire

Frozen PB010-P-F 10 million/vial Inquire



NPB-CD19+ B Cells

Product Description

Untouched NPB-CD19+ B Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic labeling system.

Positively Selected NPB-CD19+ B Cells are directly isolated from mononuclear cells using immunomagnetic CD19 MicroBeads.

Application

NPB-B Cells can be used to research:• Cell-mediated immunity pathway • B cell activation and cloning mechanisms • Genetic rearrangements of immunoglobulins• Antigen presentation • Recognition mechanisms • Cloning of memory and plasma cells • Antibody and immunoglobulin secretion • Toll-like receptors

Purity

Untouched NPB-CD19+ B Cells: The purity is guaranteed to be at least 85% as assessed by flow cytometric analysis.

Positively Selected NPB-CD19+ B Cells: The purity is guaranteed to be at least 90% as assessed by flow cytometric analysis.

Lead Time


Related ProductsCB-B Cells MPB-B Cells

Published PapersAkers, Stephen M., et al. (2010) VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers. ISEH-So-ciety for Hematology and Stem Cells, doi: 10.1016/j.exphem.2010.05.001.

Mahadevan, Daruku, et al. (2009) Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3, and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival, and Migration. SAGE-Hindawi Access to Research Human Genomics and Proteomics, 2009. http://www.allcells.com/publications/0064allcells.pdf

Baysa, Bora E., et al. (2007) A Recurrent Stop-Codon Mutation in Suc-cinate Dehydrogenase Subunit B Gene in Normal Peripheral Blood and Childhood T-Cell Acute Leukemia Bora E. PLoS ONE, 5(e46). http://www.allcells.com/publications/0012allcells.pdf

Normal Peripheral Blood—B Cells—CD19+ B Cells

No

rma

l P

eri

ph

era

l B

loo

d

42


No

rma

l P

eri

ph

era

l B

loo

d

Normal Peripheral Blood—B Cells—CD19+/IgD+ Naïve B Cells

Product Description

NPB-CD19+/IgD+ B cells are negatively isolated from MNC using immunomagnetic isolation system to deplete non-naive B cells.

Application

NPB-Memory B Cells can be used to study:• Cell-mediated immunity pathway• B cell activation and cloning mechanisms• Signal transductions• Antigen uptake and presentation• Antibody and immunoglobulin secretion• Cognate interaction of naive B cells with T helper

cells or dendritic cells

Purity


Lead Time


Cell Products


Fresh/Untouched PB010-3 1 million/vial Inquire

Frozen/Untouched PB010-3F 1 million/vial Inquire



NPB-CD19+/IgD+ B Cells

ALLCELLS

43


Cell Products


Fresh PB009-1 20 million/vial Inquire

Frozen PB009-1F 20 million/vial Inquire



NPB- Pan T Cells (CD3+)

Product Description

NPB-Pan T Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic Pan-T labeling sys-tem.

Application

NPB-Pan T Cells can be used to research the following:• T cell activation• Maintenance of the naïve T cells (CD45RA+) • Transformation to memory (CD45RO+) and or regulatory

(CD25+) T cells, and their respective functions • Intercellular T-cell regulatory and activation pathways• Antigen presentation and other receptor pathways• Recognition mechanisms

Related ProductsCB-Pan T Cells MPB-Pan T Cells

Published PapersYang, Jianchang, et al. (2008) SALL4 is a key regulator of sur-vival and apoptosis in human leukemic cells. Blood. doi: 10.1182/blood-2007-11-126326.http://www.allcells.com/publications/0106allcells.pdf

Mahadevan, Daruku, et al. (2005) Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lym-phoma identifies distinct tumor profile signatures. Mol Cancer Ther, 4(12). http://www.allcells.com/publications/0112allcells.pdf

Begovich, Ann B., et al. (2004) A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with Rheumatoid Arthritis. Am. J. Hum. Genet., 75, 330-337. http://www.allcells.com/publications/0022allcells.pdf

Purity


Lead Time

A minimum of two weeks is needed for fresh cells. Frozen products are subject to stock availability.

Normal Peripheral Blood—T Cells—CD3+ Pan T Cells

No

rma

l P

eri

ph

era

l B

loo

d

44


No

rma

l P

eri

ph

era

l B

loo

d

Cell Products






NPB-CD4+ Helper T Cells

Product Description

NPB CD4+ Helper T cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD4+ T cell labeling system.

Application

NPB-CD4+ Helper T Cells can be used to study:• Effect on B cell antibody class switching • HIV infection mechanisms and therapeutic research • Antigenic presentation, intracellular activation

mechanisms, and learned immunity • Mechanism and therapeutics of hypersensitivity and

autoimmune disease

Purity


Lead Time


Normal Peripheral Blood—T Cells—CD4+ Helper T Cells

Related ProductsCB-CD4+ T Cells MPB- CD4+ T Cells

Published PapersMahadevan, Daruku, et al. (2005) Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lym-phoma identifies distinct tumor profile signatures. Mol Cancer Ther, 4(12). http://www.allcells.com/publications/0112allcells.pdf

Lu, Xiaobin, et al. (2004) Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance. Journal of Virology, 78(13), 7079-7088. http://www.allcells.com/publications/0043allcells.pdf

Begovich, Ann B., et al. (2004) A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with Rheumatoid Arthritis. Am. J. Hum. Genet., 75, 330-337. http://www.allcells.com/publications/0022allcells.pdf

ALLCELLS

45


Cell Products






NPB-CD4+/CD25+ T Cells

Product Description

First, CD4+ T Cells are isolated using an indirect immunomagnetic depletion. Next, CD25+ cells are positively isolated using CD25 MicroBeads, leaving a highly purified CD4+/CD25+ Regulatory T Cell population.

Application

NPB-CD4+/CD25+ Regulatory T Cells can be used to study:• Homeostasis in the immune system. • Hypersensitivity and autoimmunity. • Methods to improve the body’s defense against infection

and tumors. • Activated T cells

Purity


Lead Time


Normal Peripheral Blood—T Cells—CD4+/CD25+ T Cells

No

rma

l P

eri

ph

era

l B

loo

d

46


No

rma

l P

eri

ph

era

l B

loo

d

Cell Products






NPB-CD4+/CD45RA/CD25- Naïve Helper T Cells

Product Description

NPB-CD4+/CD45RA+/CD25- Naive Helper T Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD4+/CD45RA+/CD25- labelling system.

NPB-CD4+/CD45RA+ Naïve T Cells can be used to study:• Naïve T cell activation• Memory T Cell training and activation for long-term

immunity

Purity


Lead Time


Related ProductsCB-CD4+/CD45RA+ T Cells

Normal Peripheral Blood—T Cells—CD4+/CD45RA+/CD25- Naïve Helper T Cells

Application

ALLCELLS

47


Cell Products






NPB-CD4+/CD45RO+ Memory T Cells

Product Description

NPB-CD4+ Memory T Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD4+/CD45RO+ labelling system.

Application

NPB-CD4+/CD45RO+ Memory T Cells can be used to study:• The capacity for self-renewal (as a result of high levels of

phosphorylation and the transcription factor STAT5) • Memory T cell development and maintenance specificity

for different antigens• Memory T Cell activation mechanisms and pathways

Purity


Lead Time


Normal Peripheral Blood—T Cells—CD4+/CD45RO+ Memory T Cells

No

rma

l P

eri

ph

era

l B

loo

d

48


No

rma

l P

eri

ph

era

l B

loo

d

Cell Products






NPB-CD8+ Cytotoxic T Cells

Purity


Lead Time


Product Description

NPB-CD8+ Cytotoxic T cells are negatively isolated from mono-nuclear cells using an indirect immunomagnetic CD8+ T cell labeling system.

Application

NPB-CD8+ T Cells can be used to study:• VDJ recombination mechanisms of the TcR (T cell

receptor), self/non-self recognition, and autoimmunity• Cytotoxic cell lysis and platelet activation to infected

tissues or organs • Defense mechanisms against tumor and viral infections

Normal Peripheral Blood—T Cells—CD8+ Cytotoxic T Cells

Related ProductsCB-CD8+ T Cells MPB- CD8+ T Cells

Published PapersBegovich, Ann B., et al. (2004) A Missense Single-Nucleotide Polymorphism in a Gene Encoding a Protein Tyrosine Phosphatase (PTPN22) Is Associated with Rheumatoid Arthritis. Am. J. Hum. Genet., 75, 330-337. http://www.allcells.com/publications/0022allcells.pdf

ALLCELLS

49


Cell Products






NPB-CD8+/CD45RA+ Naive Cytotoxic T Cells

Product Description

NPB-CD8+/CD45RA+ Naive Cytotoxic T cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD8+/CD45RA+ T cell labeling system.

Application

NPB-CD8+/CD45RA+ Naïve Cytotoxic T Cells can be used to study:• Homeostasis of Naive Cytotoxic T Lymphocytes in its

surrounding repertoire• Activation of Naïve Cytotoxic T Lymphocytes• Methods to redirect the Cytotoxic T Lymphocytes learning

pathway for autoimmune therapy • In vitro engineering to fight specific targets, such as

viruses or tumors

Purity


Lead Time


Normal Peripheral Blood—T Cells—CD8+/CD45RA+ Naive Cytotoxic T Cells

No

rma

l P

eri

ph

era

l B

loo

d

50


No

rma

l P

eri

ph

era

l B

loo

dPositively Selected Cell Products


Frozen PB013F 0.5 million/vial Inquire



NPB-BDCA4+ Lymphoid/Plasmacytoid Dendritic Cells

Product Description

NPB-BDCA4+ Lymphoid/Plasmacytoid Dendritic cells have been positively isolated from mononuclear cells using immunomagnetic BDCA-4 MicroBead labeling system. BDCA-4 is marker for CD11c-, CD123bright (lymphoid) dendritic cells. NPB-BDCA4+ cells possess plasmacytoid morphology and express the CD45RA cell marker. BDCA-4 is not detectable on the cell surface of other blood cells.

Application

NPB-BDCA4+ cells can be used to study:• Antigen presentation • Activation of toll-like receptors and other pattern

recognition receptors of viral immunity pathways • Interferon alpha secretion • Potential uses in anti-tumor research

Purity


Lead Time


Normal Peripheral Blood—Dendritic Cells—BDCA4+ Lymphoid/Plasmacytoid Dendritic Cells

Related ProductsMPB-BDCA4+ T Cells


ALLCELLS

51


Cell Products





Fresh PB012-P 5 million/vial Inquire

Frozen PB012-P-F 5 million/vial Inquire



NPB-CD56+ Natural Killer Cells

Purity

Untouched NPB-CD56+ Cells: The purity is guaranteed to be at least 85% as assessed by flow cytometric analysis.

Positively Selected NPB-CD56+ Cells: The purity is guaranteed to be at least 90% as assessed by flow cytometric analysis.

Normal Peripheral Blood—CD56+ Natural Killer Cells

Product Description

Untouched NPB-CD56+ Natural Killer (NK) cells are negatively selected from mononuclear cells using an indirect immunomagnetic NK cell labeling system to deplete the non-CD56+ NK cells.

Positively Selected NPB-CD56+ NK cells are directly isolated from mononuclear cells using direct immunomagnetic CD56 MicroBeads.

Application

NPB-NK Cells can be used to study:• Innate immune system against tumors and viral infections• Inhibitory receptor recognition and activation • Cytolytic mechanisms • Antibody dependent cellular cytotoxicity assay (ADCC) • FcR binding affinity • Therapeutic antibody development

Lead Time

A minimum of two weeks is needed for fresh cells. For all other products, product delivery is subject to stock availability.

Related ProductsCB Natural Killer Cells MPB Natural Killer Cells


No

rma

l P

eri

ph

era

l B

loo

d

52


No

rma

l P

eri

ph

era

l B

loo

dProduct Format Catalog # QTY/Unit Price/Unit

Fresh PB014 0.3 million/vial Inquire

Frozen PB014F 0.3 million/vial Inquire



NPB-Basophils

Product Description

NPB-Basophils are isolated from peripheral blood mononuclear cells using an indirect immunomagnetic basophil labeling system.

Application

NPB-Basophils can be to study the following: • Inflammatory responses, involving mast cell differentiation,

IgE expression, and histamine release. The study of these responses and pathways can lead to remedies for allergy and asthma.

• Anti-allergy remedies, such as transient transfection of basophils (inhibiting IgE expression) and other extracellular methods of basophil suppression.

Purity


Lead Time


Related ProductsBM-Basophils

Normal Peripheral Blood—Myeloid Cells—Basophils

ALLCELLS

53







NPB-Eosinophils

Purity


A minimum of one week is needed for fresh cells.

Product Description

RBC depleted leukocytes are collected from peripheral blood by sedimentation of red blood cells using HetaSep. Then, the granulocytes are isolated by density gradient separation and further processed to deplete any remaining RBC. Finally, the eosinophils are isolated using an indirect immunomagnetic labeling system.

Application

NPB-Eosinophils can be used to study:• Post-pubertal mammary gland development• Estrous cycles • Allograft rejection• Neoplasia • Antigenic presentation to T cells • Treatment and prevention for atopic dermatitis• Degranulation and release mechanisms for peroxidases,

nucleases, plasminogens, and major basic proteins• Cytokine and interleukin release by activation

Related ProductsBM-EosinophilsCB-Eosinophils

Normal Peripheral Blood—Myeloid Cells—Eosinophils

Lead Time

No

rma

l P

eri

ph

era

l B

loo

d

54


No

rma

l P

eri

ph

era

l B

loo





Product Description

RBC depleted leukocytes are collected from peripheral blood by sedimentation of red blood cells using HetaSep. Then, the granulocytes are isolated by density gradient separation and further processed to deplete any remaining RBC. Finally, the neutrophils are isolated using an indirect immunomagnetic labeling system.

Application

NPB-Neutrophils can be used to study:• Acute inflammation and tissue injury response • Degranulation mechanisms• Function of neutrophils to form NET (neutrophil extra-

cellular traps) that act as a bacterial killing pathway independent of phagocytosis

• Neutropenia (naturally occurring or chemotherapy induced).

Purity


Lead Time

A minimum of one week is needed for fresh cells.

Normal Peripheral Blood—Myeloid Cells—Neutrophils

Related ProductsBM-Neutrophils CB-Neutrophils

Published PapersZhao, Zhiwei, et al. (2008) Induction of CYP4F3 by Benzene Metabo-lites in Human White Blood Cells in Vivo Promeylocytic Leukemic Cell Lines and ex Vivo in Human Blood Neutrophils. Drug Metabolism and Disposition, 37 (2), 282-291.http://www.allcells.com/publications/0083allcells.pdf

Brogdon, Jennifer, et al. (2007). Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood, 109(3), 1123-1130.

NPB-Neutrophilis

ALLCELLS

55



Fresh PB029

PB030

PB031

80 billion/vial

160 billion/vial

240 billion/vial

Inquire

Inquire

Inquire



NPB-Mature Erythrocytes / Red Blood Cells

Product Description

NPB Mature Erythrocytes, also referred to as red blood cells (RBC), are obtained from normal peripheral blood using filtration method.

Application

NPB-RBC can be used to study anemia caused by (but not limited to):

• Sickle cell disease• Thalassemia• Spherocytosis• Pernicious anemia• Aplastic anemia• Pure red blood cell aplasia• Hemolysis

Purity


Lead Time

A minimum of one week is needed.

Normal Peripheral Blood—Myeloid Cells—Mature Erythrocytes(RBC)

No

rma

l P

eri

ph

era

l B

loo

d

56


No

rma

l P

eri

ph

era

l B

loo


Fresh PB025

PB026

PB027

PB028

5 billion/vial

10 billion/vial

20 billion/vial

30 billion/vial

Inquire

Inquire

Inquire

Inquire



NPB-Platelets

Lead Time


Product Description

NPB-Platelets are obtained from healthy donors with the collection of maximum three-blood volumes on a COBE Spectra™ apheresis machine. The platelets are shipped in platelet-rich plasma.

Application

NPB platelets can be used to study the following:• Aggregation and coagulation mechanisms

and pathways• Atherosclerosis • Coronary artery disease • Myocardial infarction • Cerebrovascular diseases • Stroke • Peripheral artery occlusive disease• Cancer, including prevention and treatment of transfusion

related complications

Published PapersKubota, Satoshi, et al. (2004). Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. Journal of Biochemistry, 136(3), 279-282.

Normal Peripheral Blood—Myeloid Cells—Platelets

ALLCELLS

57


Cell Products





Fresh PB011-P-1

PB011-P-2

PB011-P-3

10 million/vial

20 million/vial

40 million/vial

Inquire

Inquire

Inquire

Frozen PB011-P-F-1

PB011-P-F-2

PB011-P-F-3

10 million/vial

20 million/vial

40 million/vial

Inquire

Inquire

Inquire



NPB-CD14+ Monocytes

Purity

The purity is guaranteed to be at least 85% for untouched monocytes, and at least 90% for positively selected monocytes.

Lead Time


Product Description

Untouched NPB-CD14+ Monocytes are indirectly isolated from mononuclear cells using an immunomagnetic labeling system.

Positively-Selected NPB-CD14+ Monocytes are directly isolated from mononuclear cells using an immunomagnetic CD14 MicroBead labeling system.

Application

NPB-CD14+ Monocytes can be used to study:• Post-pubertal mammary gland development • Estrous cycle• Allograft rejection• Neoplasia • Antigenic presentation to T cells • Treatment and prevention for atopic dermatitis• Toll-like receptors and other pattern recognition

receptors

Normal Peripheral Blood—Myeloid Monocytes—CD14+ Monocytes

Related ProductsCB- MonocytesMPB-Monocytes

Published Papers Wang, Jinghong, et al. (2006) Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35. The Journal of Biological Chem-istry, doi: 10.1074/jbc.M6035003200.http://www.allcells.com/publications/0085allcells.pdf

Braselmann, Sylvia, et al. (2006). R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation. Journal of Pharmacology and Experimental Therapeutics, 319, 998-1008.http://www.allcells.com/publications/0101allcells.pdf

No

rma

l P

eri

ph

era

l B

loo

d

58


No

rma

l P

eri

ph

era

l B

loo

d

Cell Products


Frozen PB-DC001F 1.5 million/vial Inquire



NPB-Monocyte-Derived Myeloid Dendritic Cells

• Purity

These cells express the following markers: CD11c, CD40, and CD86 (>90%). These cells lack the expression of CD14 (<10%).

A minimum of two weeks is needed for fresh cells. Product delivery is subject to stock availability.

Product Description

NPB-Monocyte Derived Myeloid Dendritic Cells (MoDC) are derived from highly purified monocytes. For six to seven days, the highly purified monocytes are cultured with 10% Fetal Bovine Serum in the presence of GM-CSF and IL-4. MoDC have a longer lifespan in vitro when kept inactivated, which allows them to have a longer storage in culture.

Application

Monocyte Derived Myeloid DC can be used to study:• Antigenic endocytosis, processing, and presentation

mechanism and pathway• DC-SIGN receptor expression and its relation to HIV

infection• Toll-like receptors and other pattern recognition receptors

Normal Peripheral Blood—Monocyte—Derived Myeloid Dendritic Cells

Lead Time

ALLCELLS

59


Cell Products


Frozen PB-MDM-001F 1.5 million/vial Inquire

Media

Macrophage Basal Medium PB-MDM-002 450 ml Inquire

Macrophage Stimulatory

SupplementPB-MDM-003 50 ml Inquire



NPB-Monocyte-Derived Macrophages

Product Description

NPB-Macrophages are derived from highly purified peripheral blood monocytes and stimulated with M-CSF and IL-4 growth factors and cultured for 6-7 days.

Application

Monocyte-Derived Macrophages can be used to study the following:• Inflammation• Antigen presentation• T-Cell activation• Phagocytosis pathways• Atherosclerosis• HIV infection• Toll-like receptors and other pattern recognition

receptors

Purity

These cells have phagocytic properties and express the following markers: MHC class II (>80%), CD163 (>80%), CD18 (>80%) and CD32 (>80%).

Macrophage Basal Medium

Product Description

This product contains L-glutamine, 110mg/L sodium pyruvate, and pyridoxine hydrochloride. This product does not contain growth factors and antibiotics. pH >7.1 to <7.5. The Mac-rophage Basal Medium should be used in combination with AllCells Macrophage Stimulatory Supplement. This product is stable for one month after the stimulatory supplement has been added and stored at 2 to 8°C.

Macrophage Stimulatory Supplement

Product Description

Macrophage Stimulatory Supplement is designed to initiate and maintain growth of AllCells Monocyte Derived Macrophages. This product contains pre-selected Fetal Bovine Serum and supplements.

Lead Time

1-2 business days for frozen products. Product delivery is sub-ject to stock availability.

Normal Peripheral Blood—Monocyte-Derived Macrophages

No

rma

l P

eri

ph

era

l B

loo

d

60


MOBILIZED PERIPHERAL BLOOD

Mobilized Peripheral Blood

AllCells has been a pioneer in the use of G-CSF (Granulocyte-Colony Stimulating Factor) stimulation in normal healthy donors since

1998. The protocols in use for our Mobilized Peripheral Blood (MPB) products have been approved by an IRB and are overseen by clinical

physicians. In addition AllCells offers Plerixafor (Mozobil®) or a combination of Plerixafor (Mozobil®) and Neupogen mobilization of stem cells

from healthy donors. Mozobil, a selective CXCR4 antagonist, has been particularly beneficial as an adjuvant stem cell mobilization agent on top of

the G-CSF regimen. The Mozobil regimen requires only 1 injection as opposed to the G-CSF 3-5 day protocol.

All donors are monitored during the injection, collection and post-collection procedures to ensure the health of our donors is a priority.

AllCells is one of only a few providers of Mobilized Peripheral Blood in the world.

Please specify which mobilization factor you prefer when ordering.

Background

Granulocyte-Colony Stimulating Factor (G-CSF, Neupogen®) can stimulate bone marrow to produce a large number of hematopoietic

stem/progenitor cells. G-CSF can mobilize these stem/progenitor cells from bone marrow into the peripheral blood stream. The effects

of G-CSF have changed the practice of bone marrow transplantation. Consequently, mobilized peripheral blood cells (MPB) have become

major sources for clinical hematopoietic stem cell transplantation.

Donor Criteria

Mobilized Peripheral Blood Table of Contents

Apheresis Collection (Leuko Pak) 61


CD34 Depleted Mononuclear Cells 63

Stem/Progenitor Cells - CD34+ 64


Monocytes - CD14+ 66

For more information visit: www.allcells.com/mobilized-peripheral-blood/

• Age 18-40 years old

• Weight >140 lbs for Leuko Pak

• Complete Blood Count lab test must meet protocol specs


• Donors are screened for HIV, Hepatitis B & C

• Donors must be in good health

• Donors are required to sign consent form prior to collection

• All consent and protocols approved by an IRB

• Minimum 12 months between donations

• Twice-in-a-lifetime maximum donation

ALLCELLS

61


Product Description

One-Day G-CSF MPB-Leuko Pak- This product is obtained by 5.0-9.6 µg/kg/day of G-CSF injections for 3-5 days and apheresis on Day 5 (see regimen table below).

Leuko Pak Cell Number RangesMNC Avg. Cell Number: 2.3x1010 Range: 0.9 to 5.6x1010

CD34+ Avg. Cell Number: 1.86x108 Range: 0.6 to 4.8x108

One-Day Mozobil MPB-Leuko Pak- This product is ob-tained by a 20 mg/ml, 1.2 ml single dose of Mozobil and apher-esis 9-11 hours post injection.

Two-Day G-CSF MPB-Leuko Pak- This product is obtained by 6.9 µg - 9.0 µg/kg/day (depending on the donor’s weight) of G-CSF injections for 5 days and apheresis on Day 5 and Day 6 (1 bag delivery per day).

Leuko Pak Cell Number RangesMNC Avg. Cell Number: 6.0x1010 Range: 1.2 to 12.4x1010

CD34+ Avg. Cell Number: 4.5x108 Range: 0.9 to 8.1x108

Application

MPB-Leuko paks can be used to:

• Study post-stimulation effects of Neupogen® (G-CSF) or Mozobil® (Plerixafor) on general profiles and individual

MNC phenotypes. • Enrich CD34+ human stem cells for further culture

studies.

Lead Time

A minimum of four weeks is needed.

Related Products

NPB-Leuko Pak

Published PapersChy-Anh Tran, et al. (2012). Optimized Processing of Growth Factor Mobilized Peripheral Blood CD34 Products by Counterflow Centrifugal Elutriation. Stem Cells Translational Medicine, 1(5) http://www.allcells.com/publications/0144allcells.pdf

Campbell-Anson, Ryan E., et al. (2008). A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. Journal of Immune Based Therapies and Vac-cines, 6(1) http://www.allcells.com/publications/0003allcells.pdf

Mahmood, Kutubuddin, et al. (2005). Human cytomegalovirus plasmid-based amplicon vector system for gene therapy. Genetic Vaccines Therapy, 3, 1. Retrieved June 20, 2008,http://www.allcells.com/publications/0075allcells.pdf

Hoffman, Joseph F., et al. (2002). Na pump isoforms in human erythroid progenitor cells and mature erythrocytes. PNAS, 99(22), 4572–14577.

Mahmud, Dolores L., et al. (2002). Phosphorylation of forkhead tran-scription factors by erythropoietin and stem cell factor prevents acetyla-tion and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene, 21, 1556–1562. http://www.allcells.com/publications/0098allcells.pdf


Fresh−Leuko Pak (One-day) mPB025-Moz.A 1 Bag Inquire

Fresh−Leuko Pak (One-day) mPB025-Reg.E 1 Bag Inquire

Fresh−Leuko Pak (Two-day) mPB026 2 Bags Inquire



Mobilized Peripheral Blood (MPB)-Leuko Pak

Mobilized Peripheral Blood—Apheresis Collection—Leuko Pak

Product Regimen Qty

mPB025-Moz.A Mozobil @20 mg/ml, 1.2 ml single dose - Regimen A, apheresis 9-11 hours post injection 1 bag

mPB025-Reg.E G-CSF @5 µg/kg/day x 5 days - Regimen E, apheresis on day 5 1 bag

mPB026 G-CSF @6.9-9 µg/kg/day - Regimen C, apheresis on days 5 and 6 (2 bags) 2 bags

Mo

bil

ize

d P

eri

ph

era

l B

loo

d

62


Mo

bil

ize

d P

eri

ph

era

l B

loo

d

Product Description

These mononuclear cells (MNC) are collected using the COBE Spectra™ apheresis machine (>90% of the cells are MNC). These MPB-MNC products have been depleted of red blood cells and platelets.

Lead Time

A minimum of four weeks is needed for fresh cells. Product delivery is subject to stock availability.

Cell Products


Fresh mPB001

mPB002

mPB003

150 million/vial

250 million/vial

350 million/vial

Inquire

Inquire

Inquire

Frozen mPB004F

mPB005F

mPB006F

mPB007F

mPB008F

5 million/vial

15 million/vial

25 million/vial

50 million/vial

100 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire



MPB-Mononuclear Cells

MPB Cell Subsets Average Percentage of Cell Subsets

CD34+ 0.8%

CD133+ 0.6%

CD3+ 33%

CD4+ 18%

CD8+ 6%

CD14+ 25%

CD16+ 16%

CD19+ 5%

CD33+ 35%

CD56+ 6%

CD15+ 0.11%

The table above is for reference purposes only. Please note that the average percentage of cell subsets is referring to the recovered MNC population and not the total white blood cell population. We cannot guarantee the recovery of purifi-cation products listed above. For a specific number of a certain cell type, please consider our mobilized peripheral blood purified products.

Mobilized Peripheral Blood—Mononuclear Cells

Related Products

NPB-MNC

Published PapersLund, Troy C., et al. (2008). Granulocyte colony-stimulating factor mo-bilized CFU-F can be found in the peripheral blood but have limited expansion potential. haematologica, 93(6) http://www.allcells.com/publication/0068allcells.pdf

Mahmud, Dolores L., et al. (2002). Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene, 21, 1556–1562. http://www.allcells.com/publications/0098allcells.pdf

ALLCELLS

63


Product Description

MPB-CD34 Depleted MNC are isolated using immunomagnetic CD34 MicroBead labeling system to deplete the CD34+ cell population. This product contains only a minimal amount of CD34+ cells.

Application

MPB-CD34 Depleted MNC can be used to:• Serve as a cost-effective alternative source of

hematopoietic mononuclear cells, excluding the stem/progenitor cell population.

• Study the cell population profile changes within the mononuclear cells after G-CSF simulation.

• Research drugs that suppress GVHD for transfusion or transplantation purposes.

Lead Time


Related ProductsBM-CD34 Depleted MNCCB-CD34 Depleted MNC


Frozen mPB021F 100 million/vial Inquire



MPB-CD34-Depleted MNC

Mobilized Peripheral Blood—CD34 Depleted Mononuclear Cells

Mo

bil

ize

d P

eri

ph

era

l B

loo

d

64


Mo

bil

ize

d P

eri

ph

era

l B

loo

d

Cell Products


Fresh mPB009

mPB010

mPB011

mPB012

mPB013

1 million/vial

5 million/vial

10 million/vial

20 million/vial

30 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire

Frozen mPB014F

mPB015F

mPB016F

mPB017F

mPB018F

0.2 million/vial

1 million/vial

5 million/vial

10 million/vial

20 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire



MPB-CD34+ Stem/Progenitor Cells

Product Description

MPB-CD34+ Stem/Progenitor cells are positively selected using a direct immunomagnetic CD34 MicroBead labeling system.

Purity


Lead Time

A minimum of four weeks is needed for fresh cells.

Mobilized Peripheral Blood—Stem/Progenitor Cells—CD34+ Cells

Published PapersZhu, Xingguo, et al. (2012). NF-Y Recruits Both Transcription Activa-tor and Repressor to Modulate Tissue- and Developmental Stage-Specific Expression of Human c-Globin Gene. PLoS ONE, 7(10) http://www.allcells.com/publications/0172allcells.pdf

MacEneaney, Owen J., et al. (2011). Effects of HIV-1 GP120 and Protease Inhibitors on Apoptotic Susceptibility of CD34+ Hematopoi-etic Progenitor Cells. J Acquir Immune Defic Syndr., 56(2), 49–50. http://www.allcells.com/publications/0151allcells.pdf

ALLCELLS

65


Product Description

MPB-CD133+ Stem/Progenitor cells are positively isolated from MPB-MNC by using a direct immunomagnetic CD133 MicroBeads labeling system. The majority of CD133+ Stem/Progenitor cells also express the CD34 cell marker.

Application

MPB-CD133+ cells can be used to study expansion and dif-ferentiation capacity as nascent stem cells. MPB-CD34+ cells have the highest frequency of CD133 double-positive cells when compared to bone marrow and cord blood.

Cell Products


Fresh mPB023-1

mPB023-2

mPB023-3

mPB023-4

mPB023-5

0.5 million/vial

2.5 million/vial

5 million/vial

10 million/vial

20 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire

Frozen mPB024F-1

mPB024F-2

mPB024F-3

mPB024F-4

mPB024F-5

0.5 million/vial

2.5 million/vial

5 million/vial

10 million/vial

20 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire



MPB-CD133+ Stem/Progenitor Cells

Mobilized Peripheral Blood—Stem/Progenitor Cells—CD133+ Cells

Purity


Lead Time

A minimum of four weeks is needed. Product delivery is subject to stock availability.

Published PapersBissels, Ute, et al. (2011). Combined Characterization of microRNA and mRNA Profiles Delineates Early Differentiation Pathways of CD133+ and CD34+ Hematopoietic Stem and Progenitor Cells. STEM CELLS, 29(5). http://www.allcells.com/publications/0147allcells.pdf

Mo

bil

ize

d P

eri

ph

era

l B

loo

d

66


Mo

bil

ize

d P

eri

ph

era

l B

loo

d

Product Description

MPB-CD14+ Monocytes are positively isolated from MPB-MNC using a direct immunomagnetic CD14 MicroBeads labeling system.

Application

MPB-Monocytes can be used to study:• Down-regulation of T cells for allogeneic transplantation• The impact of G-CSF on the antigen-presenting and

macrophage-forming abilities of monocytes

Purity


Lead Time


Related ProductsCB-Monocytes NPB-Monocytes

Cell Products


Fresh mPB033-1

mPB033-2

mPB033-3

15 million/vial

25 million/vial

45 million/vial

Inquire

Inquire

Inquire

Frozen mPB033F-1

mPB033F-2

mPB033F-3

15 million/vial

25 million/vial

45 million/vial

Inquire

Inquire

Inquire



MPB-CD14+ Monocytes

Mobilized Peripheral Blood—CD14+ Monocytes

ALLCELLS

67


Bone Marrow Cells and Tissue

AllCells is able to provide whole bone marrow aspirate and bone marrow cells collected from healthy individuals. These bone

marrow products are available in fresh or frozen format.

Background

Bone Marrow (BM) contains hematopoietic stem/progenitor cells, which are self-renewing, proliferating, and differentiating

into multi-lineage blood cells. Multipotent, non-hematopoietic stem cells, such as bone marrow mesenchymal stem cells

(MSC), can be isolated from human bone marrow as well. These non-hematopoietic, bone marrow MSCs are capable of both

self-renewal and differentiation into bone, cartilage, muscle, tendons, and fat. 100 mL of bone marrow cells and tissue is

drawn into a 20 cc syringe x 12 tubes containing heparin (80 U/mL of BM) from the posterior iliac crest, at a maximum of

eight separate sites. Whole bone marrow products are diluted with PBS.

Donor Criteria

Bone Marrow Table of Contents

Aspirates (Whole Bone Marrow) 68



Stem/Progenitor Cells -CD34+ 71

Early Erythroid Progenitor Cells - CD36+ 72

Endothelial Cells - CD105+ 73

Mesenchymal Stem Cells 74

For more information visit: www.allcells.com/bone-marrow/

• Age: 18-65 years old

• Weight: >110 lbs for 25mL and 50mL donations

• Weight: >130 lbs for 100mL donations

• CBC lab tests must meet protocol specifications.



–History of heart, lung, liver, kidney disease (including asthma)

–Blood and bleeding disorders, including sickle cell disease

–Neurologic disorders

–Cancer

–Diabetes

–Positive: HIV, HbsAg, HCAb

• Donors cannot be pregnant.


before donation.


prior to the collection procedure.

• All consents and protocols have been approved by an

independent biomedical review board.

BONE MARROW

68



Fresh ABM001-1

ABM001

ABM002

ABM003

ABM004

3 ml

10 ml

25 ml

50 ml

100 ml

Inquire

Inquire

Inquire

Inquire

Inquire



BM-Whole

Product Description

Bone Marrow (BM) contains hematopoietic stem/progenitor cells, which have the potential to self-renew, proliferate, and differentiate into multi-lineage blood cells. Multipotent, non-hematopoietic stem cells, such as mesenchymal stem cells, can be isolated from human BM as well. These non-hematopoietic, mesenchymal stem cells are capable of both self-renewal and differentiation into bone, cartilage, muscle, tendons, and fat. BM is drawn into a 20 cc syringe containing heparin (80 U/mL of BM) from the posterior iliac crest, 25mL/site, from a maxi-mum of four sites. Whole BM products are diluted with PBS.

Application

BM can be used to:• Serve as a source for hematopoietic progenitor cells, mes-

enchymal stem cells, and other cell types, such as CD33+ myeloid cells and CD138+ plasma cells.

• Study hematopoietic cell differentiation pathways.• Act as controls for BM malignancies studies.

Lead Time


Related ProductsDiseased Bone Marrow Cells

Published Papers Oskouei, Behzad N., et al. (2012) Increased Potency of Cardiac Stem Cells Compared with Bone Marrow Mesenchymal Stem Cells in Cardiac Repair. Stem Cells Translational Medicine, 1(2) 116-124. http://www.allcells.com/publications/0143allcells.pdf

Yamaza, et al. (2010) Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Research & Therapy, 1(5). http://www.allcells.com/publications/0009allcells.pdf

Bone Marrow—Aspirates—Bone Marrow (Whole)

Bo

ne

Ma

rro

w

ALLCELLS

69


Product Description

BM-MNC are isolated by diluting bone marrow with PBS and using density gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate various subpopulations.

BM Cell Subset ProductsThe table below is for reference purposes only. Please note that the average percentage of cell subsets is referring to the recovered MNC population and not the total white blood cell population.

BM Cell SubsetsAverage Percentage of Cell Subsets

CD34+ 2.5%

CD133+ 1.1%

CD33+ 45%

CD105+ 0.7%

CD19+ 24%

CD14+ 7.8%

CD3+ 34%

Granulocytes 10%

RBC <0.01%

Platelets <0.01%

CD138+ Plasma Cells 0.1-0.4%

We cannot guarantee the recovery of the cell types listed above. For a specific number of a certain cell type, please consider our bone marrow purified products.


Fresh ABM024 25 million/vial Inquire

Frozen ABM007F

ABM008F

ABM009F

5 million/vial

15 million/vial

25 million/vial

Inquire

Inquire

Inquire



BM-MNC

Bone Marrow—Mononuclear Cells

Published Papers Novotny-Diermayr, V., et al. (2012) The oral HDAC inhibitor pracino-stat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer Journal, 2, e69. http://www.allcells.com/publications/0159allcells.pdf

Gao, N, et al. (2012) 3, 39-Diindolylmethane Exhibits Antileukemic Activity In Vitro and In Vivo through a Akt-Dependent Process. PLoS ONE, 7(2). http://www.allcells.com/publications/0141allcells.pdf

Majeti, Ravindra, et al. (2009) Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. PNAS, 106(9). http://www.allcells.com/publications/0060allcells.pdf

Seo, BM, et al. (2008) SHED repair critical-size calvarial defects in mice. Oral Dis. 14(5). http://www.allcells.com/publications/0107allcells.pdf

Bo

ne

Ma

rro

w

70


Bo

ne

Ma

rro

w


Frozen ABM023F 100 million/vial Inquire



BM-CD34 Depleted MNC

Product Description

BM-CD34 Depleted MNC are isolated using a direct immunomagnetic CD34 MicroBead labeling system to deplete CD34+ cells. This product contains only a minimal amount of BM-CD34+ cells.

Application

BM-CD34 Depleted MNC can be used to compare CFU-GM output with CD34+.

Related Products

CB CD34-Depleted MNC

Bone Marrow—CD34 Depleted Mononuclear Cells

Lead Time

1-2 business days for frozen products. Product delivery is subject to stock availability.

ALLCELLS

71



Fresh ABM009

ABM010

ABM011

ABM012

ABM013

0.1 million/vial

0.3 million/vial

0.5 million/vial

1 million/vial

5 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire

Frozen ABM015F

ABM021F

ABM022F

ABM017F

ABM018F

0.1 million/vial

0.3 million/vial

0.5 million/vial

1 million/vial

5 million/vial

Inquire

Inquire

Inquire

Inquire

Inquire



BM-CD34+ Stem/Progenitor Cells

Product Description

BM-CD34+ stem/progenitor cells are positively isolated using a direct immunomagnetic CD34 MicroBead labeling system.

Application

BM-CD34+ cells can be used for the following: • Study of hematopoiesis and disease pathways. • Act as a control for leukemia and leukemia stem

cell studies. • Facilitate colony-forming and stem cell toxicity assays. • Research in vitro stem cell cloning


Bone Marrow—Stem/Progenitor Cells—CD34+ Cells

Related ProductsCB-CD34+ Cells MPB-CD34+ Cells NPB-CD34+ Cells

Published PapersCokic, Vladan P., et al. (2012) JAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogeny. Journal of Translational Medicine, 10 (116). http://www.allcells.com/publications/0157allcells.pdf

Karp, Judith E., et al. (2011) Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood, 117 (12).http://www.allcells.com/publications/0168allcells.pdf

Huang, Xinqiang., et al. (2011) Regulated expression of microR-NAs-126/126* inhibits erythropoiesis from human embryonic stem cells. Blood, 117 (7). http://www.allcells.com/publications/0167allcells.pdf

Nahimana, A., et al. (2011) A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants. Blood Cancer Journal, 1 (e47). http://www.allcells.com/publications/0150allcells.pdf

Purity

Lead Time


Bo

ne

Ma

rro

w

72


Bo

ne

Ma

rro

w


Frozen ABM020F 1 million/vial Inquire



BM-CD36+ Early Erythroid Progenitor Cells

Product Description

BM-CD36+ Early Erythroid Progenitor cells are derived from BM-CD34+ cells in culture. The BM-CD34+ cells are cultured for 7 to 8 days in serum free media with the addition of SCF, EPO, IL-3 and IL-6 growth factors. The cells are harvested from culture, and the BM-CD36+ cells are positively isolated, using direct immunomagnetic CD36 MicroBeads labeling system.

Application

BM-CD36+ cells can be used to: • Study the parvovirus B19 tropism for erythroid cells• Replace the traditional CD71+ cells as an immediate and

abundant source for erythroid cell studies and transplantation studies

• Research erythropoiesis.• Serve as a control in therapeutic studies for early

erythroblastic leukemia and polycythemia vera (PV)

Purity


Related ProductsCB-CD36+ Cells MPB-CD36+ Cells

Published Papers Mulligan, George, et al. (2007). Gene expression profiling and cor-relation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 109(8), 3177-3188. http://www.allcells.com/publications/0065allcells.pdf

Lead Time

Product delivery is subject to stock availability.

Bone Marrow—CD36+ Early Erythroid Progenitor Cells

ALLCELLS

73


Cell Products


Fresh ABM028 0.3 million/vial Inquire

Frozen ABM028F 0.3 million/vial Inquire



BM-CD105+ Endothelial Cells

Product Description

BM-CD105+ Endothelial Cells are positively selected from bone marrow MNC, using a direct immunomagnetic CD105 MicroBeads labeling system.

BM-CD105+ Endothelial cells express endoglin, a type III receptor of the transforming growth factor-beta (TGF-ß) receptor family. These cells have the ability for multiple-lineage differentiation. After 14 days of culture with Alpha-MEM + 10% FBS + 1% antimycotic-antibotic, there is a four-fold expansion of BM-CD105+ Endothelial cells. These cultured cells express the following cell markers: CD105, CD13, CD29, CD44, CD49b, CD49e, CD54, CD71, CD90. The aforementioned markers are similar to the markers expressed on BM mesenchymal stem cells.

Application

BM-CD105+ Endothelial Cells can be used to study:• Angiogenesis• Anti-angiogenesis in tumor therapy research• Selective multi-potency

Purity


Lead Time


Bone Marrow—CD105+ Endothelial Cells

Bo

ne

Ma

rro

w

74


Bo

ne

Ma

rro

w

Cell Products


Frozen MSC-001F 0.75 million/vial Inquire


Media

MSC Basal Medium MSC-002 500 ml Inquire

MSC Stimulatory Supplement MSC-003 50 ml Inquire


BM-Mesenchymal Stem Cells

Product Description

Bone Marrow Mesenchymal Stem Cells (MSC) are derived from BM-MNC from the first culture passage.

Application

BM-MSC can be used to:• Study non-hematopoietic pluripotency potentials and

characteristics to develop connective tissues, such as bone and cartilage

• Act as stroma and feeder cells for expansion or differentiation of hematopoietic stem and progenitor cells

Purity

These BM-MSC have fibroblast-like morphology and express CD105+ (>90%), CD73+(>90%) and CD90+ (>90%). MSC lack expression of CD34, CD11b and CD45.

Lead Time

1-2 business days for frozen products. Product delivery is sub-ject to stock availability.

MSC Basal Medium

Product Description

Mesenchymal Stem Cell Basal Medium is designed to support AllCells BM-MSC. MSC Basal medium contains L-glutamine, 110mg/L sodium pyruvate, and pyridoxine hydrochloride. This product does not contain growth factors and antibiotics. The pH range is >7.1 to <7.5. MSC Basal Medium should be used in combination with AllCells MSC Stimulatory Supplement. This product is stable for one month after the stimulatory supplement has been added and stored at 2 to 8°C.

MSC Stimulatory Supplement

Product Description

Mesenchymal Stem Cell Stimulatory Supplement is designed to initiate and maintain growth of AllCells BM-MSC. This product contains pre-selected Fetal Bovine Serum and supplements.

Published Papers Fukushima, H., et al. (2012) SSEA-4 is a Marker of Human Deciduous Periodontal Ligament Stem Cells. Journal of Dental Research, August 14, 2012. http://www.allcells.com/publications/0152allcells.pdf

Milanesi, Anna, et al. (2012) b-Cell Regeneration Mediated by Human Bone Marrow Mesenchymal Stem Cells. PLoS ONE, 7(8). http://www.allcells.com/publications/0142allcells.pdf

Bone Marrow—Mesenchymal Stem Cells

ALLCELLS

75


CORD BLOOD

Cord Blood Table of Contents

Plasma 76




Early Erythroid Progenitor Cells - CD36+ 80

CD14+ Monocytes 81

CD19+ B Cells 82

CD3+ Pan T Cells 83

CD4+ Helper T Cells 84

CD8+ Cytotoxic T Cells 85

CD4+/CD45RA+ Naive T Cells 86

CD56+ Natural Killer Cells 87

Cord Blood Cells & Tissue

AllCells is able to provide cord blood cells from healthy individuals. These include umbilical cord stem cells, cord blood mononuclear cells,

and additional products. These cord blood products are available in fresh, frozen, lysate, or cell pellet format. AllCells is able to extract

molecular products including Comprehensive RNA and cDNA for your research needs.

Cells can be pulled from mixed or single donors. When ordering please specify preference.

Donor Criteria

• Donors are at least 18 years old.

• Donors are required to sign a procedure-specific consent form prior to the collection procedure.

• All consents and protocols have been approved by an independent biomedical review board.

Background

Cord blood (CB) is collected at the time of delivery in a 250 mL standard blood bag containing citrate-phosphate dextrose (CPD)

anticoagulant (35mL/bag). The cord blood is processed within 24 hours of collection.

For more information visit: www.allcells.com/cord-blood/

76



Fresh CB027

CB028

CB029

CB030

CB031

10 ml

20 ml

30 ml

40 ml

50 ml

Inquire

Inquire

Inquire

Inquire

Inquire

Frozen CB027F

CB028F

CB029F

CB030F

CB031F

10 ml

20 ml

30 ml

40 ml

50 ml

Inquire

Inquire

Inquire

Inquire

Inquire


CB-Plasma

Product Description

CB-Plasma is obtained by centrifugation of whole cord blood tissue. This product has a diminished number of platelets.

Application

CB-Plasma can be used to study the following:• Neonatal platelets, cytokines, and immunoglobulins• Free-radical trapping ability• Beneficial effects of cord blood plasma for cord blood

stem cell transplantation and increased efficiency during gene transfection

Lead Time

A minimum of 1-2 weeks is needed for fresh cells. Product delivery is subject to stock availability.

Related ProductsNPB Plasma

Cord Blood—Plasma

Co

rd B

loo

d

ALLCELLS

77



Frozen CB002F

CB004F

CB003F

15 million/vial

50 million/vial

150 million/vial

Inquire

Inquire

Inquire



CB-MNC

Product Description

CB-Mononuclear Cells (MNC) are isolated by diluting the CB with phosphate-buffered saline and using density gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed to isolate subpopulations.

Application

CB-MNC can be used to study:• Mesenchymal stem/progenitor cell expansion potential• Stimulation of neuro-regeneration in the hippocampus • Sources of endothelial progenitor cells and

neovascularization• Possible transplantation sources for HIV or SCID diseases • Remedies for nuclear and radioactive damage

Lead Time


Related ProductsBM-MNC MPB-MNC NPB-MNC

Published Papers Medina, Reinhold J, et al. (2010) Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Medical Genomics, 3 (18). http://www.allcells.com/publications/0010allcells.pdf

Yang, Li, et al. (2008) IL-21 and TGF-B are required for differentiation of human TH17 cells. Nature, 454(7202). http://www.allcells.com/publications/0078allcells.pdf

Cell Subsets in CBAverage Percentage of (Recoverable) Cell Subsets

CD34+ 2.5%

CD133+ 4.1%

CD19+ 45%

CD14+ 6%

CD3+ 0.7%

CD4+ 24%

CD8+ 7.8%

CD56+ 34%

CD4+/CD45RA+ 11%

Granulocytes 10%

RBC <0.01%

Platelets <0.01%

The table on the top is for reference purposes only. Please note that the average percentage of cell subsets is referring to the recovered MNC population and not the total white blood cell population. We cannot guarantee the recovery of purification products listed above. For a specific number of a certain cell type, please consider our cord blood purified products.

Cord Blood—Mononuclear Cells (MNC)

Co

rd B

loo

d

78


Co

rd B

loo

d


Frozen (Single) CB011F 100 million/vial Inquire

Frozen (Mixed) CB011F-M 100 million/vial Inquire



CB-CD34 Depleted MNC

CB CD34 Depleted MNC are isolated, using a direct immunomagnetic CD34 MicroBead labeling system to deplete the CD34+ cells. This product contains only a minimal amount of CD34+ cells.

CB-CD34 Depleted MNC/Mixed indicates that multiple donors are pooled to obtain the cord blood mononuclear cells.

CB-CD34 Depleted MNC/Single indicates that only one donor is used to obtain the cord blood mononuclear cells.

CB-CD34 Depleted MNC can be used to research endothelial cell and mesenchymal stem cell development.

Application

Related ProductsCB-MNCCB-CD34+ Cells

Cord Blood—CD34 Depleted Mononuclear Cells

Product Description Lead Time


ALLCELLS

79


Mixed Donors/Cell Products


Fresh CB005 1 million/via Inquire

Frozen CB007F

CB005F

CB008F

CB009F

0.2 million/vial

0.5 million/vial

1 million/vial

5 million/vial

Inquire

Inquire

Inquire

Inquire

Single Donor/Cell Products

Frozen CB007F-S

CB005F-S

CB008F-S

0.2 million/vial

0.5 million/vial

1 million/vial

Inquire

Inquire

Inquire



CB-CD34+ Stem/Progenitor Cells

Product Description

CB-CD34+ Stem/Progenitor cells are positively isolated using a direct immunomagnetic CD34 MicroBead labeling system.

CB-CD34+ Cells/Mixed indicates that multiple donors are pooled to obtain the cord blood CD34+ cells.

CB-CD34+ Cells/Single indicates that only one donor is used to obtain the cord blood CD34+ cells.

Application

CB-CD34+ cells can be used to study the following:• Hematopoiesis • Stem cell expansion and self-renewal • Transplantation research for hematopoietic malignancies

Purity


Cord Blood—Stem/Progenitor Cells—CD34+ Cells

Related ProductsNPB-CD34+ BMCD34+ MPBCD34+

Published Papers Wang T., et al. (2013) Derivation of Neural Stem Cells from Human Adult Peripheral CD34+ Cells for an Autologous Model of Neuroin-flammation. PLoS ONE 8(11). http://www.allcells.com/publications/0206allcells.pdf

Cokic, Vladan P., et al. (2012) JAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogeny. Journal of Translational Medicine, 10 (116). http://www.allcells.com/publications/0157allcells.pdf

Park, Tea Soon, et al. (2012) Growth Factor-Activated Stem Cell Circuits and Stromal Signals Cooperatively Accelerate Non-Integrated iPSC Reprogramming of Human Myeloid Progenitorss. PLoS ONE 7(8). http://www.allcells.com/publications/0128allcells.pdf

Co

rd B

loo

d

80


Co

rd B

loo

d


Frozen CB010M-F 1 million/vial Inquire



CB-CD36+ Early Erythroid Progenitor Cells

Product Description

CB-CD36+ Early Erythroid Progenitor cells are derived from CB-CD34+ cells in culture. CB-CD34+ cells are cultured for seven to eight days using StemSpan SFEM (StemCell Technologies, Inc.), a serum free expansion media for hematopoietic cells, EPO, SCF, IL-3, and IL-6 growth factors. The cells are harvested from culture, and the CB-CD36+ cells are positively isolated using a direct immunomagnetic CD36 MicroBead labeling system.

Application

CB-CD36+ cells can be used to: • Study the parvovirus B19 tropism for erythroid cells.• Replace the traditional CD71+ cells as an immediate

and abundant source for erythroid cell studies and transplantation studies.

• Research erythropoiesis.• Act as a control in therapeutic studies for early

erythroblastic leukemia and polycythemia vera (PV).• Study production and functions of hemoglobin.

Purity


Lead Time


Related ProductsBM-CD36+ CellsMPB-CD36+ Cells

Cord Blood—CD36+ Early Erythroid Progenitor Cells

ALLCELLS

81



Fresh CB022 5 million/vial Inquire

Frozen CB022F 5 million/vial Inquire



CB-CD14+ Monocytes

Product Description

CB CD14+ Monocytes are positively selected from mononuclear cells, using immunomagnetic CD14 MicroBeads.

Application

CB-CD14+ Monocytes can be used to study the following: • Antigen presentation and phagocytic property• Induced macrophage differentiation• Dendritic cell differentiation• Osteoclast differentiation • HIV infection mechanisms• Fc receptor binding and antibody research

Purity


Lead Time

A minimum of two weeks is needed for fresh cells. Product delivery is subject to stock availability.

Related ProductsMPB-MonocytesNPB-Monocytes

Cord Blood—CD14+ Monocytes

Co

rd B

loo

d

82


Co

rd B

loo

d



Frozen CB019F

CB020F

CB021F

1 million/vial

2.5 million/vial

5 million/vial

Inquire

Inquire

Inquire



CB-CD19+ B Cells

Product Description

CB-CD19+ B cells are positively isolated from mononuclear cells, using a direct immunomagnetic CD19 MicroBeads labeling system.

Application

CD19+ B Cells can be used to study:• Naïve B cell expansion• T Cell regulation of immuno-activity • Gene rearrangement of immunoglobulins

Purity


Lead Time

A minimum of 2 weeks is needed for fresh cells. Product delivery is subject to stock availability.

Related ProductsMPB-B Cells NPB-B Cells

Cord Blood—CD19+ B Cells

ALLCELLS

83



Fresh CB020-1 15 million/vial Inquire

Frozen CB020-1F 15 million/vial Inquire



CB-CD3+ Pan T Cells

Product Description

CB-Pan T cells are negatively isolated from mononuclear cells, using an indirect immunomagnetic Pan T labeling system.

Application

Pan T cells can be used to: • Study immunosuppression of GVHD in transplantation

experiments• Research their ability to generate anti-viral cytotoxic T

cells without prior (prenatal) exposure to viral antigens• Act as a control for childhood lymphocytic

leukemia studies

Purity


Lead Time

A minimum of 2 weeks is needed for fresh cells. Product delivery is subject to stock availability.

Related ProductsMPB-Pan T CellsNPB-Pan T Cells

Cord Blood—T Cells—CD3+ Pan T Cells

Co

rd B

loo

d

84


Co

rd B

loo

d






CB-CD4+ Helper T Cells

Product Description

Cord Blood CD4+ Helper T cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD4+ T cell labeling system to deplete the non-CD4+ cells.

Application

CB-CD4+ Helper T cells can be used to study:• The role of the T helper cells in intrauterine infections

cytokine release, and effector T cell pathways • Antigen presentation and antigen-associated activation of

T helper cells for efficient immune response in children• Classification of T cell subtypes

Purity


Lead Time


Related ProductsMPB-CD4+ Helper T Cells NPB-CD4+ Helper T Cells

Published PapersYang, Li, et al. (2008) IL-21 and TGF-Beta are required for dif-ferentiation of human TH17 cells. National Institute of Health Public Access, doi: 10.38/nature07021.

Cord Blood— T Cells—CD4+ Helper T Cells

ALLCELLS

85







CB-CD8+ Cytotoxic T Cells

Product Description

CB-CD8+ Cytotoxic T cells are negatively isolated from mono-nuclear cells, using an indirect immunomagnetic CD8 labeling system to deplete the non-CD8+ cells.

Application

CB-CD8+ Cytotoxic T cells can be used to study:• Childhood immunological response to viral infection • Memory cytotoxic T cell pathways and formation • Potential cellular engineering to fight cancer cells and

tumors

Purity


Lead Time


Related ProductsMPB-CD8+ T CellsNPB-CD8+ T Cells

Cord Blood—T Cells—CD8+ Cytotoxic T Cells

Co

rd B

loo

d

86


Co

rd B

loo

d


Fresh CB020-4-1

CB020-4-2

CB020-4-3

5 million/vial

10 million/vial

15 million/vial

Inquire

Inquire

Inquire

Frozen CB020-4-1F

CB020-4-2F

CB020-4-3F

5 million/vial

10 million/vial

15 million/vial

Inquire

Inquire

Inquire



CB-CD4+/CD45RA+ Naïve T Cells

Product Description

First, CB-CD4+ T Cells are negatively isolated using an indirect immunomagnetic CD4+ labeling system from mononuclear cells. Next, CD45RO MicroBeads are used to deplete the CD45RO+ population, leaving a purified CD4+/CD45RA+ Naïve T Cell population.

Application

CB-CD4+/CD45RA+ Naïve T Cells can be used to study:• Ex vivo expansion capability of Naive T Cells• Naive T cell differentiation to memory effector cells• Comparison of adult CD4+/CD45RA+ Naive T Cells

Purity


Lead Time


Related ProductsNPB-CD4+/CD45RA+ T Cells

Cord Blood—T Cells—CD4+/CD45RA+ Naïve T Cells

ALLCELLS

87


Co

rd B

loo

d



Frozen CB023F 1 million/vial Inquire



CB-CD56+ Natural Killer Cells

Product Description

Cord Blood CD56+ Natural Killer (NK) Cells are positively isolated from MNC using a direct immunomagnetic CD56 MicroBeads labeling system.

Application

CB-CD56+ NK cells can be used to study the following:• Neonatal infection control • Anti-leukemia and anti-tumor effect by transplantation

(due to NK cells’ enhanced sensitivity to stimulation and reduced potential for GVHD)

• Fc receptor binding and ADCC assay for potential use in therapeutic antibody development

Purity


Lead Time


Related ProductsMPB-NK CellsNPB-NK Cells

Cord Blood—CD56+ Natural Killer Cells

Co

rd B

loo

d

88


NON-HEMATOPOIETIC STEM CELLS & TISSUE

Non-Hematopoietic Stem Cells Table of Contents

Adipose-Derived Stem Cells 89

Amniotic & Placental Stem Cells 90

Human Dental Tissue & Mesenchymal Stem Cells 91

Adipose-Derived Stem Cells Over the past ten years, it has been recognized that fat is not only an energy reservoir, but also a rich source of multipotent stem cells.

Subcutaneous adipose deposits are ubiquitous and easily accessible in large quantities with a minimal invasive procedure (by liposuction

aspiration). It has been described that stem and progenitor cells in the uncultured stromal-vascular fraction (SVF) from adipose tissue

amount to up to 3% of the cells, which can be up to 2,500-fold higher than the frequency of stem cells in bone marrow. Adipose-derived

stem cells (ASC) are capable of expansion in vitro, and have the capacity to differentiate into multiple cell lineages, including adipocytes,

osteoblasts and chondrocytes.

Amniotic & Placental Stem CellsHuman placenta, besides playing a critical and fundamental role in fetal development, nutrition and tolerance, represents a significant

source of stem and progenitor cells. Four cell populations are isolated from fetal placenta: human amniotic epithelial cells (hAEC) and

human chorionic mesenchymal stem cells (hCMSC). The minimal criteria for defining hAEC and hCMSC are as follows: adherence to

plastic, formation of fibroblast colony-forming units and differentiation into osteogenic, adipogenic, chondrogenic, vascular/endothelial and

neurogenic lineages. Both cell types are positive for CD90, CD73 and CD105 and negative for CD34, CD45, and CD11b.

Human Dental Tissue & Mesenchymal Stem CellsStem cells have been isolated from many tissues and organs, including dental tissue. Five types of dental stem cells have been

established: dental pulp stem cells (DPSC), stem cells from human exfoliated deciduous teeth (SHED), stem cells from apical papilla

(SCAP), periodontal ligament stem cells (PDLSC), and dental follicle stem cells (DFSC). The main characteristics of dental stem cells

are their potential for multilineage differentiation and self-renewal capacity. Dental stem cells can differentiate into odontoblasts,

adipocytes, neuronal-like cells, glial cells, osteoblasts, chondrocytes, melanocytes, myotubes, endothelial cells and pancreatic beta cells.

The multipotency of dental stem cells may be attributable to their embryonic origin which is the neural crest. Similar to bone marrow

mesenchymal cells, DPSCs, SHED, DFSC and PDLSC express CD13, CD44, CD90, CD146 and CD166, CD105 and Stro-1, but are

negative for CD3, CD8, CD11b, CD14, CD15, CD19, CD33, CD34, CD45, and HLA-DR.

Adipose-derived Stem Cells Background References:

• Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int. 2012;2012:812693.

• Gimble JM, Katz AJ, Bunnell BA Adipose-derived stem cells for regenerative medicine. Circ Res. 2007 May 11;100(9):1249-60.

For more information visit: www.allcells.com/non-hematopoietic-stem-cells/

ALLCELLS

89



Frozen ASC001F 1 million/vial Inquire


Adipose-derived Stem Cells

Non-Hematopoietic Stem Cells—Adipose-derived Stem Cells

No

n-H

em

ato

po

ieti

c:

Ad

ipo

se-d

eri

ved

Product Description

AllCells’ adipose-derived stem cells (ASC) are isolated from single donor, P2 from the stromal vascular fraction(SVF) of lipoaspi-rates (obtained by conventional vacuum-assisted liposuction methods) through culturing on plastic. ASC are cultured up to second passage, harvested, and characterized. They can be identified by flow cytometry, as they express: CD73+, CD90+, CD105+, CD45-, CD34- and CD11b-.

Application

Can be used for experimental (non-clinical) research on wound healing, soft tissue defects, inflammatory bowel disease (Crohn’s disease), autoimmune diseases, critical limb ischemia and cardiovascular diseases.

Lead Time

1-2 business days

Published PapersThomas A. Mendel, et al. (2013) Pericytes Derived from Adipose-Derived Stem Cells. PLoS ONE 8(5). http://www.allcells.com/publications/0185allcells.pdf

90


Non-Hematopoietic Stem Cells—Amniotic and Placental Stem Cells

Product Description

Fluid Phase Amniotic Stem Cells (FPASC) are obtained from human amniocentesis specimens. FPASC represent about 1% of the cells found in amniotic fluid. They are characterized by slow proliferation in culture for approximately 1 week, become adherent to plastic and can be passaged at 70% confluency every two to three days, retaining a normal karyotype. Purification of isolated FPASc can be readily performed by selection for expression of the membrane stem cell factor receptor c-Kit. In addition, FPASC express embryonic markers such as Oct-4 and SSEA-4. They also express mesenchymal and/or neuronal markers such as CD29, CD44, CD73, CD90 and CD105. FPASCs can be directed into a wide range of cell types representing the three primary embryonic lineages of mesoderm, endoderm and ectoderm, including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. They have a very high renewal capacity and can be expanded for over 250 population doubling without any loss of chromosomal telomere length.

Human Amniotic Epithelial Cells (hAEC) Cells are isolated from the surface layer of the amniotic membrane of fresh placentas. hAEC cells retain embryonic stem cell like characteristics and express CD117 (c-Kit) and SSEA-3 and -4. hAEC also express molecular markers of pluripotent stem cells including Nanog, Oct-4 and Sox-2. These cells are useful for tissue differentiation of all three germ layers, including the ectoderm, endoderm, and the mesoderm. Some examples of tissue differentiation applications include conversion into pancreatic islet cells, hepatocyte like cells, cardiomyocytes and neuron like cells.

Human Chorionic Mesenchymal Stem Cells (hCMSC) are derived from extraembryonic mesoderm and are isolated from fresh chorion following mechanical and enzymatic removal of the trophoblastic layer. They adhere and proliferate in cell culture and retain their stem cell characteristics beyond passage 10. Differentiation of hCMSC to all three germ layers, ectoderm (neural), mesoderm (skeletal muscle, cardiomyocytic and endothelial) and endoderm (pancreatic) has been reported. The embryonic stem

cell marker SSEA-4 has been identified on hCMSC as well as CD349 and CD140b.

Application

• Considered an attractive candidate progenitor cell type for tissue engineering applications• Can be frozen and thawed and are adherent to plastic

Lead Time

1-2 business days lead time for all 3 products

Product Format Cell Type Catalog # QTY/Unit Price/Unit

Frozen Amnionitc Fluid Stem Cells (hAFSC)

HAF001F 1 million/vial Inquire

Frozen Amniotic Epithelial Stem Cells (hAEC)

HAF002F 1 million/vial Inquire

Frozen Chorionic Mesenchymal Stem Cells (hCMSC)

HC001F 1 million/vial Inquire


Amniotic and Placental Stem Cells

No

n-H

em

ato

po

ieti

c:

Am

nio

tic

ALLCELLS

91


No

n-H

em

ato

po

ieti

c:

De

nta

l

Non-Hematopoietic Stem Cells—Dental Pulp Tissue and Stem Cells

Product Description

Stem Cells From Human Exfoliated Deciduous Teeth (SHED) are considered to be the most ‘immature’ of the Dental Stem Cells and show the highest proliferative capacity when grown in culture. Similar to the DPSCs from third molars, SHED are very durable in culture and have been passaged over 80 times with no detectable signs of senescence or telomere shortening. SHED express the embryonic stem cell (ESC) markers Oct-4, Nanog, SSEA-3 and SSEA-4, and tumor recognition antigens (TRA-1-60 and TRA-1-81). When cultured in neurogenic medium, SHED form sphere-like clusters which adhere to the culture dish or float freely in the culture medium.

Dental Follicle Stem Cells is an ectomesenchymal tissue surrounding the enamel organ and the dental papilla of the developing tooth germ prior to eruption. The tissue contains the progenitor cells that form the periodontium, (cementum, periodontal ligament, and alveolar bone). In culture DFSC adhere to plastic, proliferate and show a typical fibroblast-like morphology. DFSCs express the embryonic marker Oct-4 and the neural progenitor markers Notch-1 and nestin.

Dental Pulp Stem Cells are derived from the pulp tissues of exfoliated deciduous teeth, primary incisors and permanent third molar teeth. The dental pulp, third molars in particular are a significant stem cell source due to greater numbers of stem cells residing in the pulp. DPSCs from third molars express developmentally important transcription factors, such as Oct-4, Sox-2, Nanog and c-Myc, which is an indicator of their pluripotency. Flow-cytometric analysis revealed DPSCs is positive for CD73, CD90, CD105 and CD166, but negative for CD34, CD45 and CD133, suggesting that these cells are mesenchymal-like stem cells. Under specific culture condi-

tions, DPSCs differentiate into osteogenic, adipogenic and neurogenic cells, as well as form tube-like structures in Matrigel assay.

Application

• Good candidates for future research as a new, powerful tool for therapy.• The efforts made in the research of dental stem cells have clarified many mechanisms underlying the biological processes in

which these cells are involved.

Lead Time



FrozenFollicular Stem Cells FT002F 1 million/vial Inquire

Frozen Dental Pulp Stem CellsAdult Teeth

DP003F 1 million/vial Inquire

Frozen Dental Pulp Stem CellsDeciduous Teeth

DP004F 1 million/vial Inquire


Dental Pulp Tissue—Mesenchymal Stem Cells

92


DISEASED CELLS & TISSUE

This image was originally published in ASH Image Bank. John Lazarchick. Leukemic phase of multiple myeloma - 1. ASH Image Bank. 2011; 2011-4094. The American Society of Hematology.

This image was originally published in ASH Image Bank. Gridhar U Adiga; Peter C Cote'; Cheryl L Gardner. Bone marrow necrosis in myelodysplastic syn-drome - 5. ASH Image Bank. 2011; 2011-1250. The American Society of Hematology.

This image was originally published in ASH Image Bank. Peter Maslak. Primary induction failure: AML - 1. ASH Image Bank. 2011; 2011-1298. The American Society of Hematology.

This image was originally published in ASH Image Bank. Ruth Rose. Granular ALL - 1. ASH Image Bank. 2011; 2011-2723. The American Society of Hematology.

ALLCELLS

93


DISEASED CELLS & TISSUE

Diseased Cells & Tissue

Resulting from numerous customer requests, AllCells has established a nationwide network of clinical collection sites to

supply various types of disease cells for research use. These facilities supply clinically-relevant, peripheral blood and bone

marrow with sample medical history for use in pre-clinical studies. We have amassed a cell repository of patient samples for

your research needs.

All diseased cells and tissue products are obtained from volunteers participating in an Institutional Review Board (IRB) or

Human Subject Committee approved donor program. Donors sign an informed consent from and are aware of the fact that

these samples are used for research purposes only. Donors must be over the age of 18.

For collections and projects visit us on the web at www.allcells.com/technical-support/ or contact us at [email protected].

Clinical Information

A Clinical Report will be available for each diseased product. The report may include patient information such as age,

gender, race, weight, height; classification of the disease and staging; and treatment history.

The Clinical Report is a medical information of the patient and not all tests are performed at the time of the blood sample

draw. Please note that all test results are not always concurrent or reflective of each other. Amount of data given per sample

may vary.

Certificate of Analysis

A Certificate of Analysis is provided with the product information; this document details the cell number and the cell viability

of the product vial. All diseased fresh tissue & cell products do not include viral test results as a standard release criteria

prior to delivery. Frozen products are negative for Hepatitis B, Hepatitis C and HIV I/II using antibody based testing.

Diseased Cells & Tissue Table of Contents

Diseased Custom Products 94

Hematological Oncology 95-111

Autoimmune 112-124

For more information visit: www.allcells.com/diseased/

94


DISEASED CUSTOM PRODUCTS

Custom Disease Products & Services

In addition to standard disease catalog products, AllCells offers customized diseased tissue procurement services, and

related cell processing & analysis according to your research project specifications. AllCells collaborates with an

increasing number of IRB-approved clinical collection sites, specialized medical centers and healthcare groups to recruit

the most qualified patient specimens sourced within the Unites States. Examples of bespoke diseased tissue/cell

collection services may include (but are not limited to):

• Whole blood, bone marrow, serum, plasma, MNCs, purified hematologic cells, urine, and skin lesion biopsy

• Whole blood from patients with various types of hematologic cancers, solid tumor cancers, infectious, autoimmune,

and other disease types

• Collection volumes ranging from 10ml to 400ml depending on tissue type and disease type

• Special collection conditions such as type of anticoagulant e.g. EDTA, sodium heparin, sodium citrate, SST, PST, and

other specialized tubes may be available upon request

• Patient’s current medical diagnostic stage, treatment stage, drug treatment, lab tests and clinical report

• Control normal donor samples matched with age, gender, ethnicity; we are able to provide matching tissue and/or cell

types from the same donor

Most fresh tissue specimens can be delivered to USA destinations via FedEx over night and arrive within 24hrs from

collection time. Note: All fresh samples do not include viral test results as standard release criteria prior to delivery

unless otherwise specified. Frozen products include viral tests that are negative for Hep B, Hep C and HIV 1 & 2 . Frozen

products can be shipped worldwide, and are available directly from AllCells or through one of our authorized Distributors.

AllCells Tissue Procurement Team specializes in servicing your specific tissue/cell research project needs. Please contact

your local Sales Representative and/or email us at [email protected] to discuss your project criteria and learn more

about our capabilities in this area.

ALLCELLS

95


HEMATOLOGICAL ONCOLOGY CELLS & TISSUE

Hematological Oncology Table of Contents

Leukemia Background 95-96Acute Lymphoid Leukemia (ALL) 97-98 ALL Peripheral Blood 97 (Plasma, Mononuclear Cells, CD19+ B Cells) ALL Bone Marrow 98 (Plasma, Mononuclear Cells, CD19+ B Cells) Acute Myeloid Leukemia (AML) 99-100 AML Peripheral Blood 99 (Plasma, Mononuclear Cells) AML Bone Marrow 100 (Plasma, Mononuclear Cells, CD34+ Cells)Chronic Lymphoid Leukemia (CLL) 101-102 CLL Peripheral Blood 101 (Plasma, Mononuclear Cells, CD19+/CD5+ B Cells)

CLL Bone Marrow 102 (Plasma, Mononuclear Cells, CD19+/CD5+ B Cells) Chronic Myeloid Leukemia (CML) 103-104 CML Peripheral Blood 103 (Plasma, Mononuclear Cells) CML Bone Marrow 104 (Plasma, Mononuclear Cells, CD34+ Cells)Multiple Myeloma 105-107 MM Peripheral Blood 106 (Plasma, Mononuclear Cells) MM Bone Marrow 107 (Plasma, Mononuclear Cells)Myelodysplastic Syndrome (MDS) 108-109 (Mononuclear Cells)Non-Hodgkin's Lymphoma 110-111

Hematological Oncology Cells & Tissue

AllCells specializes in highly purified mononuclear cells from peripheral blood and bone marrow. We also provide

specifically selected leukemia blood cells from patients. These samples are made available from newly diagnosed patients

and can be provided in frozen, fresh formats depending on availability. Please contact us for any other special requests.

Background

Leukemia refers to a cancer of the blood-forming (hematopoietic) tissues found in the body. This cancer starts in the bone

marrow and usually spreads quickly into the blood. Over time, leukemia can spread to the lymph nodes, the spleen, the liver,

the covering of the brain and spinal cord, the spinal fluid, and other organs.

There are two ways to classify leukemia: acute or chronic and lymphoid or myeloid. In acute leukemia, the leukemia cells

are derived from early progenitor cells, the immature “blasts.” In chronic leukemia, the leukemia cells are derived from

mature lineage-specific, abnormal cells. These cells live longer than normal cells and build up over time, causing tumors.

Lymphoid leukemia develops from lymphoblasts or lymphocytes in the bone marrow. Myeloid leukemia develops from

myeloid cells in the bone marrow. Consequently, there are four major types of leukemia: acute lymphoid leukemia, acute

myeloid leukemia, chronic lymphoid leukemia, and chronic myeloid leukemia.

Please note that due to the nature of the disease and sensitivity of the cancer patients, product availability is limited.

For more information visit: www.allcells.com/leukemia/

96


Acute Lymphoid Leukemia (ALL)

Acute lymphoblastic leukemia (ALL), is a form of leukemia, or cancer of the white blood cells, characterized by excess lymphoblasts. Malignant, immature white blood cells continuously multiply and are overproduced in the bone marrow. ALL causes damage and death by crowding out normal cells in the bone marrow and by spreading (metastasizing) to other organs.

Leukemia—Types—Background

Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

Chronic Lymphoid Leukemia (CLL)

Chronic Lymphoid Leukemia (CLL) also known as B cell chronic lymphocytic leukemia (B-CLL) is a slow growing cancer of the blood that affects older adults. Chronic Lymphoid Leukemia cells originate in the bone marrow and then spread to the blood and lymph nodes. Characterization by flow cytometry demonstrates that these CLL cells are CD19+ and CD5+. Prognosis of CLL is dependent on the cytogenic profile of the cancer. Deletions of part of the short arm of chromosome 17 (del 17p) or deletions of the long arm on chromosome 11 (del 11q) indicate a poorer outcome while deletions of the long arm of chromosome 13 (del 13q) favors a better prognosis for CLL patients.

Chronic Myeloid Leukemia (CML)

Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder, in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. CML was the first malignancy to be linked to a clear genetic abnormality — the chromosomal translocation known as the Philadelphia Chromosome.

Le

uk

em

ia T

ype

s

This image was originally published in ASH Image Bank. Peter Maslak. Relapsed CML - 1. Bone Marrow aspirate from a patient with increasing WBC count on imanitib. ASH Image Bank. 2011; 2011-1300. The American Society of Hematology.

CML

ALLCELLS

97


Newly Diagnosed/Untreated Plasma


Frozen ALL-PB011F 5 ml Inquire

Newly Diagnosed/Untreated Mononuclear Cells

Frozen ALL-PB001F 10 million/vial Inquire

Newly Diagnosed/Untreated CD19+B Cells

Frozen ALL-B006F

ALL-B007F

5 million/vial

10 million/vial

Inquire

Inquire


ALL-PB-Plasma

Product Description

ALL-PB-Plasma is obtained by centrifugation of ALL peripheral blood. This product has a diminished number of cells. ALL-Plasma are available in the newly diagnosed/untreated stages.ALL-PB-MNC are isolated from ALL peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. ALL-MNC are available in the newly diagnosed/untreated stage.ALL-PB-CD19+ B cells are positively isolated from adult ALL peripheral blood MNC, using a direct immunomagnetic CD19 MicroBead labeling system. ALL-PB-CD19+ B cells are available in the newly diagnosed/untreated stages.

Application

ALL-PB-Plasma can be used to study ALL lymphoblast and lymphocyte secretion in the plasma.ALL-PB-MNC can be used research new drug candidates, including various molecular and genetic drug delivery methods. Study any negative effects of treatment on non-malignant cells and to help minimize damage to non-leukemia cells.ALL-CD19+ B Cells can be used for cytogenetic and mutational analysis of B-ALL diseases, such as ALL-L3 or Burkitt’s lymphoma/leukemia.

The purity of CD19+ B Cells is guaranteed to be at least 90% as assessed by flow cytometric analysis.

Lead Time


Related ProductsALL-BM-MNCNPB-Plasma NPB-MNCALL-BM-CD19+ B CellsNPB-BM-CD19+ B Cells

Diseased Cells—ALL—Peripheral Blood—Plasma, Mononuclear Cells, CD19+

B Cells

Acute Lymphoid Leukemia

Purity

Le

uk

em

ia:

AL

L

98


Le

uk

em

ia:

AL

L



Frozen ALL-BM011F 5 ml Inquire


Frozen ALL-BM001F 10 million/vial Inquire

Newly Diagnosed/Untreated CD19+ B Cells

Frozen ALL-B012F

ALL-B013F

5 million/vial

10 million/vial

Inquire

Inquire


ALL-BM-Plasma

Product Description

ALL-BM plasma is obtained by centrifugation of the ALL-bone marrow. This product has a diminished number of cells and platelets. ALL-BM-MNC are isolated from bone marrow by diluting the whole bone marrow with phosphate-buffered saline and using gradient separation techniques. MNC can be processed to isolate subpopulations. ALL-BM-CD19+ B cells are positively isolated from adult ALL-BM-MNC, using a direct immunomagnetic CD19 MicroBead labeling system.

Application

ALL-BM-Plasma can be used to research B- lymphoblast secretion and activity in bone marrow.ALL-BM-MNC can be used as a possible source for isolating leukemia stem cells.ALL-BM-CD19+ can be used to study leukemia stem/progenitor cells for precursor B acute lymphoblastic leukemia/lymphoma, research molecular mechanisms for B cell loss of function and malignancy and serve as diagnostic tools to aid classification of various subtypes of B-ALL

The purity of CD19+ B Cells is guaranteed to be at least 90% as assessed by flow cytometric analysis.

Lead Time


Related ProductsALL-PB-PlasmaALL-PB-MNCALL-PB-CD19+

Diseased Cells—ALL—Bone Marrow—Plasma, Mononuclear Cells, CD19+B

Purity

ALLCELLS

99




Frozen AML-PB011F 5 ml Inquire


Frozen AML-PB001F 10 million/vial Inquire


Product Description

AML-PB-Plasma is obtained by centrifugation of AML peripheral blood. AML-PB-plasma has a diminished number of cells and platelets. AML plasma is available in the newly diagnosed/untreated stages.AML-PB-MNC are isolated from AML-PB by diluting the blood with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate subpopulations.

Application

AML-PB-Plasma can be used to study and analyze leukemia cell and progenitor cell protein secretion into the serum or plasma.AML-PB-MNC can be used to test the efficacy of different diagnostic tools (e.g. cellular morphology, immunocytometry, and cytogenetics).

Related ProductsAML-BM-PlasmaNPB-Plasma

Diseased Cells—AML—Peripheral Blood—Plasma, Mononuclear Cells

Acute Myeloid Leukemia

Lead Time


Le

uk

em

ia:

AM

L

100


Le

uk

em

ia:

AM

L

AML-BM Plasma is obtained by centrifugation of the adult AML-BM. Plasma has a diminished number of cells and platelets. BM is obtained from adult AML patients. BM-MNC are isolated by diluting the bone marrow with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate cell subpopulations. AML-BM-CD34+ cells are selected from adult AML-BM-MNC. The BM-CD34+ stem/progenitor cells are positively isolated using a direct immunomagnetic CD34 MicroBead labeling system.

AML-BM Plasma can be used to study and analyze possible leukemia stem and progenitor cell protein secretion into the serum plasma.AML-BM-MNC can be used to study the induction chemotherapy effects performing as general cell suppressors of active proliferation.AML-BM-CD34+ cells can be used to research novel genetic mutations, such as in Flt-3, for subtyping and therapeutic research.



Frozen AML-BM015F 5 ml Inquire


Frozen AML-BM001F 10 million/vial Inquire

Newly Diagnosed/Untreated CD34+ Cells

Frozen AML-BM006F

AML-BM007F

1 million/vial

5 million/vial

Inquire

Inquire


Diseased Cells—AML—Bone Marrow—Plasma, Mononuclear Cells, CD34+Cells

Product Description

Application

Related ProductsAML-PB-PlasmaBM-PlasmaBM-CD34+ CellsAML-PB-CD34+ Cells

Purity


Lead Time


ALLCELLS

101




Frozen CLL-PB011F 5 ml Inquire


Frozen CLL-PB001F

CLL-PB002F

10 million/vial

50 million/vial

Inquire

Inquire

Newly Diagnosed/Untreated CD19+/CD5+

Frozen CLL-B013F

CLL-B014F

1 million/vial

5 million/vial

Inquire

Inquire


Product Description

CLL-PB Plasma is obtained by centrifugation of the CLL-PB-MNC. Plasma has a diminished number of cells and platelets. CLL-PB-MNC are isolated from CLL-peripheral blood by diluting the blood with phosphate-buffered saline and using gradient separation. MNC can be processed to isolate subpopulations. CLL-PB-CD19+/CD5+ B cells are isolated from CLL peripheral blood mononuclear cells using a direct immunomagnetic CD19+ MicroBead labeling system.

Application

CLL-PB Plasma can be used to study the cell secretion and protein analysis into the serum or plasma. CLL-PB-MNC can be used to research improved methods for diagnosis and prognosis from early to late CLL stages as well as study B lymphocytosis effects on other cells, which cause problems, such as cytoreduction.

Purity

Diseased Cells—CLL—Peripheral Blood—Plasma, Mononuclear Cells, CD19+/CD5+ B Cells

The purity of CD19+/CD5+s guaranteed to be at least 90% as assessed by flow cytometric analysis.


Chronic Lymphoid Leukemia

Le

uk

em

ia:

CL

L

Lead Time

102


Le

uk

em

ia:

CL

L



Frozen CLL-BM011F 5 ml Inquire


Frozen CLL-BM001F 10 million/vial Inquire

Newly Diagnosed/Untreated CD19+/CD5+ B Cells

Frozen CLL-B037F

CLL-B038F

1 million/vial

5 million/vial

Inquire

Inquire


Product Description

CLL BM-Plasma is obtained by centrifugation of the CLL bone marrow. Plasma has a diminished number of cells and platelets. CLL-BM-MNC are isolated by diluting CML bone marrow with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. CLL-BM-MNC can be processed further to isolate subpopulations. CLL-PB-CD19+/CD5+ B cells are isolated from CLL bone marrow mononuclear cells using a direct immunomagnetic CD19+ MicroBead labeling system.

Application

CLL-BM-Plasma can be used to study extracellular proteins that could play a role in the cause and progression of the CLL-B cell malignancies. CLL-BM-MNC can be used to examine the capacity to generate cellular immune response to newly established CLL-associated antigens.CLL-PB-CD19+/CD5+ B cells can be used to study the transition from the mantle zone to the bone marrow microenvironment.

The purity of CLL-PB-CD19+/CD5+ is guaranteed to be at least 90% as assessed by flow cytometric analysis.

Purity

Related ProductsCLL-PB-PlasmaBM-Plasma

Diseased Cells—CLL—Bone Marrow—Plasma, Mononuclear Cells,CD19+/CD5+ B Cells

ALLCELLS

103


Related ProductsCML-BM-PlasmaCML-BM-MNCNPB-MNC

Chronic Phase Plasma


Frozen CML-PB011F 5 ml Inquire

Chronic Phase Mononuclear Cells

Frozen CML-PB001F 10 million/vial Inquire


Diseased Cells—CML—Peripheral Blood—Plasma, Mononuclear Cells

Product Description

CML-PB Plasma is obtained by centrifuging CML peripheral blood. Plasma has a diminished number of cells and platelets. CML plasma is available in the chronic phase and accelerated or blast crisis phase. CLL-PB-MNC are isolated from CML peripheral blood by diluting the blood with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate subpopulations.

Application

CML-PB Plasma can be used to study Leukemia cell secretion in to the serum or plasma and other possible leukemia candidate and target proteins and pathways in the serum or plasmaCML-PB-MNC can be used to improve methods of diagnosis, classification, and prognosis. In addition, researchers can use these cells to study leukemia cells’ ability to affect and expel healthy cells.

Lead Time


Chronic Myeloid Leukemia

CML-PB-Plasma

Le

uk

em

ia:

CM

L

104


Le

uk

em

ia:

CM

L

Chronic Phase Plasma


Frozen CML-BM011F 5 ml Inquire

Chronic Phase Mononuclear Cells

Frozen CML-BM001F 10 million/vial Inquire

Chronic Phase CD34+

Frozen CML-BM008-1F

CML-BM008-2F

0.2 million/vial

1 million/vial

Inquire

Inquire


CML-PB-MNC

Background

Chronic Myeloid Leukemia (CML) is often divided into three phases, based on clinical characteristics and laboratory findings. In the absence of interventions, CML typically begins in the chronic phase (85% of CML patients). Over the course of several years, the cancer progresses to an accelerated phase and ultimately to a blast crisis phase.

Product Description

CLL-PB-MNC are isolated from CML peripheral blood by diluting the blood with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate subpopulations. CML-PB-MNC are available in the chronic phase and accelerated or blast crisis phase.

Application

Chronic Phase - CML-PB-MNC can be used to improve methods of diagnosis, classification, and prognosis. In addition, researchers can use these cells to study leukemia cells’ ability to affect and expel healthy cells.

Accelerated/Blast Crisis - CML-PB-MNC can be used to improve methods of diagnosis, classification, and prognosis.

Lead Time


Related ProductsCML-BM-MNCNPB-MNC

Diseased Cells—CML—Bone Marrow—Plasma, Mononuclear Cells, CD34+Cells

ALLCELLS

105


MULTIPLE MYELOMA

Multiple Myeloma (MM) Table of Contents

MM Peripheral Blood

(Plasma, Mononuclear Cells) 106

MM Bone Marrow

(Plasma, Mononuclear Cells) 107

Multiple Myeloma Cells & Tissue

Background

Multiple Myeloma (MM) is a type of incurable cancer of the plasma cells. Normal plasma cells make antibodies that attack

foreign microorganisms and viruses in the body. MM occurs when these plasma cells grow out of control, becoming

malignant and form a tumor in the bone marrow. MM has several types of characterizations. An excessive amount of

plasma cells can cause problems in the bone marrow where blood cells are made. Consequently, the bone marrow may not

be able to make enough red blood cells, platelets, or normal white blood cells to sustain normal body functions.


For more information visit: www.allcells.com/multiple-myeloma/

106




Frozen MM-PB011F 5 ml Inquire


Frozen MM-PB001F 10 million/vial Inquire


Product Description

MM-PB-Plasma is obtained by centrifugation of MM peripheral blood. Plasma has a diminished number of cells.

MM-PB-MNC are isolated from MM-peripheral blood by diluting the blood with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed further to isolate subpopulations.

Application

MM-PB-Plasma can be used to study production and manifestation of free serum or urine immunoglobulin, or paraprotein. These paraproteins are indicators of disease stages.

MM-PB-MNC can be used to find more efficient ways of diagnosing effects from specific translocations, such as FGFR3 over expression.

Lead Time


Related ProductsBM-MNCMM-BM-MNC

PublicationsAndrew T. Hutchinson et al. (2013) Formation of Assemblies on Cell Membranes by Secreted Proteins: Molecular Studies of Free Lambda Light Chain Aggregates Found on the Surface of Myeloma.. Biochemical Journal Immediate Publication http://www.allcells.com/publications/0186allcells.pdf

Diseased Cells—MM—Peripheral Blood—Plasma, Mononuclear Cells

Mu

ltip

le M

yelo

ma

ALLCELLS

107




Frozen MM-BM011F 5 ml Inquire


Frozen MM-BM001F 10 million/vial Inquire


MM-BM-Plasma

Diseased Cells—MM—Bone Marrow—Plasma, Mononuclear Cells

Product Description

MM-BM Plasma is obtained by centrifuging the MM-bone marrow. The plasma has a diminished number of cells and platelets. MM-BM-MNC are isolated by diluting MM-bone marrow with phosphate-buffered saline and using gradient separation.

Application

MM-BM-Plasma can be used to study bone deterioration and lesions (by detecting of hypercalcemia) and hyperviscosity syndrome therapies.MM-PB-Plasma can be used to study production and manifestation of free serum or urine immunoglobulin, or paraprotein. These paraproteins are indicators of disease stages.

Lead Time


Related ProductsMM-PB-PlasmaNPB-PlasmaBM-MNCMM-PB-MNC

Mu

ltip

le M

yelo

ma

108


MYELODYSPLASTIC SYNDROME (MDS)

Myelodysplastic Syndrome (MDS) Table of Contents

MDS Bone Marrow Mononuclear Cells 109

Myelodysplastic Syndrome Cells & Tissue

Background

The myelodysplastic syndromes (MDS, formerly known as “preleukemia”) are a diverse collection of hematological conditions united by ineffective production (dysplasia) of myeloid blood cells; these conditions risk transformation to acute myelogenous leukemia (AML). Myelodysplastic syndromes are bone marrow stem cell disorders resulting in disorderly and ineffective hematopoiesis manifested by irreversible quantitative and qualitative defects in hematopoietic cells. In a majority of cases, the course of disease is chronic with gradually worsening cytopenias due to progressive bone marrow failure. Approximately one-third of patients with MDS progress to AML within months to a few years.


For more information visit: www.allcells.com/multiple-myeloma/

ALLCELLS

109


Mye

lod

ysp

last

ic S

ynd

rom

e



Frozen MDS-BM001F 10 million/vial Inquire


MDS-BM-MNC

Product Description

AllCells has isolated mononuclear cells (MNCs) from the bone marrow of Myelodysplastic Syndrome (MDS) patients. Patients participating in our MDS donor program have been characterized as Newly Diagnosed/Untreated.

Frozen MDS BM MNC - BM is obtained from adult Myelodysplastic Syndrome patients. BM-MNC are isolated by diluting the bone marrow with phosphate-buffered saline and using gradient separation techniques. After centrifugation,the MNC layer is collected. MNC can be processed further to isolate cell subpopulations.

Related ProductsAML-BM-MNC

Diseased Cells—Myelodysplastic Syndrome (MDS)—Bone Marrow—Mononuclear Cells

This image was originally published in ASH Image Bank. Peter Maslak. Post-BMT aspirate - 1. ASH Image Bank. 2011; 2011-3540. The American Society of Hematology.

Lead Time


110


NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's Lymphoma Cells & Tissue

AllCells is able to provide custom collections of B-cell lymphomas, including Diffuse Large B-cell Lymphoma (DLBCL),

Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FLL), and Waldenstrom's Macroglobulinemia (WM) from either bone

marrow and/or peripheral blood samples of newly diagnosed/untreated or relapsed/refractory patients. Medical history

of each patient is available and may include treatment history, serum biochemistry, bone marrow aspirate smear analysis,

cytogenics, and immunophenotyping.

Background

Lymphomas are types of cancers derived from lymphocytes and are typically treated by combinations of chemotherapy,

monoclonal antibodies, immunotherapy, radiation, and hematopoietic stem cell transplantation.

Non-Hodgkin’s Lymphoma (NHL) is a collective term for a broad range of lymphomas that are not classified as

Hodgkin’s lymphoma. NHL can either be a cancer of B cells or T cells. B-cell non-Hodgkin lymphomas include

Burkitt’s lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor

B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell non-Hodgkin lymphomas include anaplastic large cell

lymphoma, and precursor T-lymphoblastic lymphoma.

For custom collections and projects visit us on the web at www.allcells.com/technical-support/ or

contact us at [email protected].

ALLCELLS

111


Diffuse Large B Cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma (DLBCL) is an “intermediate-grade” and aggressive type of malignant B cell lymphoma. DLBCL can arise from an immunoblastic origin, or can transform from the follicule center large cell neoplasm. This transformed cell can be further classified into large non cleaved (centroblastic) cells or large cleaved (large centrocytic) cells. DLBCL is frequently associated with t(8;14) and t(14;18): chromosomal rearrangements pertaining to Myc and Bcl-2 genes. In addition, there may be some chromosomal mutation involving Bcl-6 on chromosome 3.

DLBCL can also be called “histiocytic” lymphoma, which refers to the morphologic expression of the transformed lymphocytes. DLBCL is the most frequent type of extranodal lymphoma with the least common bone marrow involvement.

Follicular Lymphoma (FLL)

Follicular Lymphoma (FLL) is a type of “indolent” Non-Hodgkin’s Lymphoma and is defined by follicule center B Cells, which express a follicular pattern. FLL’s genetic origin has been correlated to t(14;18), which causes excessive expression of the Bcl-2 gene, and some reported cases Bcl-6 translocation at 3q27. Typically, follicular B cells express surface-markers CD10, but not CD5. The “tumors” or lymph follicles contain a mixture of “small” cleaved follicle center cells (centrocytes) and “large” non-cleaved follicle center cells (centroblasts): the former usually in predominance. FLL is generally indolent but can sometimes progress to more aggressive large cell lymphomas, such as DLBCL.

Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma (MCL) is one of the rarer types of NHL. MCL is a disease of the naïve pre-germinal center B cells, located in the “mantle zone” surrounding the normal germinal center follicles. A distinctive translocation at t(11;14)(q13;q32) causes upregulation of Bcl-1, development arrest, and unlimited proliferation of the mantle-zone B cells. This chromosomal translocation causes the over-expression of Bcl-1’s protein product, Cyclin-D1. In addition, these mantle-zone B cells express the CD5 marker. MCL is one of the few NHLs that can cross the blood-brain barrier.

Waldenström's Macroglobulinemia (WM)

Waldenström’s Macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, WM is one of the rarest types of NHL. WM is a malignant small lymphocytic lymphoma with plasmacytoid features. While this disease has not been linked to a single mutation, researchers have found a WM associated with the 6p21.3 locus. WM is characterized by large monoclonal IgM in the serum and symptoms, such as peripheral neuropathy and hyperviscosity syndrome. WM is distinguished from Multiple Myeloma by its indolent nature and less frequent bone marrow involvement. Patient monitoring is usually recommended before any necessary treatment.

Diseased Cells-Non-Hodgkin's Lymphoma

This image was originally published in ASH Image Bank. John Lazarchick. Lymphomatous peritoneal effusion - 3. Mature B-cell neoplasms. ASH Image Bank. 2011; 2011-3729. The American Society of Hematology.

DLBCL

112


AUTOIMMUNE CELLS & TISSUE

Graves' Thyroid 113

Hashimoto's thyroiditis 114

Multiple Sclerosis (MS) 115

Osteoarthritis (OA) 116

Psoriasis (PSO) 117

Rheumatoid Arthritis (RA) 118

Systemic Lupus Erythematosus 119

Type I Diabetes (DIA1) 120

Type II Diabetes (DIA2) 121

Autoimmune Cells & Tissue AllCells provides patient samples of Autoimmune cells isolated from Rheumatoid Arthritis, , Osteoarthritis, Systemic Lupus Erythematosus (SLE), Psoriasis, Type I & Type II Diabetic, and Multiple Sclerosis patients. Autoimmune plasma and autoimmune peripheral blood mononuclear cells are available from each disease type. These are available in frozen or fresh formats upon request.

Background Autoimmune Diseases arise from an inappropriate immune response of the body against substances and tissues normally present within the body. This disease may be restricted to certain organs or involve a particular tissue located in the body. Treatment of Autoimmune Diseases is typically with immunosuppression or medication which decreases the immune response.

For a disease to be classified as an Autoimmune Disease there must be direct evidence from transfer of pathogenic antibodies or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, or circumstantial evidence from clinical clues.

Autoimmune specimens can be used in preclinical research, drug discovery, drug toxicity, biomarker development, and pre-selection of indication for clinical trials.

Autoimmune Table of Contents

For more information visit: www.allcells.com/autoimmune/

ALLCELLS

113


Fresh OA GTR -Whole blood is drawn from Graves' Thyroid patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH). Frozen GTR PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Graves' Thyroid peripheral blood plasma is obtained by centrifugation of the Graves' Thyroid PB. Frozen GTR PB MNC - Peripheral blood mononuclear cells are isolated from Graves' Thyroid peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Graves' Thyroid PB MNC is available upon request.

Whole Blood


Fresh GTR-WB40-VK2

GTR-WB100-VK2

GTR-WB400-VK2

GTR-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen GTR-WB011F-VK2

GTR-WB011F-VNH

5 ml

5 ml

Inquire

Inquire

Peripheral Blood Mononuclear Cells

Frozen GTR-WB001F 10 million/vial Inquire



Graves' Thyroid specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Graves' Thyroid (GTR)—Whole Blood, Plasma,Mononuclear Cells

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). It is more common in women than in men.

Treatment generally involves inhibiting the overproduction of thyroid hormones.

Background


Au

toim

mu

ne

: G

rave

s' T

hyr

oid

114


Au

toim

mu

ne

: H

TR

Fresh HTR WB- Whole blood is drawn from Hashimoto's Thyroiditis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen HTR PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. HTR peripheral blood plasma is obtained by centrifugation of the HTR PB. Frozen HTR PB MNC - Peripheral blood mononuclear cells are isolated from HTR peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh HTR PB MNC is available upon request.

HTR specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Hashimoto's Thyroiditis (HTR)—WholeBlood, Plasma,Mononuclear Cells

Hashimoto's disease is a condition in which your immune system attacks your thyroid. Inflammation from Hashimoto's disease, also known as chronic lymphocytic thyroiditis, often leads to an underactive thyroid gland.

Treatment may includes hormone replacement therapy.

Background


Whole Blood


Fresh HTR-WB40-VK2

HTR-WB100-VK2

HTR-WB400-VK2

HTR-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen HTR-WB011F-VK2

HTR-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen HTR-WB001F 10 million/vial Inquire



ALLCELLS

115


Fresh MS WB- Whole blood is drawn from Multiple Sclerosis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen MS PB Plasma - Plasma is isolated from pheriperal blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. MS peripheral blood plasma is obtained by centrifugation of the MS PB. Frozen MS PB MNC - Peripheral blood mononuclear cells are isolated from MS peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh MS PB MNC is available upon request.

MS specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Multiple Sclerosis (MS)—Whole Blood, Plasma, Mononuclear Cells

Multiple Sclerosis also known as (Disseminated Sclerosis or Encephalomyelitis Disseminata) is an inflammatory disease in which the fatty myelin sheaths around the axons of the brain and spinal cord are damaged leading to demyelination and scarring.

The disease usually occurs in young adults and is more common in women than in men. In MS the body’s own immune system attacks the myelin. When myelin is lost, the axons can no longer effectively conduct electrical signals.

Most likely MS occurs as a result of some combination of genetic, environmental, and infectious factors. Epidemiological studies of MS have provided hints on possible causes for the disease however the exact cause of the disease is still unknown.

Background


Whole Blood


Fresh MS-WB40-VK2

MS-WB100-VK2

MS-WB400-VK2

MS-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen MS-WB011F-VK2

MS-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen MS-PB001F 10 million/ vial Inquire



Au

toim

mu

ne

: M

ult

iple

Sc

lero

sis

116


Au

toim

mu

ne

: O

ste

oa

rth

riti

s

Fresh OA WB -Whole blood is drawn from Osteoarthritis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH). Frozen OA PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Osteoarthritis peripheral blood plasma is obtained by centrifugation of the Osteoarthritis PB. Frozen OA PB MNC - Peripheral blood mononuclear cells are isolated from Osteoarthritis peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Osteoarthritis PB MNC is available upon request.

Whole Blood


Fresh OA-WB40-VK2

OA-WB100-VK2

OA-WB400-VK2

OA-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen OA-WB011F-VK2

OA-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen OA-PB001F 10 million/vial Inquire



Osteoarthritis specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Osteoarthritis (OA)—Whole Blood, Plasma,Mononuclear Cells

Osteoarthritis also known as Degenerative Arthritis or Degenerative Joint Disease, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. A variety of causes (heredity, developmental, metabolic, and mechanical) may initiate processes leading to a loss of cartilage.

Treatment generally involves a combination of exercise, lifestyle modification, and analgesics. OA is the most common form of arthritis and the leading cause of chronic disability in the United States, affecting 27 million people. Osteoarthritis is a highly-studied indication within the therapeutic area of Inflammatory Diseases.

Background


ALLCELLS

117


Au

toim

mu

ne

: P

sori

asi

s

Fresh PSO WB - Whole blood is drawn from Psoriasis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen PSO PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Psoriasis peripheral blood plasma is obtained by centrifugation of the Psoriasis PB. Frozen PSO PB MNC - Peripheral blood mononuclear cells are isolated from Psoriasis peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Psoriasis PB MNC is available upon request.

Whole Blood


Fresh PSO-WB40-VK2

PSO-WB100-VK2

PSO-WB400-VK2

PSO-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen PSO-WB011F-VK2

PSO-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen PSO-PB001F 10 million/vial Inquire



Lead Time

Psoriasis is an autoimmune disease that appears on the skin and occurs when epidermal cells cause an immune response that in turn speeds up the growth cycle of skin cells. Psoriasis has been linked to an increased risk of stroke.

The disorder is a chronic recurring condition that varies in severity from minor localized patches to complete body coverage. Psoriasis can also cause inflammation of the joints which is known as psoriatic arthritis. Between 10-30% of all people with psoriasis experience psoriatic arthritis.

The cause of psoriasis is not fully understood but it is believed to have a genetic component. Various environmental factors have been suggested as aggravating to psoriasis including stress and withdrawal of systemic corticosteroids. Psoriasis has a large hereditary component involving many genes however it is unclear how these genes work together. Many involve the immune system, particularly the major histocompatibility complex (MHC) and T cells.


Diseased Cells—Psoriasis (PSO)—Whole Blood, Plasma,Mononuclear Cells

Psoriasis specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Background

118


Fresh RA WB - Whole blood is drawn from Rheumatoid Arthritis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen RA PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. RA peripheral blood plasma is obtained by centrifugation of the RA PB. Frozen RA PB MNC - Peripheral blood mononuclear cells are isolated from Rheumatoid Arthritis peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations.

Whole Blood


Fresh RA-WB40-VK2

RA-WB100-VK2

RA-WB400-VK2

RA-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen RA-PB011F-VK2

RA-PB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen RA-PB001F 10 million/vial Inquire



OA specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Rheumatoid Arthritis (RA)—Whole Blood,Plasma,Mononuclear Cells

Rheumatoid Arthritis is a chronic inflammatory disorder affecting many tissues and organs but principally attacks the synovial joints. About 1% of the world’s population is afflicted by rheumatoid arthritis; women 3x more often than men. Onset is most frequent between the ages of 30-40 but people of any age can be affected.

When RA is clinically suspected, tests for the presence of rheumatoid factor (RF) are conducted. A negative RF does not rule out a positive diagnosis; rather the arthritis is characterized as seronegative. This is the case in about 15% of patients.

Rheumatoid Arthritis is a highly-studied indication within the therapeutic area of Inflammatory Diseases.

Background


Au

toim

mu

ne

: R

he

um

ato

id A

rth

riti

s

ALLCELLS

119


Fresh SLE WB- Whole blood is drawn from Systemic Lupus Erythematosus patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen SLE PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. SLE peripheral blood plasma is obtained by centrifugation of the SLE PB. Frozen SLE PB MNC - Peripheral blood mononuclear cells are isolated from MS peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh MS PB MNC is available upon request.

Lead Time

Diseased Cells—Systemic Lupus Erythematosus (SLE)—Whole Blood, Plasma, Mononuclear Cells

Systemic Lupus Erythematosus is a Type III Hypersensitivity Reaction caused by an antibody immune complex formation. Often referred to as 'lupus', SLE is a systemic autoimmune disease that can affect any part of the body.

SLE is treatable using immunosuppression, mainly with cyclophosphamide, corticosteroids, and other immunosuppressants. There is currently no cure for SLE. SLE can be fatal although with recent medical advances, fatalities are becoming increasingly rare. Survival for people with SLE in the United States and Canada has risen to approximately 95% at 5 years, 90% at 10 years, and 78% at 20 years.

Background


Whole Blood


Fresh SLE-WB40-VK2

SLE-WB100-VK2

SLE-WB400-VK2

SLE-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen SLE-WB011F-VK2

SLE-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen SLE-PB001F

10 million/ vial Inquire



Au

toim

mu

ne

: S

LE

Product Description

Application

MS specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

120


Au

toim

mu

ne

: D

IA1

Fresh DIA1 WB - Whole blood is drawn from Type I Diabetes patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen DIA1 PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Type I Diabetes peripheral blood plasma is obtained by centrifugation of the Type I Diabetes PB. Frozen DIA1 PB MNC - Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations.

DIA1 specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Application

Diseased Cells—Type I Diabetes (DIA1)—Whole Blood, Plasma,Mononuclear Cells

Diabetes Type I also referred to as Diabetes Mellitus Type I (formally juvenile diabetes), results from autoimmune destruction of insulin-producing beta cells of the pancreas. The subsequent lack of insulin leads to an increase of blood and urine glucose.

Eventually Type I Diabetes is fatal unless treated with insulin. Pancreatic transplants have been used to replenish a natural supply of insulin. Pancreatic islet cell transplantation is experimental though more procedures are occurring annually.

Type I Diabetes is a polygenic disease. Depending on locus or combination of loci, it can be dominant, recessive, or somewhere in-between. The strongest gene, IDDM1, is located in the MHC Class II region on chromosome 6 at staining region 6p21. The appearance of Diabetes-related autoantibodies has been shown to be able to predict the appearance of Diabetes Type I before any hyperglycemia occurs.


Whole Blood


Fresh DIA1-WB40-VK2

DIA1-WB100-VK2

DIA1-WB400-VK2

DIA1-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen DIA1-PB011F-VK2

DIA1-PB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen DIA1-PB001F 10 million/vial Inquire



Product Description Lead Time

Background

ALLCELLS

121


Fresh DIA2 WB - Whole blood is drawn from Type II Diabetes patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen DIA2 PB Plasma - Plasma is isolated from peripheral blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. Frozen DIA2 PB MNC - Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation, the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Diabetic Type II PB MNC is available upon request.

DIA2 specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Product Description

Application

Lead Time

Diseased Cells—Type II Diabetes (DIA2)—Whole Blood, Plasma,Mononuclear Cells

Au

toim

mu

ne

: D

IA2

Diabetes Type II formally known as Non-insulin Dependent Diabetes Mellitus or Adult Onset Diabetes, is a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. This is in contrast to Diabetes Mellitus Type I in which there is an absolute insulin deficiency due to destruction of islet cells of the pancreas.

Type II Diabetes makes up about 90% of cases of Diabetes with the other 10% due primarily to Type I Diabetes and Gestational Diabetes. Obesity is thought to be the primary cause of Type II Diabetes in people who are genetically predisposed to the disease.


Background

Whole Blood


Fresh DIA2-WB40-VK2

DIA2-WB100-VK2

DIA2-WB400-VK2

DIA2-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Frozen DIA2-WB011F-VK2

DIA2-WB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen DIA2-PB001F 10 million/vial Inquire



122


AUTOIMMUNE: INFLAMMATORY BOWEL DISEASE CELLS & TISSUE

Inflammatory Bowel Disease Table of Contents

Crohn's Disease (CRO) 123

Ulcerative Colitis (UC) 124

Inflammatory Bowel Disease Cells & Tissue

AllCells sources samples of Inflammatory Bowel Disease (IBD) cells isolated from Crohn’s Disease and Ulcerative

Colitis patients. IBD plasma and peripheral blood mononuclear cells are available from each disease type. These are

available in frozen, fresh formats upon request.

Patient treatment history and clinical reports are available for each sample.

Donor Criteria & Screening

IBD cells and tissue products are obtained from volunteers participating in an Institutional Review Board (IRB) or

Human Subject Committee approved donor program. All donors sign an informed consent form and are aware that

these cells are used for research purposes. Donors must be over the age of 18.

Background

Inflammatory Bowel Disease is a group of inflammatory conditions of the colon and small intestine. The major types of

IBD are Crohn’s Disease and Ulcerative Colitis. IBD typically present with extra-intestinal manifestations such as liver

problems, arthritis, skin manifestations, and eye problems.

IBD may require immunosuppression to control symptoms such as prednisone, TNF inhibition, azathioprine,

methotrexate, or 6-mercaptopurine. Once the inflammation is successfully controlled, the patient is switched to a lighter

drug to keep the disease in remission.

IBD specimens can be used in preclinical research, drug discovery, drug toxicity, biomarker development, and pre-

selection of indication for clinical trials.

For more information visit: www.allcells.com/ibd/

ALLCELLS

123


Whole Blood


Fresh CRO-WB40-VK2

CRO-WB100-VK2

CRO-WB400-VK2

CRO-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Fresh CRO-PB011F-VK2

CRO-PB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen CRO-PB001F 10 million/vial Inquire



Au

toim

mu

ne

: C

roh

n's

Dis

ea

se

Diseased Cells—Crohn's Disease (CRO)—Whole Blood, Plasma,Mononuclear Cells

Fresh CRO PB-Whole blood is drawn from Crohn's Disease patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen CRO PB Plasma - Plasma is isolated from pheriperal blood collected into your choice of anticoagulant: EDTA(VK2) or sodium heparin. Crohn's Disease peripheral blood plasma is obtained by centrifugation of the PB. Frozen CRO PB MNC - Peripheral blood mononuclear cells are isolated from Crohn's Disease peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Crohn's PB MNC is available upon request.

CRO specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Lead Time

Crohn’s Disease,also known as Regional Enteritis, is a type of Inflammatory Bowel Disease that may affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of symptoms. Primarily, Crohn’s Disease causes abdominal pain, diarrhea, vomiting, weight loss, and may also cause complications outside the gastrointestinal tract such as skin rashes, arthritis, inflammation of the eye, tiredness, and lack of concentration.

There is no cure for Crohn’s Disease and remission may not be possible or prolonged, if achieved at all. In cases where remission is possible, relapse can be prevented and symptoms controlled with medication, lifestyle change, and in some cases surgery. Treatment for Crohn’s Disease only occurs when symptoms are active and involves first treating the acute problem then maintaining remission.


Product Description

Application

Background

124


Diseased Cells—Ulcerative Colitis (UC)—Whole Blood, Plasma, Mononuclear Cells

Fresh UC PB - Whole blood is drawn from Ulcerative Colitis patients in your choice of anticoagulant: EDTA(VK2) or sodium heparin(VNH).Frozen UC PB Plasma - Ulcerative Colitis peripheral blood plasma is obtained by centrifugation of the PB. This product has a diminished number of cells and platelets. Fresh Ulcerative Colitis PB plasma is available upon request.Frozen UC PB MNC - Peripheral blood mononuclear cells are isolated from Ulcerative Colitis peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. MNC can be processed further to isolate subpopulations. Fresh Ulcerative Colitis PB MNC is available upon request.

Lead Time

Ulcerative Colitis is a form of Inflammatory Bowel Disease of the colon that includes characteristic ulcers or open sores. The main symptom of active disease is usually constant diarrhea mixed with blood of gradual onset. UC is an intermittent disease with periods of exacerbated symptoms and periods that are relatively symptom-free. Treatment is generally required for the disease to go into remission. Ulcerative Colitis occurs in 35-100 people for every 100,000 in the United States.

Standard treatment for UC depends on extent of involvement and disease severity. The goal is to induce remission initially with medications followed by the administration of maintenance medications to prevent relapse of the disease.


Whole Blood


Fresh UC-WB40-VK2

UC-WB100-VK2

UC-WB400-VK2

UC-WB400-VNH

40 ml

100 ml

400 ml

400 ml

Inquire

Inquire

Inquire

Inquire

Plasma

Fresh UC-PB011F-VK2

UC-PB011F-VNH

5 ml

5 ml

Inquire

Inquire


Frozen UC-PB001F 10 million/vial Inquire



Product Description

Background

UC specimens can be used in:• Pre-clinical research• Drug discovery• Drug toxicity• Biomarker development• Pre-selection of indication for clinical trials

Application

Au

toim

mu

ne

: U

lce

rati

ve C

oli

tis

ALLCELLS

125


ANIMAL PRIMARY CELLS & TISSUE

Animal Primary Cells Table of Contents

Non-Human Primate (NHP) 126Mouse (Murine) 127-132Rat 133-141

Pig (Porcine) 142

Non-Human Primate Cells & Tissue

Non-human primate cells are obtained from NIH-supported primate research centers. The blood or bone marrow is taken

from live normal/untreated non-human primates as a part of the research centers’ tissue program. AllCells offers blood and

bone marrow non-human primate products from the following species: M. fascicularis, M. nemestrina, or M.mulatta. None of

the aforementioned species are endangered or threatened by extinction.

For more information visit: www.allcells.com/non-human-primate/

Mouse Cells & Tissue

The rat and mouse are great models for pre-clinical research. They are some of the smallest mammals with a great degree

of genetic homology to human, which makes them perfect candidates for efficient tissue procurement and study. AllCells

uses mouse cells from C57BL/6 mice for primary tissue and cell isolation.

For more information visit: www.allcells.com/mouse/

Rat Cells & Tissue

The rat and mouse are great models for pre-clinical research. They are some of the smallest mammals with a great degree

of genetic homology to human, which makes them perfect candidates for efficient tissue procurement and study. AllCells

uses rat cells from Sprague-Dawley (SD) rats for primary tissue and cell isolation.

For more information visit: www.allcells.com/rat/

126


Related ProductsHuman BM-MNCHuman PB-MNC

Product Description

NHP-Plasma is processed through centrifugation to diminish cells and platelets.NHP-PB-MNC are enriched by density separation. NHP-BM-MNC are isolated from bone marrow by diluting the bone marrow with phosphate-buffered saline and using gradient separation techniques. After centrifugation, the MNC layer is collected. MNC can be processed to isolate subpopulations. NHP-BM-CD34+ cells are isolated from NHP bone marrow mononuclear cells using a direct immunomagnetic CD34+ MicroBead labeling system.

Application

NHP products can be used to study:• Non-human primate lymphocyte and monocyte functions • Evolutionary conservation and homology between human and

non-human primate lymphocytes and monocytes• The homology of BM-CD34+ cells between humans and non-

human primates, especially M. fascicularis (cynomolgus) monkeys.

• The hematopoietic stem cell potential of the non-human primate bone marrow CD34+ cells.

• Myeloid lineage differentiation and maturation• Neutrophil transplantation potential

Animal Cells—Non-Human Primate—Plasma/Mononuclear/CD34+ Stem Cells

An

ima

l C

ell

s: N

on

-Hu

ma

n P

rim

ate

Plasma


Frozen/PB-Plasma NHP-PB001 5 ml Inquire

Frozen/BM-Plasma NHP-BM001 5 ml Inquire


Frozen NHP-PB002 10 million/vial Inquire

Bone Marrow Mononuclear Cells

Frozen NHP-BM002 10 million/vial Inquire

Bone Marrow CD34+ Stem/Progenitor Cells

Frozen NHP-BM004 1 million/vial Inquire


ALLCELLS

127



FrozenMBM-001F

MBM-002F

5 million/vial

10 million/vial

Inquire

Inquire


Mouse—Bone Marrow—MNC

Animal Cells—Mouse—Bone Marrow—Mononuclear Cells

Product Description

Mouse bone marrow is procured from the mouse femurs. The mononuclear cells are enriched by density gradient separation.

Application

Mouse BM-MNC can be used:• Directly or in culture, as the source of an animal

model for human bone marrow hematopoietic stem cell and mesenchymal stem cell research

• For novel hematopoietic cell marker and protein identification as well as pathway analysis

• As an animal model for transplantation and engraftment studies

• To study homology or cross-species conservation in hematopoiesis and mesenchymal qualities among mammals or larger group of organisms

Purity

The purity is guaranteed to be above 90% as assessed by flow cytometric analysis.

Lead Time


Related ProductsHuman BM MNCRat BM MNC

An

ima

l C

ell

s: M

ou

se

128


An

ima

l C

ell

s: M

ou

se

Animal Cells—Mouse—Peripheral Blood—Mononuclear Cells


FrozenMOSPB-001F

MOSPB-002F

5 million/vial

10 million/vial

Inquire

Inquire


Mouse—Peripheral Blood—MNC

Product Description

Mouse peripheral blood mononuclear cells are collected from fresh blood which enriches lymphocytes and monocytes while depleting mature granulocytes. The mononuclear fraction is then further processed to eliminate red blood cells and platelets.

Application

Mouse PB-MNC can be used to study: • Isolate and study MNC subpopulations• Act as controls for therapeutic research, involving

lymphocytes and monocytes• Study the relationship among MNC subpopulation (for

example, the relationship among T Cells, B Cells, and monocytes)

Purity

The purity is guaranteed to be above 90% as assessed by flow cytometric analysis

Lead Time


ALLCELLS

129


Animal Cells—Mouse—Astrocytes

Cerebellar


Frozen Cerebellar MOCR-001F 0.5 million/vial Inquire

Cortex

Frozen Cortex MCTX-001F 0.5 million/vial Inquire

Hippocampal

Frozen Hippocampal MOHP-001F 0.5 million/vial Inquire


Mouse—Astrocytes

Product Description

Different parts of the C57BL/6 mouse brain, including the cortex, hippocampus, and cerebellum, are dissociated enzymatically and mechanically into suspension of single cells. Next, the cells are seeded, and the astrocytes are enriched in vitro, using specific medium and cultural conditions.

Application

Mouse Astrocytes can be used to study:• Astrocyte structure and function, such as calcium activation,

glutamate release and recycling• Metabolic support of neurons • Regulation of synaptic transmission• Communication with oligodendrocytes • Vasomodulation • Astrocytes' role in the blood brain barrier• Conservation or homology in mammals or in the greater

spectrum of organisms • Astrocytoma and other diseases

Purity


Lead Time


An

ima

l C

ell

s: M

ou

se

130


An

ima

l C

ell

s: M

ou

se

Animal Cells—Mouse—Embryonic Fibroblast


Frozen MEF-001(CF-1)

MEF-001(ICR)

MEF-002(CF-1)

MEF-002(ICR)

1 million/vial

1 million/vial

4 million/vial

4 million/vial

Inquire

Inquire

Inquire

Inquire

P2, Irradiated

Frozen MEF-005(CF-1)

MEF-005(ICR)

MEF-006(CF-1)

MEF-006(ICR)

1 million/vial

1 million/vial

5 million/vial

5 million/vial

Inquire

Inquire

Inquire

Inquire


Mouse—Embryonic Fibroblast

Product Description

Mouse primary embryonic fibroblasts(MEF) are dissociated from day 13.5 and 14 mouse embryos. MEF(P0, untreated) can be passaged a limited number of times for 4-5 population doublings. They display morphologic and growth properties equivalent to freshly prepared cells when approved media and supplements are used. MEF(P2,Irradiated) are used as a feeder layer for culturing embryonic stem cell(ESCs),including mouse and human ESCs, in their undifferentiated state.

Application

Mouse Embryonic Fibroblast can be used to study: • MEF are used as a feeder layer in mouse and human

pluripotent stem cell culture.

Purity

MEF is characterized by immunofluorescence with antibody specific to fibronectin.MEF is negative for mycoplasma, bacteria, yeast, and fungi.

Lead Time


P0, Untreated

ALLCELLS

131


Animal Cells—Mouse—Splenocytes


FrozenMSPL-001F

MSPL-002F

25 million/vial

50 million/vial

Inquire

Inquire


Mouse—Splenocytes

Product Description

Mouse spleen is dissociated into a single cell suspension. Next, the splenocytes are enriched by density separation.

Application

Mouse Splenocytes can be used to study: • Growth factor and cytokine release from lymphocytes as

well as monocytes and Kupffer cells.• Function and mechanism of normal and diseased models

in the reticuloendothelial system.• Homing and processing of red blood cells.• Antigen-recognition conditioning and proliferation of

lymphocytes and monocytes.• Reserve mechanisms for red blood cells and monocytes.

Purity


Lead Time


An

ima

l C

ell

s: M

ou

se

132


An

ima

l C

ell

s: M

ou

se

Animal Cells—Mouse—Purified Cells from Spleen

CD4+ T Cells


Frozen MSPL-011F 5 million/vial Inquire

CD8+ T Cells


CD19+ B Cells


CD11b+ Cells



Mouse—Purified Cells from Spleen

Product Description

Mouse spleen is dissociated into a single cell suspension. The splenocytes are enriched by density separation. CD4+ T Cells, CD8+T Cells, CD19+ B and CD11b+ Cells are isolated using specific immunomagnetic methods.

Application

Mouse-CD4+ T Cells can be used to study:• Regulation• Gene rearrangement • Antigen recognition and activation • Growth factor and cytokine receptor studies • Autoimmunity • Normal and diseased pathways

Mouse-CD8+ T Cells can be used to study: • Self/non-self recognition • Tumor and viral particles detection• Cytolytic properties • Immunosuppression for organ/tissue transplantation

Mouse-CD19+ B Cells can be used to study:• B lymphopoiesis• Rearrangement of the immunoglobulin genes • Antibody production and to further distinguish • Functions of B cell subsets

Purity


Lead Time


ALLCELLS

133



Frozen RBM-001F

RBM-002F

5 million/vial

10 million/vial

Inquire

Inquire


Rat—BM—MNC

Animal Cells—Rat—Bone Marrow—Mononuclear Cells

Product Description

Rat bone marrow is procured from the rat femurs. The MNC are subsequently enriched by density gradient separation.

Application

Rat-BM-MNC can be used:• Directly or in culture, as the source of an animal model

for human bone marrow hematopoietic stem cell and mesenchymal stem cell research

• For novel hematopoietic cell markers • For protein identification• For pathway analysis• As animal model for transplantation and engraftment studies.• To study homology or cross-species conservation in

hematopoiesis and mesenchymal qualities among mammals or larger group of organisms

Lead Time


Related ProductsMouse BM-MNC

An

ima

l C

ell

s: R

at

134


An

ima

l C

ell

s: R

at


Frozen RBM-005F

RBM-006F

RBM-007F

0.5 million/vial

1 million/vial

5 million/vial

Inquire

Inquire

Inquire


Rat—BM—Mesenchymal Stem Cells

Animal Cells—Rat—Bone Marrow—Mesenchymal Stem Cells

Product Description

Bone marrow is procured from rat femurs. Bone marrow mononuclear cells are expanded for up to 2 weeks on tissue culture plastic with MSC media. Sprague-Dawley Rat MSC express CD90 and CD29. They do not express CD45 and CD11b.

Background

Mesenchymal Stem Cells, or MSCs have long been believed to be a collective, heterogeneous pool of cells responsible for the replenishment of supportive and connective tissues of the body, such as bone, cartilage, adipose, muscle, other soft tissues, as well as the bone marrow stroma where hematopoietic stem and progenitor cells expand and thrive. Their role in the interactions with and expansion support of hematopoietic stem cells in the bone marrow is absolutely critical in the maintenance of the entire blood cells system. Recent studies have begun to utilize the dynamic and multi-potent properties of MSC in hopes to engineer them into more diverse types of cells and tissues.

Application

As an animal model, Rat-BM-MSC can be used to:• Study non-hematopoietic pluripotency potentials and

characteristics to develop connective tissues, such as bone and cartilage

• Act as stroma and feeder cells for expansion or differentiation of hematopoietic stem/progenitor cells

Purity

Purity is guaranteed over 90%.

Lead Time


Related ProductsHuman Bone Marrow MSCMouse-MSC

ALLCELLS

135


Animal Cells—Rat—Bone Marrow—CD90+ Cells


Frozen RBM-003F

RBM-004F

1 million/vial

5 million/vial

Inquire

Inquire


Rat—Bone Marrow—CD90+ Cells

Product Description

CD90/Thy-1 is considered a surrogate marker for various kinds of stem cells, particularly hematopoietic stem cells. Murine HSC falls under the CD90/Thy-1hi sub-population. In rats CD90 is also expressed on thymocytes, recent thymic emigrants, neurons, and other cell types.

Application

Rat-BM-CD90 can be used for:• The study of rat hematopoiesis • Stem cell biology• Pluripotent studies

Purity is guaranteed over 90%.

Lead Time


Procedure

The CD90+ cells are isolated via immunomagnetic method from purified density-rich bone marrow mononuclear cells.

Related ProductsHuman CD34NHP CD34

Purity

An

ima

l C

ell

s: R

at

136


An

ima

l C

ell

s: R

at

Animal Cells—Rat—Peripheral Blood—Mononuclear Cells


Frozen RPB-001F

RPB-002F

5 million/vial

10 million/vial

Inquire

Inquire


Product Description

Rat peripheral blood mononuclear cells are collected from fresh blood which enriches lymphocytes and monocytes while depleting mature granulocytes. The mononuclear fraction is then further processed to eliminate red blood cells and platelets.

Application

Rat PB-MNC can be used to:• Isolate and study MNC subpopulations.• Act as controls for therapeutic research, involving lymphocytes and monocytes.• Study the relationship among MNC subpopulation (for example, the relationship among T Cells, B Cells, and monocytes)

Purity

The purity is guaranteed to be above 90%.

Lead Time


Rat—Peripheral Blood—Mononuclear

ALLCELLS

137


Animal Cells—Rat—Astrocytes

Cerebellar


Frozen RACR-001F 0.5 million/vial Inquire

Cortex

Frozen RCTX-001F 0.5 million/vial Inquire

Hippocampal

Frozen RAHP-001F 0.5 million/vial Inquire


Product Description

Different parts of the rat brain, including the cortex, hippocampus, and cerebellum, are dissociated enzymatically and mechanically into suspension of single cells. Next, the cells are seeded, and the astrocytes are enriched in vitro, using specific medium and cultural conditions.

Application

Rat Astrocytes can be used:• In animal studies of astrocyte structure and functions• To study function conservation or homology in mammals • To research astrocytoma and other diseases.

Purity


Lead Time


Rat—Astrocytes

An

ima

l C

ell

s: R

at

138


An

ima

l C

ell

s: R

at

Animal Cells—Rat—Meningeal Cells, Microglia


Frozen RMGC-001F 0.5 million/vial Inquire

Microglia

Frozen RM-001F 1 million/vial Inquire


Meningeal Cells

Product Description

Rat meninx is isolated surgically from the outer membrane of the rat brain. Next, the meninx is enzymatically segregated into single cell suspension and cultivated by a primary culture process before harvest and cryopreservation. The rat meningeal cells are positive for fibronectin, negative for: GFAP, smooth muscle actin and thylol.

Microglia are specialized immune cells of the brain. Microglia is isolated from day 2 rat brain tissue. Microglia act as brain macrophages when programmed cell death occurs during brain development or when the CNS is injured or pathologically damaged. Microglia can express CD 11b/c.

Application

Rat Meningeal Cells can be used to study:• Structure and the protective and supportive functions of the

rat brain• Diseases such as meningitis and meningiomaRat microglia cells can be used to:• Research Alzheimer and Parkinson’s disease • Research on the role of microglia in synaptic plasticity• Leveraging microglia for therapeutic roles• Neurodegenerative disease conditions

Purity


Lead Time


ALLCELLS

139



Frozen RIS-001F

RIS-002F

400 IEq

600 IEq

Inquire

Inquire


Rat—Lysis Islets

Lead Time


Product Description

Rat Pancreatic Islets are isolated from male rats weighing between 301 to 325 grams and approximately 8.5 to 9.5 weeks of age. AllCells Rat Pancreatic Islets are measured by IEq standard. Rat pancreatic islets purity is verified by dithizone or Newport Green, and the viability by propidium iodide/acridine orange counter stains. Upon request, the islets can be stabilized in overnight culture prior to shipment.

Application

Rat Lysis Islets can be used for the following:• Diabetic studies• GSIS Assay• Short and long-term culture and survival experiments• Cryopreservation studies• Immunosupression studies for transplantation

Animal Cells—Rat—Lysis Islets

An

ima

l C

ell

s: R

at

140


An

ima

l C

ell

s: R

at

Animal Cells—Rat—Splenocytes


Frozen RSPL-001F

RSPL-002F

25 million/vial

50 million/vial

Inquire

Inquire


Product Description

Rat spleen is mechanically dissociated into a single cell suspension. The splenocytes are enriched by density separation. The rat splenocytes can be used to isolate CD4+ T cells, CD8+ T Cells, and CD45R+ B Cells, using specific immunomagnetic methods.

Application

Rat Splenocytes can be used to study: • Growth factor and cytokine release from lymphocytes,

monocytes, and Kupffer cells• Function and mechanism of normal and diseased models

in the reticuloendothelial system• Homing and processing of red blood cells• Antigen-recognition conditioning and proliferation of

lymphocytes and monocytes• Reserve mechanisms for red blood cells and monocytes

Rat—Splenocytes

Purity


Lead Time


ALLCELLS

141


An

ima

l C

ell

s: R

at

CD4+ T Cells


Frozen RSPL-011F 5 million/vial Inquire

CD8+ T Cells


CD45R+ B Cells



Product Description

Rat spleen is mechanically dissociated into a single cell suspension. The splenocytes are enriched by density separation. CD4+ T cells, CD8+ T Cells, and CD45R+ B Cells and then isolated using specific immunomagnetic methods.

Application

Rat-CD4+ T Cells can be used to study:• Regulation• Gene rearrangement • Antigen recognition and activation • Growth factors and cytokine receptors • Autoimmunity • Normal and diseased pathways

Rat-CD8+ T Cells can be used to study: • Self/non-self recognition • Tumor and viral particles detection• Cytolytic properties • Immunosuppression for organ/tissue transplantation

Rat-CD45R+ B Cells can be used to study:• B lymphopoiesis• Rearrangement of the immunoglobulin genes • Antibody production • Functions of B cell subsets

Rat—Purified Splenocytes

Purity


Lead Time


Animal Cells—Rat—Purified Splenocytes

142



Frozen

PORC-PB001F

PORC-PB002F

PORC-PB003F

10 million/vial

100 million/vial

200 million/vial

Inquire

Inquire

Inquire


Pig—Peripheral Blood—MNC

Animal Cells—Pig—Peripheral Blood—Mononuclear Cells

Product Description

AllCells’ Porcine Mononuclear Cells are isolated from fresh blood of Yorkshire pigs . The mononuclear fraction is then further processed to eliminate red blood cells and platelets.

Background

Swine have increasingly become utilized as biomedical research models in the last two decades. This increased use as an animal model is not only a result of regulatory pressure on other large animal species, but also because swine are recognized as a suitable animal model for human disease based upon their comparative anatomy and physiology. Swine are used as general surgical models of most organs and systems, for cardiovascular research including atherosclerosis, for digestive system models, and in recent years in transplantation and xenografic research.

They are being explored as models in many other systems because of the widespread availability of both domestic and miniature breeds. Hand-in-hand with this increase in the number of swine in research, have come technical developments in surgery, anesthesia, husbandry and handling techniques. These technical advancements have made it easier to use this species in research and have also improved the humane care and use of swine by research institutions worldwide.

Background Reference:http://www.nal.usda.gov/awic/pubs/swine/swine.htm

Application

Pig PB-MNC can be used to:• Isolate and study MNC subpopulations• Study cytokines secretion curves• Act as controls for porcine therapeutic research,

involving lymphocytes and monocytes

Lead Time

These frozen products have a lead time of 1-2 business days.

Related ProductsHuman PB MNC

An

ima

l C

ell

s: P

ig

ALLCELLS

143


Cell Culture Media, Cryopreservation Media and Cytokines

AllCells features basic and defined Cell Culture Media to suit your specific cell culture needs. In addition we have begun

manufacturing our own AllCells Cryopreservation Media, formulated to work best with our products. For most general

research purposes, we provide an array of the most commonly-used human cell culture media. For our specific cell

products, i.e. mesenchymal stem cells (MSCs), AllCells features defined media for the expansion and proliferation of these

cell types. See following pages for all of our Cell Culture products!

For more information visit: www.allcells.com/media/ and www.allcells.com/cytokines/

Basic Cell Culture Media:

Dulbecco's Modified Eagle's Medium (DMEM-001)

Dulbecco's Modified Eagle's Medium (DMEM-002)

Iscove's Modification of DMEM (IMDM-001)

Roswell Park Memorial Institute (RPMI-001)

Defined Cell Culture Media:

MSC (adult stem cell culture):

MSC Basal Medium BM MSC, 500 ml (MSC-002)

MSC Stimulatory Supplement BM MSC, 50ml (MSC-003)

Macrophage:

Macrophage Basal Medium for Normal PB Monocyte Derived Macro-

phages, 450 mL (PB-MDM-002)

Macrophage Stimulatory Supplement for Normal PB Monocyte Derived

Macrophages, 50mL (PB-MDM-003)

Cryopreservation Media:

AllCells Cryopreservation Media (CRYO-001)

Cytokines:

Human Flt-3-Ligand

Human Granulocyte Stimulating Factor

Human Granulocyte Macrophage Stimulating Factor

Human Interleukin-3

Human Interleukin-4

Human Interleukin-6

Human Macrophage Colony Stimulating Factor

Cytokines Continued:

Human Stem Cell Factor

Human Thrombopoietin

CELL CULTURE PRODUCTS

144


Product Description

Dulbeco's Modified Eagle's Medium (DMEM-001) with 4.5g/L glucose, sodium pyruvate & L-glutamine. This media contains L-glutamine, Sodium Bicarbonate and Sodium Pyruvate. pH 7.2 + 0.2, Osmolality 335 + 30 mOsm

Dulbeco's Modified Eagle's Medium (DMEM-002 ) with 1g/L glucose, sodium pyruvate & L-glutamine. This media contains L-glutamine, Sodium Bicarbonate and Sodium Pyruvate. pH 7.2 + 0.2, Osmolality 335 + 30 mOsm

Iscove's Modification of DMEM (IMDM-001 ) with L-glutamine & 25mM HEPES. This media contains L-glutamine, HEPES, Sodium Bicarbonate and Sodium Pyruvate. pH 7.2 + 0.2, Osmolality 265 + 310 mOsm

Roswell Park Memorial Institute (RPMI-001) with L-glutamine & HEPES. This media contains L-glutamine, HEPES, and Sodium Bicarbonate. pH 7.2 + 0.2, Osmolality 290 + 30 mOsm

AllCells Cryopreservation Media (CRYO-001) This media contains DMSO and proprietary reagents that increase the viability of cryopreserved cells. Store at -80 C. This media has a shelf life of 3 months from the date of manufacture when stored properly. Avoid multiple freeze thaws of this media. Cryopreservation media is shipped on dry ice. MSDS available upon request.

Stability/Storage

Store at 2 - 80C. Protect from light. These products have a shelf-life of 18 months from the date of manufacture when stored prop-erly. Avoid freezing of this media as it may cause precipitation upon thawing.

Shipping Information

Media is shipped at 40C on cold gel pack. MSDS available upon request.

Cell Culture Media

Catalog # QTY/Unit Price/Unit

DMEM-001 500 ml/bottle Inquire

DMEM-002 500 ml/bottle Inquire

IMDM-001 500 ml/bottle Inquire

RPMI-001 500 ml/bottle Inquire

Cryopreservation Media

CRYO-001 50 ml/bottle Inquire


Cell Culture Products—Basic Cell Culture & Cryopreservation Media

Ce

ll C

ult

ure

Pro

du

cts

ALLCELLS

145


Cell Culture Products—Defined Cell Culture Media

Mesenchymal Stem Cell Media


MSC-002 500 ml/bottle Inquire

MSC-003 500 ml/bottle Inquire

Macrophage Media

PB-MDM-002 450 ml/bottle Inquire

PB-MDM-003 50 ml/bottle Inquire


Product Description

Mesenchymal Stem Cell Basal Medium (MSC-002)-designed to support AllCells BM-MSC. MSC Basal Medium contains L-glutamine, 110mg/L sodium pyruvate, and pyridoxine hydrochloride. This product does not contain growth factors and antibiotics. The pH range is 7.1 to 7.5. MSC Basal Medium should be used in combination with AllCells MSC Stimulatory Supplement.

MSC Stimulatory Supplement (MSC-003)- designed to initiate and maintain growth of AllCells BM-MSC. This product contains pre-selected Fetal Bovine Serum and supplements.

Macrophage Basal Medium (PB-MDM-002)- product contains L-glutamine, 110mg/L sodium pyruvate, and pyridoxine hydrochloride. This product does not contain growth factors and antibiotics. pH is 7.1 to 7.5. The Macrophage Basal Medium should be used in combination with AllCells Macrophage Stimulatory Supplement. This product is stable for one month after the stimulatory supplement has been added and stored at 2 to 8°C.

Macrophage Stimulatory Supplement (PB-MDM-003)- designed to initiate and maintain growth of AllCells Monocyte Derived Macrophages. This product contains pre-selected Fetal Bovine Serum and supplements.

Stability/Storage

Store at 2 - 80C. Protect from light. These products have a shelf-life of 18 months from the date of manufacture when stored prop-erly. Avoid freezing of this media as it may cause precipitation upon thawing.


Media is shipped at 40C on cold gel pack. MSDS available upon request.

Ce

ll C

ult

ure

Pro

du

cts

146


Ce

ll C

ult

ure

Pro

du

cts

Product Description

AllCells Cytokines and Growth Factors are protein products used in tissue culture for human cell types. They can be utilized for proliferation and/or differentiation of hematopoietic and immune cells.

Stability/Storage

Storage Prior to Reconstitution: -20ºC Product Reconstitution: Sterile water at 100µg/mL.Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80 ºC and avoid repeat freeze thaws.


Shipped at room temperature. MSDS available upon request.

Human Flt-3 Ligand


GF-FTL3L-2UG 2 ug/vial Inquire



Human Granulocyte Colony Stimulating Factor

GF-G-CSF-2UG 2 ug/ vial Inquire

GF-G-CSF-10UG 10 ug/vial Inquire

GF-G-CSF-100UG 100 ug/vial Inquire

Human Granulocyte Macrophage Stimulating Factor

GF-GM-CSF-5UG 5 ug/ vial Inquire

GF-GM-CSF-20UG 20 ug/vial Inquire

GF-GM-CSF-100UG 100 ug/vial Inquire


Cell Culture Products—Cytokines

ALLCELLS

147



Human Interleukin-3


GF-IL-3-2UG 2 ug/vial Inquire



Human Interleukin-4




Human Interleukin-6





Product Description


Stability/Storage




Ce

ll C

ult

ure

Pro

du

cts

148


Ce

ll C

ult

ure

Pro

du

cts

Product Description


Stability/Storage




Human Macrophage Colony Stimulating Factor


GF-M-CSF-2UG 2 ug/vial Inquire



Human Stem Cell Factor

GF-SCF-2UG 2 ug/vial Inquire



Human Thrombopoietin

GF-TPO-2UG 2 ug/vial Inquire





ALLCELLS

149


TECHNICAL NOTES

Technical Notes Table of Contents

• How to Count Cells 150

• How to Thaw Frozen Cells 151

• How to Freeze Cell Products 152-153

• How to Purify Bone Marrow MNC 154-155

• How to Count Leuko Pak 156

• How to Deplete Red Blood Cells 157

• How to Passage & Subculture Cells:

-Mesenchymal Stem Cells 158

-Monocyte-Derived Macrophages 159

• How to Isolate MNC Using a Ficoll Gradient 160

For more information including PDF versions of the Technical Notes and our BioTube Technical Videos visit: www.allcells.com/support/how-to/

150


When you receive an AllCells product, please count the cells IMMEDIATELY. AllCells is not liable for any cell loss during subsequent processing. Please note: For Leuko Paks, please refer

to "How to Count: Leuko Pak" page 156.How to CountIn a biosafety hood, use a 5 mL pipet to mix the cell suspension very well and to separate any cell clumps. For any cells in a 1.5 or 2 mL tube, mix cells with a P1000 pipet.

Take a 10 µL sample from the vial. Mix the 10µL sample with 10µL of trypan blue. Dilute the cells if necessary and count the number of cells in 4 quadrants of hemacytometer (see red quadrants in figure

below right) to determine the viability. Table 1: Common Dilution FactorsN = # of cells counted on all 4 squares of a hemacytometer

d = dilution factor

Trypan Blue MethodEquation for Cell Count:# of cells/vial = N / 4 x d x ____mL = _____x 104

Equation for Viability:# of cells excluded by trypan blue / total number of cells x 100% = ______%

Table 2: Common Dilution Factors for MNC Products with RBC (Cord Blood and Bone Marrow Mononuclear Cell Products)

Methylene Blue MethodEquation for Cell Count:

# of cells/vial_____ / x 20 x d x ___mL = _____ x 106

NOTE: Methylene Blue Method will not give you the cell viability. To find cell viability use Trypan Blue Method.

If your cell count is significantly lower than what AllCells claims,

please take the following steps:

1. Check the cell suspension and see if there are any cell clumps. If so, try to separate the cells using a P1000 pipet tip. Most of the cell clumps should be small and easily separable.

2. The optimal cell concentration is 50 to 100 cells on one large hemacytometer square (total 200 to 400 per hemocytometer). Please make the proper dilution or adjust the concentration and count again.

3. Immediately report any significant discrepancies to AllCells.

Hemacytometer MethodHausser BrightLine Directions for Use (http://www.hausserscientific.com/hausserbrightlinedirect.htm)

Usage: cell countsCell Depth: 0.100mm+/- 2% (1/10mm)Volume: 0.1 MicroliterRuling Pattern: Improved Neubauer, 1/400 Square mm

Neubauer Ruling (Diagram credit: Hausser Scientific)

To clean the counting chamber: After counting, remove the cover glass and clean the counting chamber with water or a mild cleaning solution (10% solution of bleach). Dry the counting chamber with a soft cloth or wipe, or rinse with acetone.

For a technical video of this guide visit our BioTube page at:www.youtube.com/user/AllCells

Tube Size Cell Number/Unit Number

Cell Sample

0.4%Trypan Blue Amount

PBS (1x) Dilution Factor

1.5 to 2mL 0.5 to1 x106 10µL 10µL --- 2

5mL 5 x106 10µL 10µL --- 2

15mL 10 x106 10µL 10µL --- 2

15mL 15 to 20 x106 10µL 10µL 80µL 10

50 mL 30 to100 x106 10µL 10µL 80µL 10

Tube Size Cell Number/Unit Number

Cell Sample

*3% Acetic Acid with Methylene Blue Solution

50 mL 100-200 x106 25 µL 475 µL

50 mL 200-400 x106 25 µL 475 µL

*StemCell Technologies, Inc., Vancouver; Cat. No. 07060, Tel: 604-877-0713

Technical Notes—How to Count Cells

Te

ch

nic

al

No

tes

ALLCELLS

151


Shipping and StorageFor short-term storage (< 1 month), store in -80° C freezer. For long-term storage (> 1 month), store in the “vapor phase” of a liquid nitrogen tank.

General Medium Requirements• IMDM, α-MEM, or RPMI-1640 containing 10% FBS• DNase I

Thawing Cells1. In a 37°C water bath, warm medium (IMDM, α-MEM, or RPMI-

1640) containing 10% FBS.

2. Clean the frozen vial with 70% alcohol before thawing. In a biosafety hood, twist the cap a quarter-turn to relieve pressure, and then retighten the cap.

3. In a 37°C water bath, quickly thaw the vial for approximately 2 minutes. Be careful not to submerge the entire vial in the water bath. Do not remove the vial until a tiny ice-crystal is left.

4. Remove vial from water bath and clean the outside of the vial with 70% alcohol.

5. In a biosafety hood, measure the cell suspension volume.

6. Count the cells using the Trypan Blue Method. Take a 10µl sample from the vial. Mix 10µl of the sample with 10µl of trypan blue. Dilute the cells if necessary and count the number of cells on a hemacytometer to determine the viability.

N = # of cells counted on all 4 squares of a hemacytometerd= dilution factor

Equation for Cell Count: # of cells/ vial = N / 4 x d x ____ml = _____ x 104

Equation for Viability: # of cells excluded by trypan blue/ total number of cells x 100% = ______%

7. (Optional) In order to avoid occasional clumping, when thawing units with large cell numbers (>100x106), add DNase I to a 50ml conical tube.a. To thaw purified cells for culture purpose, a total of 100µg is needed. b. To thaw mononuclear cells for cell culture purpose, a total of 300µg is needed.

Note: DNase I should not be used if the cells are used for purification of genomic DNA or if cDNA is for RNA synthesis.

8. Aseptically, using sterile techniques, transfer the cell suspension to the 50ml conical tube, which contains DNase I.

9. Rinse the vial with 1ml of 37°C medium. In the 50ml conical tube, slowly add the rinse drop by drop (5 seconds per drop) to the cells while gently shaking the tube.

10. Next, slowly add the 37°C medium drop by drop (5 seconds per drop) to the cells up to a total volume of 15 to 20 ml (about 10 times or more than the volume of the vial).

11. Centrifuge the cell suspension at 200xg at room temperature for 15 minutes.

12. Using a pipet, carefully remove most of the supernatant (save the supernatant in a second tube). Leave a few milliliters of the supernatant behind so the cell pellet is not disturbed. Gently resuspend the cell pellet in the remaining few milliliters of medium.

Note: DMSO is heavier than medium. Try to aspirate and discard the supernatant soon after centrifugation.

13. While gently shaking the tube, slowly add an additional 15 to 20ml of fresh medium to the tube.

14. Centrifuge the cell suspension at 200xg (1000 RPM on Beckman Coulter™ Centrifuge) at room temperature for 15 minutes.

15. Using a pipet, carefully remove all but 2ml of supernatant. Gently resuspend the cell pellet in the remaining 2ml of medium and count. If the cell count is lower than expected, centrifuge the supernatant saved in Step 11 at a higher speed, count and combine if necessary.

16. Plate the cells in appropriate-sized dish/flask. Incubate in a humidified incubator specified for tissue culture at 37°C with 5% CO2. Your cells are now ready for downstream applications.


Table 3: Typical Cell Suspension Volumes

Cell Unit Cell Suspension Volume

< 1 x 106 1.2 ml

> 1x106 1.8 ml

Technical Notes—How to Thaw Frozen Cells

Te

ch

nic

al

No

tes

152


Te

ch

nic

al

No

tes

The below information is for customers who have extra fresh cell products or have fresh cells that are not needed immediately for processing. Please note once Cryopreservation Media is added the process cannot be stopped and should be followed through to completion. Freezing cells risks poorer viability and poorer cell recovery after thaw.

How to Freeze Cell Products (with the exception of bone marrow mononuclear cells)

Reagent and Materials Required

• Cryopreservation Media (80% FBS, 20% DMSO) NOTE: for better results use AllCells Cryopreservation Media CRYO-001 (see Procedure 1. below)

• Isocove’s Modified Dulbecco’s Medium (IMDM)

• Ice

Equipment Required

• Refrigerated centrifuge

• Biosafety hood (Class II)

• Compound microscope

• 2mL Cryogenic vials

• Freezing rack

• 1 to 10 mL pipets

• Conical centrifuge tubes

• Isopropanol graded freezing containers

• -20oC freezer

• -80oC freezer

Procedure1. Thaw AllCells Cryopreservation Media (CRYO-001) with

proprietary blend of reagents to increase cell viability. Alternately, prepare cryopreservation solution of 80% FBS and 20% DMSO up to 2 days in advance and store at 4oC.

2. Label cryogenic vials with the appropriate vial and donor information.

3. Place ice at the bottom of a freezing rack, place vials in the freezing rack, store in a -20oC freezer for at least 10 minutes until ready for use. .

4. Count the cells with preferred primary cell counting method (see Technical Notes pg. 150)

5. Centrifuge cells at 200xg (1000 RPM on Beckman Coulter™ Centrifuge) for 5 minutes at 4oC and remove supernatant from cell pellet.

6. Based on the desired concentration of cells/vial, calculate

the amount of IMDM required to resuspend cells using the formulas:

a. # cells/desired concentration of cells per vial = # vials needed

b. 0.9mL/vial X # vials = # mL of Cryopreservation Media required

Resuspend the cell pellet in this volume of cold (4oC) IMDM.

7. Mix the suspension well by pipetting up and down. Incubate cells on ice for approximately 5 to 10 minutes.

8. In a small bowl, add ice and water to make a homogenous ice-water bath.

9. Place the cell suspension tube in the ice-water bath. Add the Cryopreservation Media to the cell suspension at a rate of 3 to 5 seconds per drop. Shake the tube constantly to ensure even mixing.

10. Remove freezing rack from freezer and place in the hood. Mix the cells well by pipetting and aliquot 1.8mL of cells to each cryogenic vial.

11. Freeze cells at a controlled rate of 1oC/min by placing vials in an alcohol-graded freezing container(s) and incubating at -80oC for a minimum of 4 hours to a maximum of overnight.

12. Transfer vials to vapor phase of liquid-nitrogen storage.

Cells stored in the vapor phase can be stored long-term up to several years. When commencing downstream applications on the cells, follow the protocol on How to Thaw Cells by referring to the Technical Note pg. 151.


Technical Notes—How to Freeze Extra Primary Cell Products

ALLCELLS

153


How to Freeze Bone Marrow MNC

Reagents Required

• Washing Buffer: PBS (Ca2+ and Mg2+ free) with 2mM EDTA and 10% FBS

• CryostorTM CS5

• Fetal Bovine Serum (FBS)

• Ice

Equipment Required



• 2mL Cryogenic vials


• 1 to 10 mL pipets

• Isopropanol graded freezing containers

• -20oC freezer

• -80oC freezer

Procedure1. Determine the number of vials needed and the

concentration of freeze.

a. Concentration of cells <1x106 freeze at 1.2mlb. Concentration of cells >1x106 freeze at 1.8ml

2. Centrifuge the cells in a 50ml conical tube at 200xg at 4°C for 10 minutes without brake. Remove the supernatant.

3. Use Cryostor™ CS5. Resuspend a small amount of Cryostor CS5 with a P1000 pipettman. Bring the cell suspension to the required amount for freezing.

4. Aliquot the appropriate amounts of cell suspension in the cryogenic vials for freeze.

5. Place vials in isopropanol graded freezing containers and place in a -80 °C freezer. For long-term storage (>1 month), we recommend moving vials to the vapor phase of liquid-nitrogen storage.

Technical Notes—How to Freeze Cell Products—Bone Marrow-MNC

Te

ch

nic

al

No

tes

154


Te

ch

nic

al

No

tes

The BM-MNC population is approximately 20-30% of white blood cells.

AllCells is not responsible for the recovery number of MNC or other purified cells. For a specific number of a certain cell type please consider our bone marrow purified products.

Reagents Required

• Ficoll-Paque™ PLUS or Lymphocyte Separation Media (1.077 density)

• Washing Buffer: PBS (Ca2+ and Mg2+ free) with 2 mM EDTA and 10% Fetal Bovine Serum

• Fetal Bovine Serum (FBS)

• Ice

• 0.4% Trypan Blue (to check for dead cells)

• 3% Acetic Acid Methylene Blue Equipment Required



• Hemacytometer


• 5 to 10ml pipets

• 10 –200µl pipettors

• 10 – 200µl tips

• 50ml conical centrifuge tubes

• 40µm mesh nylon strainer (Becton Dickinson Biosciences, REF 3523)

The following process:

• Should be performed in a sterile biosafety hood (Class II) to avoid bacterial contamination.

• Is written for MNC isolation using 50ml conical centrifuge tubes.

Procedure

1. The whole BM product is shipped to you at room temperature. It is highly recommended to store the whole BM product at room temperature before MNC isolation.

2. Before MNC isolation, please count the whole BM product with methylene blue to determine the WBC number in the sample (please refer to How to Count Fresh Cells Technical Notes).

3. Place the cell strainer on top of a sterile 50 ml conical tube. Wet the strainer using 1 ml PBS. Slowly, run the BM through the strainer. Wash the strainer with 5-10 ml of PBS (without exceeding appropriate dilution ratio); discard the strainer.

4. Bring your BM cell suspension up to a 1:2 dilution (bone marrow: PBS) in 50ml conical tubes. Dilute every 10ml of your bone marrow product with 20ml of PBS.

5. Invert the tube several times. Carefully and slowly, under-lay every 30ml of diluted blood with 14 ml of room temperature Ficoll-Paque into each tube. Avoid creating air bubbles in the Ficoll layer.

6. Centrifuge for 30 minutes at 400xg (1300 rpm for Beckman Coulter™ Centrifuge) at 25°C in a swinging-bucket rotor (no brake).

7. Remove the upper layer, leaving the mononuclear cell layer undisturbed at the interphase.

8. Carefully collect the interphase cells and a small part of the cells underneath the interphase.

Note: Do not disturb the red pellet as this will cause granulocyte contamination.

9. Transfer to a sterile 50 ml conical tube.

10. Centrifuge your sample at 1700xg (3000 rpm for Beckman Coulter™ Centrifuge) at 4°C for 10 minutes, no brake.

11. Remove the supernatant. Resuspend the cells with 5 ml of cold (4°C) Washing Buffer, using a 5ml pipet.

12. Fill the tube up to 50ml with cold Washing Buffer.

13. Count the cells using the Methylene Blue Method (See "How to Count Fresh Cells").

14. Centrifuge at 200xg (1000 rpm for Beckman Coulter™ Centrifuge) at 4°C for 10 minutes, no brake.

15. Resuspend the cell pellet with proper culture media and count the cells. Adjust the MNC concentration with proper culture media and proceed to your experiment.

BM Unit Size Total PBS (x1) Added to BM For Shipment

3ml 1.5ml

10ml 4 ml

25ml 15ml

50ml 30ml

100ml 60ml

Technical Notes—How to Purify Bone Marrow MNC

Te

ch

nic

al

No

tes

ALLCELLS

155


Frequently Asked Questions Q. Can bone marrow cells be used in colony formation assays?

A. Yes, our purified bone marrow CD34+ cells have been used in colony formation assays, and they perform extremely well.

Q. After ficolling, my BM-MNC have many red blood cells (RBC). Is this normal? If so, how do I get rid of them?

A. It is extremely difficult to collect only MNC during ficolling. The amount of RBC you harvest depends on donor variation and technique. You can use Ammonium Chloride for RBC lysis.

Note: Excessive exposure to ammonium chloride can potentially damage leukocytes.

Q. How do I get rid of clumps in my mononuclear cells?

A. You can use a 40 µm cell strainer to strain the clumps out.

Technical Notes—How to Purify Bone Marrow MNC (continued)

Te

ch

nic

al

No

tes

156


Te

ch

nic

al

No

tes

6. Take 25µl sample of blood and place into 1.5 ml centrifuge tube with 475 µl Methylene Blue.

7. Add 80µl of DPBS into a mixing well (rounded non-sterile 96 well plate). Invert the 1.5 ml tube several times to mix the blood and Methylene Blue thoroughly.

8. Take a 20µl sample from the 1.5 ml tube and mix with 80µl DPBS. Load the hemacytometer with 20 µl of diluted sample.

9. Count the total number of mononucelar cells using Methylene Blue Method.

a. Methylene Blue Method Equation for Cell Count:# of cells/vial_____ / 20 x d x ___mL = _____ x 106

b. To assess viability, use Trypan Blue Method. Mix equal volumes of cell to trypan blue (10µl:10µl) and dilute appropriately where necessary.

Equation for Viability: # of cells excluded by trypan blue/ total number of cells x 100% = ______%

To Process PB-MNC from Leuko Pak

1. Count the cells from Leuko pak as detailed above.

2. Refer to "How to Deplete RBC," page 157.

Blood is obtained from normal healthy volunteers with collection of maximum three-blood volume on COBE SpectraTM apheresis machine.

Reagent and Materials Required

• Sterile Room Temperature Washing Buffer: 500mL DPBS with 2mM EDTA

• Cold Washing Buffer: 500mL DPBS+10mL Fetal Calf Serum (FCS) or Fetal Bovine Serum (FBS) + 2mM EDTA

• Cold Shipping Buffer: 500mL DPBS+8mL Bovine Serum Albumin (BSA; 0.5%)

• Ammonium Chloride Solution (0.8% NH4Cl with 0.1mM EDTA). Use approximately 10 to 15ml of ammonium chloride per 2-5x108 MNC per tube.

• 50mL Conical Tubes

• 5mL and 25mL pipets

• Latex gloves

Equipment Required

• Class II Biological Safety Cabinet

• Beckman Centrifuge

• Pipettors

• Stainless Steel Surgical Scissors

• Stainless Steel Clamps

Safety Precautions

• Protective gloves should be worn at all times.• Use a safety pipetting device for all pipetting. • NEVER PIPET BY MOUTH

Procedure1. Upon receipt of the apheresis blood, verify that the product

label is correct and donor information sheet is provided.

2. Remove the blood bag from biohazard bag. Place the apheresis bag in a Biological Safety Hood and examine the bag for leaks or clumps.

3. Mix the blood bag well and locate the blood transfer line.

4. Disinfect the blood transfer line with an alcohol swab and cut using sterile scissors.

5. Wipe the cut blood transfer line with an alcohol swab. Wait 1 minute until any remaining alcohol has evaporated. Carefully place 5ml of the blood in a sterile 50ml conical centrifuge tube and clamp the transfer pack to prevent any spills.

Technical Notes—How to Count: Leuko Pak

ALLCELLS

157


Te

ch

nic

al

No

tes

Technical Notes—How to Deplete Red Blood Cells

Materials and Reagents

• Dulbecco’s Phosphate Buffered Saline (DPBS) with 2mM EDTA

• WB (washing buffer, 2% Fetal Bovine Serum (FBS), 2mM EDTA in DPBS)

• Ammonium Chloride (StemCell Technologies Cat# 07850)

Equipment


• Ice in a bucket

• Pipettor

• Biosafety hood

Safety Precautions

• Protective gloves should be worn at all times

• Use a safe pipetting device for all pipetting

• NEVER PIPET BY MOUTH

Procedure For Lysis of RBC From Whole Blood

1. Transfer 25ml of blood into a 50ml conical tube and centrifuge at 200xg (or 1000 rpm on Beckman Coulter™ Centrifuge) in a swinging bucket rotor for 10 minutes at room temperature.

2. Discard the supernatant and resuspend the blood with 25ml of DPBS (containing 5mM EDTA) and centrifuge at 200xg (1000 rpm) for 10 minutes at room temperature.

3. Discard the supernatant and add the Ammonium Chloride at 9:1 ratio. For example, 9ml of Ammonium Chloride to 1ml of blood. You should have 45ml of Ammonium Chloride to 5ml of blood.

4. Mix the cell and Ammonium Chloride and place on ice for 10 minutes to allow lysis of the RBC.

5. Centrifuge the tube at 500xg (1500rpm) for 10 minutes in 4oC.

6. Discard the supernatant and wash the cells twice with WB. The cells are ready for use.

Procedure For RBC Lysis from Mononuclear Cells

1. Centrifuge the cells after collecting the lymphocyte layer from the separation medium.

2. Discard the supernatant and resuspend cells with 25 ml of WB.

3. Centrifuge the tube at 200xg (1000 rpm) for 10 minutes at room temperature.

4. Discard the supernatant and add the Ammonium Chloride at 4:1 ratio. For example, 4ml of Ammonium Chloride to 1ml of blood.

5. Mix the cells and Ammonium Chloride and place on ice for 10 minutes to allow lysis of the RBC.

6. Fill the tube with WB up to 25ml and centrifuge the tube at 200xg (1000rpm) for 10 minutes at 4oC.

7. Discard the supernatant and wash the cells twice with WB. The cells are ready for use.

This protocol is designed for human peripheral blood, bone marrow and cord blood for red blood cells (RBC) preparations. This protocol outlines the procedure for depletion of RBC from whole blood and from mononuclear cells.

158


Te

ch

nic

al

No

tesThawing and Culturing Cells

1. Calculate the number of flasks needed. The recommended seeding density for AllCells BM Mesenchymal Stem Cells (MSC) is 5,000 to 10,000 cells/cm2. For example, one vial of AllCells MSC (7.5x105/vial) would be sufficient for 1 to 2 T75 flasks or 3 to 6 T25 flasks.

2. Prepare the culture media: a. Add 2mM concentration of L-glutamine and the entire contents of 50ml AllCells Stimulatory supplement (Cat.No.MSC-003) to 450ml of AllCells Basal Medium (Cat. No. MSC-002). b. Add 2 to 3 ml/5 cm2 of the mixed media into the T75 or T25 flasks. c. In a 37°C, 5% CO2 humidified incubator allow the flasks to equilibrate in for at least 30 minutes.

3. Wipe the frozen vial with 70% alcohol before thawing. In a biosafety hood, briefly twist the cap a quarter-turn to relieve pressure, then retighten the cap.

4. In a 37°C water bath, quickly thaw the vial. Be careful not to submerge the entire vial in the water bath. Do not remove the vial until a tiny ice-crystal is left. Wipe the outside of the vial with 70% alcohol.

5. In a biosafety hood, take a 10ul sample from the vial. Mix the 10µl sample with 10µl of trypan blue. Dilute the cells if necessary and count the number of cells on a hemacytometer to determine the viability.


Equation for Cell Count: # of cells/ vial = N/4 x d x____ml = _____104

Equation for Viability: # of cells excluded by trypan blue/ # total number of cells x 100% = ______%

**This is a very important step to determine if the cell viability number matches what AllCells claims.

Maintaining Cell Culture

1. Change the growth medium the day after seeding and every other day thereafter.

2. In a sterile container, warm an appropriate amount of Complete Medium to 37°C.

3. Remove the medium and replace with the warmed, fresh medium; return the flask to the incubator.

Note: Avoid repeated warming and cooling of the medium. If the entire contents are not needed for a single procedure, transfer only the required volume to a sterile secondary container. Subculturing Cells

1. Subculture the cells when they are 70 to 80% confluent (about 10 days). Many mitotic figures should be visible throughout the flask.

2. For each 25cm2 of cells to be subcultured:

a. Prepare 2 ml of Trypsin/EDTA, 5 ml of HEPES Buffered Saline Solution (HEPES-BSS), 4 ml of Trypsin Neutralizing Solution (TNS such as 10% FBS-DPBS). Allow the aforementioned items to come to room temperature.

b. From one culture flask, remove the medium and rinse the flask with 5 ml of room temperature HEPES-BSS. (This is an IMPORTANT step. The culture medium contains complex proteins that neutralize the effect of trypsin.) Remove the HEPES-BSS from the flask.

c. Repeat Step b for each culture flask.

3. Add 2 ml of Trypsin/EDTA solution to each T25 flask. Allow the trypsinization to continue until approximately 90% of the cells have lifted up from the T25 flask. This entire process takes about two to six minutes. Hit the flask against the palm of your hand to release the majority of cells from the culture surface. If only a few cells detach, wait 30 seconds and repeat this motion again. If cells still do not detach, wait and repeat every 30 seconds thereafter.

4. After cells have detached, neutralize the trypsin in the flask with 4 ml of room temperature Trypsin Neutralizing Solution.

5. Quickly transfer the detached cells to a sterile 15ml centrifuge tube and rinse the flask with a final 2 ml of HEPES-BSS to collect residual cells. Add this rinse to the centrifuge tube.

Technical Notes—How to Passage and Subculture—Mesenchymal Stem Cells

ALLCELLS

159


General Media Requirements

Monocyte Derived Macrophages (MDM) will mature if cultured with Macrophage Basal Medium (Cat. No. PB-MDM-002) in conjunction with Macrophage Stimulatory Supplement (Cat. No. PB-MDM-003).

Types of Culture Vessels• 96 well plate• 35mm tissue culture dish• 100mm tissue culture dish• T25 flask• T75 flask

Thawing and Culturing Cells1. Calculate the number of culture vessels needed. The

recommended seeding density for AllCells MDM is 10x104 cells/cm2. For example, one vial of AllCells MDM (1.5x106/vial) would be sufficient for six T25 flask or two 100mm dish.

2. Prepare the Complete Culture Medium: Add 2mM concentration of L-glutamine, 1% of the antibiotic-antimycotic stock solution and the entire contents of 50ml AllCells Stimulatory supplement (Cat. No. PB-MDM-003) to 450ml of AllCells Basal Medium (Cat. No. PB-MDM-002).

3. Wipe the frozen vial with 70% alcohol before thawing.

4. In a biosafety hood, briefly twist the cap a quarter-turn to relieve pressure, then retighten the cap.

5. In a 37°C water bath, quickly thaw the vial. Be careful not to submerge the entire vial. Do not remove the vial until a tiny ice-crystal is left.

6. Wipe the outside of the vial with 70% alcohol.

7. Count cells by taking 10µl from the vial to mix with 10µl of trypan blue solution. Count cells with a hemacytometer .


Equation for Cell Count: # of cells/ vial = N/4 x d x____ml = _____104

Equation for Viability: # of cells excluded by trypan blue/ # total number of cells x 100% = ______%

**This is a very important step to determine if the cell viability number matches what AllCells claims.

8. Initiate the culture. Resuspend and dispense 10,000 cells/cm2 from the vial into the culture vessel.

9. Add the desired volume of prepared culture medium to the vessel.

10. Gently rock the culture vessel to evenly distribute the cells and place in 5% CO2 incubator.

Note: It is not necessary to wash the cells because this action is more damaging than the effects of DMSO residue in the culture. Maintaining Cell Culture

1. Change the growth medium the day after seeding and every other day thereafter.

2. In a sterile container, warm an appropriate amount of complete culture medium to 37°C. Remove the medium and replace it with the warmed, fresh medium

3. Return the flask to the incubator.

Note: Avoid repeated warming and cooling of the medium. If the entire contents are not needed for a single procedure, transfer only the required volume to a sterile secondary container.

Technical Notes—How to Passage and Subculture—Monocyte-Derived Macrophages

Te

ch

nic

al

No

tes

160


Technical Notes—How to Isolate MNC Using a Ficoll Gradient

AllCells is not responsible for the recovery number of MNC or other purified cells. For a specific number of a certain cell type please consider our purified products.

Reagents Required• Ficoll-Paque™ PLUS or Lymphocyte Separation Media• (1.077 density)• Washing Buffer: PBS (Ca2+ and Mg2+ free) with• 2 mM EDTA • Ice• 0.4% Trypan Blue (to check for dead cells)• 3% Acetic Acid Methylene Blue

Equipment Required• Refrigerated centrifuge• Biosafety hood (Class II)• Hemacytometer• Compound microscope• 5 to 10ml pipets• 10 –200µl pipetman• 10 – 200µl tips• 50ml conical centrifuge tubes• 40µm mesh nylon strainer (Becton Dickinson Biosciences,

REF 3523)

The following process:• Should be performed in a sterile biosafety hood (Class II)to avoid bacterial contamination.• Is written for MNC isolation using 50ml conical centrifugetubes.

Procedure

1. The whole tissue product is shipped to you at room temperature. It is highly recommended to store the whole tissue product at room temperature before MNC isolation.

2. Before MNC isolation, please count the whole tissue product with methylene blue to determine the WBC number in the sample (please refer to How to Count Fresh Cells Technical Notes).

3. Bring your tissue cell suspension up to a 1:2 dilution in 50ml conical tubes. Dilute every 10ml of your tissue product with 20ml of PBS.

4. Invert the tube several times. Carefully and slowly, under-lay every 30ml of diluted blood with 14 ml of room temperature Ficoll-Paque into each tube. Avoid creating air bubbles in the Ficoll layer.

5. Centrifuge for 30 minutes at 400xg (1300 rpm for Beckman

Coutler™ Centrifuge) at 25°C in a swinging-bucket rotor(no brake).

6. Remove the upper layer, leaving the mononuclear cell layer undisturbed at the interphase.

7. Carefully collect the interphase cells and a small part of the cells underneath the interphase.

Note: Do not disturb the red pellet as this will cause granulocyte contamination.

8. Transfer to a sterile 50 ml conical tube.

9. Centrifuge your sample at 1700xg (3000 rpm for Beckman Coutler™ Centrifuge) at 4°C for 10 minutes, no brake.

10. Remove the supernatant. Resuspend the cells with 5 ml of cold (4°C) Washing Buffer, using a 5ml Pipetman.

11. Fill the tube up to 50ml with cold Washing Buffer.

12. Count the cells using the Methylene Blue Method (See "How to Count Fresh Cells").

13. Centrifuge at 200xg (1000 rpm for Beckman) at 4°C for 10 minutes, no brake.

14. Resuspend the cell pellet with proper culture media and count the cells. Adjust the MNC concentration with proper culture media and proceed to your experiment.


Te

ch

nic

al

No

tes

ALLCELLS

161


INDEX - ALPHABETICAL

A

Acute Lymphoid Leukemia (ALL) 97-98Bone Marrow 98

CD19+ B Cells 98Mononuclear Cells 98Plasma 98

Peripheral Blood 97CD19+ B Cells 97Mononuclear Cells 97Plasma 97

Acute Myeloid Leukemia (AML) 99-100Bone Marrow 100

CD34+ Cells 100Mononuclear Cells 100Plasma 122

Peripheral Blood 99Mononuclear Cells 99Plasma 99

Adipose-derived Stem Cells 89Amniotic/Placental Cells 90Animal Primary Cells 125-142Apheresis Collection (Leuko Pak) 7, 16-18, 35, 39, 61Autoimmune Diseased Cells 112-124

B

B Cells 41-42, 82, 97-98Basophils 52Bioservices 19-27Bone Marrow (Human, Healthy) 16-18, 67-74

Aspirates 16-18, 68CD34-Depleted Mononuclear Cells 70Mononuclear Cells 69Myeloid Cells

CD36+ Early Erythroid Progenitor Cells 72Stem/Progenitor Cells - CD34+ Cells 71Mesenchymal Cells 74

CD105+ Endothelial Cells 73Mesenchymal Stem Cells 74

Whole 68

C

CD133+ Cells 65CD34+ Cells 40, 64, 71, 100, 104, 126Cell-based Assays 20-22Cell Culture Media 143-148Cell Separation Methods 11Chronic Lymphoid Leukemia (CLL) 101-102

Bone Marrow 102 CD19+/CD5+ B Cells 102Mononuclear Cells 102Plasma 102

Peripheral Blood 101 CD19+/CD5+ B Cells 101Mononuclear Cells 101Plasma 101

Chronic Myeloid Leukemia (CML) 103-104Bone Marrow 104

CD34+ Cells 104Mononuclear Cells 104Plasma 104


Cord Blood 75-87CD34-Depleted Mononuclear Cells 78Lymphoid Cells

CD3+ Pan T Cells 83CD4+/CD45RA+ Naïve T Cells 86CD4+ Helper T Cells 84CD8+ Cytotoxic T Cells 85CD19+ B Cells 82CD56+ NK Cells 87

Mononuclear Cells (MNC) 77Myeloid Cells

CD14+ Monocytes 81CD36+ Early Erythroid Progenitor Cells 80

Plasma 76Stem/Progenitor Cells

CD34+ Cells 79Crohn's Disease Cells 123Cryopreservation Media 144Custom Products/Projects 17-18, 30-32, 94Culture Media 144-145Cytokines 146-148 FTL-3L 146 G-CSF 146 GM-CSF 146 IL-3 147 IL-4 147 IL-6 147 M-CSF 148 SCF 148 TPO 148Cytotoxic T Cells 48-49, 85

Ind

ex

: A

lph

ab

eti

ca

l

162


Ind

ex

: A

lph

ab

eti

ca

l

Alphabetical Index

D

Dental Pulp Stem Cells 91Delivery Information 6-8Dendritic Cells 50, 58Diffuse Large B Cell Lymphoma (DLBCL) 110-111Diseased Cells 92-124DNA Analysis 23

E

Early Erythroid Progenitor Cells (CD36+) 72, 80, ELISA, ELISpot 21Endothelial Cells 73Eosinophils 53Erythrocytes 55

F

Flow Cytometry 23Fluorescence-activated Cell Sorting (FACS) 23Follicular Lymphoma (FL) 110-111

G

G-CSF Mobilized Cells 11, 60-61Genotyping Services 26

H

Helper T Cells 44, 46, 84Hematopoietic Assays 22HLA-Typing 27How To Count Cells 150How To Count Leuko Pak 156How To Freeze Cells Products 152-153How To Isolate MNC Using a Ficoll Gradient 160How To Passage and Subculture Cells 158-159How to Purify Bone Marrow MNC 154-155How to Thaw Frozen Cells 151

I

Immunoassays 21Immunophenotyping 23, 27Immunoprecipitation 25In vitro proliferation/inhibition assays 24Inflammatory Bowel Diseased Cells 122-124ISHAGE 23

L

Leukemia Cells 95-104Leuko Pak (Apheresis Collection) 35, 61Leukocytes 53-54Lupus (SLE) Diseased Cells 119

M

Macrophages 59, 159Mantle Cell Lymphoma (MCL) 110-111Media 143-148Memory T Cells 47Mesenchymal Stem Cells (MSC) 74, 89-91, 134, 158Mobilized Peripheral Blood 60-66

CD34-Depleted Mononuclear Cells 63Leuko Pak 61Mononuclear Cells 62Myeloid Cells

CD14+ Monocytes 66Stem/Progenitor Cells

CD34+ Cells 64CD133+ Cells 65

Monocytes 57-59, 66, 81Mouse Cells 127-132

Astrocytes 129Bone Marrow MNC 127Mouse Embryonic Fibroblast 130Splenocytes 131

Mozobil 11, 17, 61Multiple Myeloma (MM) 105-107

Bone Marrow 107Mononuclear Cells 107Plasma 107


Multiple Sclerosis (MS) Diseased Cells 115Mutation Analysis 26Myelodysplastic Syndrome Diseased Cells 108-109

N

Natural Killer Cells 51, 87Neutrophils 54Non-Hematopoietic Stem Cells 88-91Non-Hodgkin’s Lymphoma 110-111Non-Human Primate Cells 126Normal Peripheral Blood 34-59

Leuko Pak 34-35Lymphoid Cells

BDCA4+ Lymphoid/Plasmacytoid Dendritic Cells 50CD4+/CD25+ Regulatory T Cells 45

ALLCELLS

163


Ind

ex

: A

lph

ab

eti

ca

l

Alphabetical Index

CD4+/CD45RA+/CD25- Naïve T Cells 46CD4+/CD45RO+ Memory T Cells 47CD4+ Helper T Cells 44CD8+/CD45RA+ Naive Cytotoxic T Cells 49CD8+ Cytotoxic T Cells 48CD19+ B Cells 41CD19+/IgD+ Naive B Cells 42CD56+ NK Cells 51Pan T Cells 43

Mononuclear Cells 39Myeloid Cells

Basophils 52CD14+ Monocytes 57Eosinophils 53Mature Erythrocytes (RBC) 55Monocyte Derived Immature Myeloid Dendritic Cells 58Monocyte Derived Macrophages 59Neutrophils 54Platelets 56

Plasma 38Stem/Progenitor CD34+ 40Whole Blood 36-37

O

Ordering Information 6-8, 9Osteoarthritis Diseased Cells 116

P

Pancreatic Islets 139Pig Cells 142Placental/Amniotic Cells 90Plasmacytoid Dendritic Cells 50Platelets 56Protein Analysis 25Psoriasis (PSO) Diseased Cells 117

R

Rat Cells 133-141Astrocytes 137Bone Marrow —CD90 Cells 135 Bone Marrow —Mesenchymal Stem Cells 134Bone Marrow—Mononuclear Cells 133Peripheral Blood--Mononuclear Cells 136Meningeal 138Microglia 138Pancreatic Islets 139Splenocytes 140

Red Blood Cells 55Rheumatoid Arthritis Diseased Cells 118

T

T Cells 43-49, 83-86Technical Notes 149-160Technical Support 9Terms & Conditions 13-14Tissue Collection Facility 15-18Tissue Culture Services 24Toxicology Studies 24Type I Diabetes Diseased Cells 120Type II Diabetes Diseased Cells 121

U

Ulcerative Colitis Diseased Cells 124

W

Waldenström’s Macroglobulinemia (WM) 110-111Website Information 9

164


NOTES

ALLCELLS

165


QUICK REFERENCE GUIDE

• Age: 18-55 years old (18-40 years old for mobilized donation)

• Weight: >110 lbs for 25mL and 50mL BM donations

• Weight: >130 lbs for 100mL BM donations

• Weight: >140 lbs for Normal and Mobilized Leuko Pak donation

• CBC lab tests must meet protocol specifications



–History of heart, lung, liver, kidney disease (including asthma)

–Blood and bleeding disorders, including sickle cell disease

–Neurologic disorders

–Cancer

–Diabetes

–Positive: HIV, HbsAg, HCAb



before donation


prior to the collection procedure

• All consents and protocols have been approved by an

independent biomedical review board

• Minimum 12 months between mobilized donations

• Twice in a lifetime maximum for mobilized donations

Donor Criteria

166


Quick Reference Guide

Cell Subset ProductsThe table below is for reference purposes only. Please note that the average percentage of cell subsets is referring to the recovered MNC population and not the total white blood cell population.

CellsNormal Peripheral Blood

Mobilized Peripheral Blood- Reg E

Bone Marrow Cord Blood Whole Blood

CD34+ 29 % 0.83% 0.73 % 0.58 % 0.55 %

CD133+ 0.09 % 0.23 % 1 % 0.21 % 0.4 %

CD33+ 29 % 33 % 27 % 21 % 9 %

CD105+ 0.41 % 2 % 0.89 % 1 % 1 %

CD56+ 2 % 3 % 1 % 2.6 % 1 %

CD19+ 1 % 10 % 2 % 1 % 1 %

CD16+ 4 % 8 % 30 % 33 % 39 %

CD15+ 4 % 16 % 63 % 40 % 44 %

CD14+ 16 % 22 % 4 % 12 % 6 %

CD8+ 23 % 19 % 6 % 10 % 9 %

CD4+ 3 % 24 % 3 % 21 % 12 %

CD3+ 60% 45 % 27 % 28 % 43 %

CD4+/CD45RA+ 35 %

Basophils 0.3%

Neutrophils and

Eosinophils

0.2%

Granulocytes 10% 10%

RBC <0.01% <0.01% <0.01%

Platelets <0.01% <0.01% <0.01%

CD138+ Plasma Cells 0.1-0.4%

We cannot guarantee the recovery of the cell types listed above. For a specific number of a certain cell type, please consider our purified products.

UK & IrelandCaltag Medsystems Ltd,

Whiteleaf Business Centre,11 Little Balmer,

Buckingham, MK18 1TF, UKTel: +44-(0)-1280- 827460 Fax: +44-(0)-1280- 827466

[email protected]

France & SpainCliniSciences S.A.S.

183, av. Georges Clémenceau 92000

Nanterre, FranceTel: +33-9-7740-0909Fax: [email protected]

Germany, Austria, & SwitzerlandCellSystems

Biotechnologie Vertrieb GmbHLangeler Ring 5

53842 Troisdorf, GermanyTel: +49-2241-25515

Fax: [email protected]

ASIA

EUROPE

AllCells, LLC1301 Harbor Bay Parkway, Suite 200

Alameda, CA 945021-888-535-3444

Fax: 510-521-7600www.allcells.com

AllCells ShanghaiShanghai Ju Ke Science Park

333 Guiping RoadBuilding 7, 2nd Floor

Xuhui District, 200233Shanghai, China

Tel: +86-(0)21-6485-3421Fax: +86-(0)21-6485-0144

www.china.allcells.com

JapanVeritas, Inc.

2-7-14 Yashima BuildingToranomon, Minato-ku,Tokyo 105-0001, JapanTel: +81-(0)3-3593-3211Fax: +81-(0)3-3593-3216 [email protected]

JapanWako Pure Chemical

Industries, Ltd.1-2, Doshomachi 3-Chome,

Chuo-ku,Osaka 540-8605, Japan

Tel: +81-120-052-099Fax:+81-120-052-806

[email protected]

MalaysiaAxon Scientific Sdn Bhd

No. 7-4, Jalan SP2/7, Taman Serdang Perdana, Seri

Kembangan, Selangor DE. Malaysia

Tel: +60-3-8945-1482Fax: +60-3-8941-9421

[email protected]

SingaporeAxil Scientific PteLtd

41 Science Park Road #04-08, The Gemini, Singapore Science

Park II, Singapore 117610. Tel: +65-6775-7318Fax: +65-6775-7211

[email protected]

FOR A FULL LIST OF INTERNATIONAL DISTRIBUTORS, VISIT WWW.ALLCELLS.COM/CONTACT-US

your reliable source of primary cells and · product catalog 2015-2016. allcells 1 toll free phone:...

Documents